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1.   Introduction: Mitochondria  
In general, mitochondria are considered the powerhouses of the cell [1]. 
Mitochondria are organelles, which convert sugars, fats and proteins inside the 
mitochondrial double membrane into adenosine triphosphate (ATP), the cellular 
source of energy. Mitochondria are present in varying numbers per cell type, 
tissue, and organs, usually depending on their energy requirements. Originally, 
mitochondria were free-living prokaryotes but more than a billion years ago an 
endosymbiotic event made the free-living bacterium part of what became a 
eukaryotic cell [2]. During evolution the parasite changed into a central 
mutualistic organelle, we nowadays know as mitochondria, which was 
accompanied with strong reduction in gene number and genome size. Only a small 
amount of genetic material remained in the mitochondria, which is the current 
mitochondrial DNA (mtDNA) [3]. Although energy production is the main function 
of mitochondria, other cellular processes, such as heme synthesis, cellular 
apoptosis, and calcium homeostasis, are also carried out by mitochondria [4]. 
1.1. Mitochondrial Energy Production 
Several processes generate ATP from glucose, such as glycolysis, the tricarboxylic 
acid (TCA) or Krebs cycle, the respiratory chain and ATP synthesis (Figure 1). 
Glycolysis generates 2 ATPs during the oxidation of glucose to pyruvate. Pyruvate 
is being transported into the mitochondrial matrix and converted into Acetyl-CoA, 
which is a substrate for the TCA cycle. The TCA cycle produces energy-rich 
metabolites, such as FADH2, NADH, GTP, and 2 ATPs. At the mitochondrial inner 
membrane, electrons from NADH and FADH2 pass through the electron transport 
chain to oxygen, which is reduced to water. Electrons from NADH are transferred 
to Complex I (CI) and electrons from FADH2 to Complex II (CII), followed in both 
cases by transfer to Co-enzyme Q (CoQ). CoQ transports the electrons to Complex 
III (CIII) and via cytochrome c to Complex IV (CIV). The function of the electron 
transport chain is to generate a transmembrane proton electrochemical gradient. 
This gradient is used by the ATP synthase complex, often referred to as complex 
V, to generate 32 ATP from ADP via oxidative phosphorylation (Figure 1). ATP 
transport to the cytosol is processed via the ADP/ATP transporter, better known 
as adenine nucleotide transporter (ANT) [5].  
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Figure 1. Cellular respiration and mitochondrial energy production. The primary role of 
mitochondria is the production of cellular energy (ATP) by a process called oxidative 
phosphorylation. In total, each glucose molecule undergoing cellular respiration produces 
38 ATP molecules: 2 ATPs from glycolysis, 2 ATPs from Krebs cycle, and 34 ATPs from 
oxidative phosphorylation. By RegisFrey - Own work, CC BY-SA 3.0, 
https://commons.wikimedia.org/w/index.php?curid=4389845.
1.2. The Structure of the Mitochondria
Mitochondria contain an outer and inner membrane composed of a phospholipid 
bilayer and proteins. The outer mitochondrial membrane encloses the entire 
organelle, which contains protein import machineries and protein channels that 
allow transport of small molecules and proteins into the mitochondrial inter-
membrane space. The inner mitochondrial membrane, which is folded into a 
number of cristae to increase the surface area, contains multiple proteins such as 
the respiratory chain complexes, Adenosine Triphosphate (ATP) synthase, 
assembly proteins, and metabolite import machineries [6]. The space enclosed by 
the mitochondrial inner membrane is called the mitochondrial matrix. This matrix 
contains enzymes, tRNAs, mitochondrial ribosomes, and copies of mtDNA. 
Additionally, also other enzymes, involved in the urea cycle, in branched chain 
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amino acid metabolism, and in heme synthesis are present in the mitochondrial 
matrix [6]. 
1.3. The Mitochondrial and the Nuclear Genome 
The mitochondria have a dual genetic origin, with a small part of the genetic 
information, being present in the mtDNA and the vast majority in the nuclear DNA. 
The mtDNA is a 16,569kb circular double-stranded molecule, containing 37 genes 
(22 transfer RNAs (tRNA) genes, 2 ribosomal RNAs (rRNA) genes and 13 protein 
encoding genes, which are all structural subunits of the enzyme complexes of the 
respiratory chain, being 7 subunits of Complex I (CI), 1 of Complex III (CIII), 3 
Complex IV (CIV), and 2 of Complex V (CV), (Figure 2). The majority of the 
structural proteins of the OXPHOS complexes and the proteins involved in mtDNA 
replication, transcription, translation, in assembly of the OXPHOS protein 
complexes, maintenance, and in mitochondrial quality control are encoded by 
around 1500 nDNA genes [6]. The proteins are targeted to the mitochondria by 
specific import sequences. An inventory of human mitochondrial genes is 
represented in the MitoCarta2.0 inventory, comprising a still incomplete collection 
of 1158 nuclear and mtDNA genes encoding proteins with a likely mitochondrial 
function [7]. Nuclear mitochondrial genes are inherited from both parents, but the 
mtDNA shows exclusive maternal transmission, as the paternal mtDNA in the 
sperm is eliminated upon fertilization.  
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Figure 2. The mitochondrial DNA (mtDNA). The human circular mitochondrial DNA consists 
of 16,569bp, encoding 22 tRNA’s, 2 rRNA’s, and 13 core-subunits of the OXPHOS complexes. 
Complex I genes are orange, complex III genes are purple, complex IV genes are rose, 
complex V genes are yellow, rRNA genes are green, tRNA genes are blue and black border 
lines. Adapted from Van der Wijst, GPM. et al., Scientific Reports 7, Article number: 177 
(2017).
1.4. Mitochondrial DNA Transcription, Translation, and Replication
Mitochondrial DNA replication is under control of nuclear encoded proteins, which 
are involved in the unwinding of the double stranded mtDNA, the synthesis of the 
mtDNA strands and the supply of nucleotides (Figure 3). The mtDNA contains a 
non-coding control region which is 1000bp long. This region, also called 
displacement loop (D-Loop), forms a three-stranded structure which functions as 
start-site of replication. mtDNA replication is linked to mtDNA transcription, which 
Chapter 1
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produces the 37 RNAs (ribosomal, 22 transfer, and 13 messenger RNAs). 
Mitochondrial transcription can originate from three sites: one L-strand promoter, 
and two H-strand promoters and requires mRNA polymerase (POLRMT), 
transcription factor A (TFAM), and mitochondrial transcription factor B2 (TFB2M) 
(Figure 2). Transcription of mtDNA needs TFAM, which binds to the promoters on 
the heavy and the light strands of the mtDNA, but also covers the mtDNA as a 
sort of protective histone [8]. The genes are transcribed as a polycistronic RNAs, 
from which the specific tRNA, rRNA and mRNA are being cleaved [8]. Termination 
of transcription is regulated by specific termination factors, including mTERF.  
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Figure 3. Mitochondrial replication and nucleotide metabolism. A schematic overview of the 
pathways involved in mitochondrial replication and nucleotide metabolism. Adapted from 
Camara Y. et al. Feeding the deoxyribonucleoside salvage pathway to rescue mitochondrial 
DNA, Drug discovery today. 2013, Doi:10.1016/j.drudis.2013.06.009. 
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For translation of the mtDNA-encoded proteins, mitochondrial transfer RNAs are 
charged with the corresponding amino acids by nuclear-encoded amino-acyl tRNA 
synthetases (e.g. AARS2, DARS2, EARS2 etc.). The mitochondrial ribosomes 
contain mtDNA encoded rRNA/tRNAs and nuclear encoded ribosomal proteins 
(e.g. MRPL3, MRPL44), translation elongation factors (e.g. GFM1, TSFM, and 
TUFM), recycling and release factors (e.g. C12orf65, GFM2), and catalyzing 
maintenance enzymes (e.g. MTFMT, MPV17) required for synthesis of the 13 core-
subunits of the OXPHOS proteins (Figure 4).  
mtDNA maintenance mt-tRNA modification mt-tRNA synthetases mt-ribosmal proteins
mt-translation, 
initiation, elongation, 
termination factors
mRNA stability
factors
RC subunit and
assembly genes
Mitochondrial OXPHOS proteins
OMIM
IMIM CI CII CIII CIV CV
mtDNA deletion and depletion
Mitochondrial
DNA 16,569bp 
Nuclear DNA
transfer 
-RNA
tRNA 
modification
Aminoacyl-
tRNA
synthetases
tRNA tRNA Ribosomerecycling Elongation
ribosomal-
RNA
messenger
-RNA
Termination
Initiation
Protein synthesisMitochondrial translation
mtDNA; 37 mitochondrial 
genes (2rRNAs, 22tRNAs 
and 13 polypeptides) 
Mitochondrial matrix
Cytoplasma
The Mitochondrial Biogenesis
Figure 4. Mitochondrial biogenesis. A schematic overview of the pathways involved in 
mitochondrial biogenesis. Adapted from Kamps R. et al., Eur J Hum Genet. 2018 EJHG. 
 
1.5. Mitochondrial Disease 
1.5.1. Clinical Heterogeneity 
Mitochondrial diseases are the most common genetic metabolic diseases, affecting 
approximately 1 in 5,000 individuals. Mitochondrial diseases form a clinically and 
genetically heterogeneous group of disorders, which generally manifest in tissues 
or organs with a high-energy requirement. Mitochondrial disease can affect 
multiple organs and lead to specific syndromes, like MELAS Mitochondrial 
Encephalomyopathy Lactic Acidosis and Stroke-like episodes, but they can also 
affect only a single organ or system, like blindness, in Leber hereditary optic 
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neuropathy (LHON). Also, more general manifestations, like sensorineural hearing 
loss, seizures, ataxia, myopathy, diabetes or cardiomyopathy [8, 9], can be part 
of the spectrum of mitochondrial diseases. The adagium is that mitochondrial 
diseases can display any symptom, at any age and any time. In general, the 
course of mitochondrial diseases is progressive, causing substantial morbidity and 
mortality [10]. No effective treatment exists for the vast majority of mitochondrial 
diseases [4].  
The clinical diagnosis of a mitochondrial disease is often difficult to establish and 
therefore a scoring system has been developed for children and adults. The 
mitochondrial disease criteria (MDC) for children are based on the presence of 
specific clinical signs and symptoms (maximum 4 points), neuroimaging and 
metabolic abnormalities (maximum 4 points), and histological abnormalities 
(maximum 4 points) [11]. Score 1: mitochondrial disorde unlikely; score 2-4: 
possible mitochondrial disorder; score 5-7: probable mitochondrial disorder; score 
8-12: definite mitochondrial disorder. For adults the clinical diagnosis of 
mitochondrial disease is based on the modified Walker criteria for mitochondrial 
disease [12]. This scoring system consists of major and minor criteria, which 
results in a definite mitochondrial disease score (2 major, or 1 major + 2 minor), 
or in a probable score (1 major + 1 minor, or 3 minor), or in a possible score (1 
major, or clinical + 1 minor). 
1.5.2. Laboratory Assays  
In addition to an extensive clinical evaluation, also electron-microscopy, 
biochemical (ATP, lactate), and/or enzymological measurements can be 
performed to establish a diagnosis of a mitochondrial disease. The latter 
examination is usually performed on a muscle tissue biopsy, or in patient-derived 
cell lines (fibroblasts). A needle biopsy suffices, which is usually very well-
tolerated [6] and the enzymatic assay can be performed on fresh or frozen 
material. By using specific compounds, each enzyme complex can be tested 
individually and a deficiency determined. In case the enzyme deficiency is also 
present in fibroblast, this allows complementation assays to validate a genetic 
defect. 
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1.5.3. Genetic Diagnosis  
Due to the dual genetic origin of mitochondria, a causative genetic defect can be 
found in either the mtDNA or in a nuclear gene. In only very few cases, the clinical 
and biochemical criteria point directly to a gene, like in Leigh syndrome with 
complex IV deficiency, which is generally caused by mutations in the Surf 1 gene. 
Such a gene can be efficiently screened by Sanger sequencing. Sanger sequencing 
is also used to test relatives of patients with an established genetic defect. In the 
majority of less straightforward cases, as a first step, usually the entire mtDNA of 
16,569bp is being analysed by next-generation sequencing (NGS). Sequencing is 
performed on a NGS platform using enrichment of a single entired long-range 
mtDNA PCR fragment as a library preparation step, these steps are according 
manufacture’s instructions. The quantification accuracy of using NGS in mtDNA 
samples is determined by varying the threshold levels of different substitutions 
mutations, small indels, and large deletions. The levels of large deletions are 
confirmed by quantitative qPCR method. A similar qPCR technique is used to 
determine mtDNA depletion in tissue, were mtDNA copy number (MTND1) is 
normalised to the nuclearDNA copy number (B2M). Since, each cell contains 
multiple copies of mtDNA and each cell can contain multiple mitochondria, a 
mutation only leads to disease, if the mutation load exceeds a tissue-specific 
threshold [13]. This combination of 2 types of mtDNA (wild-type and mutated 
mtDNA) is called heteroplasmy, whereas having accuracy one mtDNA type is 
called homoplasmy. The chance of identifying an mtDNA mutation is highest in 
the affected tissue, as differences in mutation load exist between tissues and a 
mutation can also disappear, for example, from blood. In the affected tissue the 
mutation load is usually highest and when using blood, the coverage has to be 
sufficiently high to detect low-mutation loads. It is also relevant to exclude 
involvement of the mtDNA as this has important consequences for the recurrence 
risk. In case, no causative genetic defect has been identified in the mtDNA, nuclear 
genes will be sequenced. This can be a targeted panel approach, only screening 
known mitochondrial (disease) genes, or an unbiased analysis of all genes (whole 
exome sequencing or whole genome sequencing). The latter approach allows the 
identification of novel genes as well, which may require functional validation to 
unambiguously link the gene defect to the disease.     
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1.5.4. Difficulty in Establishing a Genetic Diagnosis 
The clinical and dual genetic heterogeneity makes the diagnosis of mitochondrial 
diseases challenging. As extensive evaluation of clinical symptoms, biochemistry, 
immunohistochemistry, and quality and quantity of the mitochondria are not 
sufficient to pinpoint specifically a genetic cause and as 2 genomes are involved 
with possibly >1500 genes, it is evident that finding the genetic cause is a real 
odyssey. At the start of my thesis period, only 25% of the patients had a genetic 
diagnosis after extensive, costly and time-consuming sequential sequencing of 
individual candidate genes. Family studies and linkage analysis were fundamental 
to characterize unknown genes. However, the emergence of NGS has opened up 
a successful sequencing-based approach, allowing a more complete, more rapid 
and more successful diagnostic strategy.  
1.6. Transmission of Mitochondrial Disease 
Mitochondrial diseases have a dual genetic origin, which has implication for the 
transmission and recurrence risks. Nuclear gene defects may inherit in autosomal 
recessive or X-linked fashion or in autosomal dominant modus, but also de novo 
variants are quite frequent and should be considered. The mtDNA is transmitted 
by a mother to her children and during oogenesis a drastic decrease in mtDNA 
copy number occurs, which is followed by an amplification of this subset in 
maturing oocytes, the so-called mitochondrial genetic bottleneck. In carriers of a 
heteroplasmic mtDNA mutation, due to this bottleneck, the mtDNA mutation load 
can vary considerably among the oocytes of such a carrier and in the resulting 
offspring [13]. If a patient carries an mtDNA mutation as the cause of disease, 3 
situations can apply with respect to recurrence. First, the mutation is de novo in 
the patient, which is the case for about 25% of patients with an mtDNA disease. 
The recurrence is low, as the mother does not carry the mutation, and prenatal 
diagnostics (PND) is offered for reassurance [14]. Second, the mother is carrier 
of a heteroplasmic mutation. In that case preimplantation genetic diagnostics 
(PGD) can be offered and unaffected embryos with a mutation load below the 
threshold of expression can be transferred [14, 15]. Finally, in case of a 
homoplasmic mutation or a very high mutation load in the mother, which makes 
it impossible or unlikely to select healthy embryos, mitochondrial replacement 
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therapy (MRT) is the method of choice [16]. MRT is allowed in the UK for severe 
mtDNA disease cases, in which PGD is unlikely to be successful.  
Despite the high impact the bottleneck has on the transmission of mtDNA disease, 
it is still poorly understood which mechanisms are involved. The size of the 
bottleneck is an issue of debate and if positive or negative selection occurs on 
mutations in addition to random genetic drift. Data on PGD embryos indicate that 
for some mutations only genetic drift applies, but for others this is complemented 
with positive (on mitochondrial membrane potential, m.8993T>G) or negative 
selection (on OXPHOS function, m.3243A>G) [18]. It is evident that insight in 
these mechanisms influences the reproductive choices and the chances of having 
unaffected offspring. 
 
2. Animal Models to Study the Transmission of mtDNA Variants and 
Disease  
A number of limitations prevent an accurate study of transmission of mtDNA 
disease in humans. The main issue is the availability of oocytes and embryos to 
study the transmission of heteroplasmic mtDNA variants [17]. Due to these 
limitations, family studies have been performed in order to get indirect information 
on the segregation of these variants [18, 19]. Studies have reported random 
segregation and selection alike. Mouse models have been performed as well, both 
for fundamental investigations on the bottleneck as well as for limited studies on 
the transmission of mtDNA variants.  Rodents have high numbers of offspring, but 
the number of strains carrying mtDNA mutations is still small [2]. A commonly 
used model for transmission is the ‘mutator mouse’ which is a mouse model with 
a proofreading-deficient mitochondrial DNA polymerase (PolgA) [20]. In 
particular, a critical Aspartate residue has been replaced with an Alanine residue 
of the second exonuclease domain (D257A). In the offspring, the mtDNA 
mutations are random and unevenly distributed and can accumulate clonally in 
somatic cells, causing a mosaic of respiratory chain deficiency in tissues such as 
heart, skeletal muscle and brain [20]. Moreover, the analysis of these tissues has 
shown that mtDNA mutator mice contain an increased load (~ 3-5 times) of the 
somatic point mutations in the mtDNA and an increase in amount of mtDNA 
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eliminated [20]. Eventually, the increase in somatic mtDNA mutations is 
associated with a reduction in the duration of life and early onset of aging-related 
phenotypes [20].   
Zebrafish could be a good alternative model to study the mtDNA bottleneck, being 
cheap, easy to manipulate and producing large amounts of offspring. The mtDNA 
of zebrafish contains the same number of 37 evolutional genes as the human 
mtDNA of which also 13 are protein-encoding genes. Also, many nuclear structural 
OXPHOS, sub- and assembly units are evolutionary similar to human, which 
makes the zebrafish potentially an excellent model to study mitochondrial and 
mtDNA transmission. A first study on mtDNA copy number in oocytes, primordial-
germ-cells and non-germ-cells in zebrafish has been performed by our group, 
which revealed that the genetic bottleneck is a well-conserved process between 
different species and ranging from fish to man [21]. During embryogenesis the 
genetic bottleneck showed a depth of mtDNA copy number ~170 mtDNA 
molecules per primordial-germ-cell and ~50 mtDNA molecules in a non-germ-cell, 
which is in the range of what has been reported for mammals [21] and occurring 
at the same moment during development. Also, the large increase in mtDNA copy 
number during oogenesis is comparable validating further the relevance of using 
zebrafish for studying the human bottleneck.  The zebrafish seems to be a highly 
suitable model organism for these studies, as it is possible to isolate at low costs 
large amounts of primordial-germ-cells, oocytes, and early somatic cells, to 
characterize the complete mitochondrial bottleneck in early embryonic 
development [21, 22] and study the factors underlying this bottleneck by 
manipulating the possible factors involved.  
Aims and Thesis Outline 
Mitochondrial diseases result from a reduced energy production capacity in the 
mitochondria due to deficiencies in the oxidative phosphorylation (OXPHOS) 
system. These are characterized by highly heterogeneous and tissue-specific 
clinical manifestations, typically involving tissues with high energy requirements, 
like brain, heart and muscle. As the OXPHOS system is under dual genetic control, 
mutations in both the mitochondrial DNA and nuclear DNA can lead to 
mitochondrial disease. Mainly as a consequence of the large genetic heterogeneity 
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(possibly more than 1500 genes involved) and clinical variability, for the majority 
of patients a genetic cause was unknown at the start of the project. The first aim 
of this thesis was to identify and functionally characterize the underlying genetic 
cause in either the mtDNA or in nuclear genes in patients with OXPHOS disease 
and to prevent recurrence in the offspring. In case of nuclear gene mutations 
prenatal diagnosis or preimplantation diagnosis can be offered to prevent the 
recurrence of the mitochondrial disorder. However, in case of mtDNA disease this 
is more complex as the mitochondrial bottleneck defines how mtDNA mutations 
are being distributed. Therefore, the second aim of this thesis is to develop an 
animal model to study and manipulate the mitochondrial bottleneck. Zebrafish 
seems the best model to characterize the factors which define the transmission of 
mitochondria and the mitochondrial DNA. These 2 aims were split in the following 
objectives: 
1) To demonstrate the impact of next-generation sequencing on genetic testing 
2) To identify novel gene defects in patients with oxidative phosphorylation 
deficiency using next-generation sequencing and to characterize potentially 
disease-causing variants functionally in patient-derived or human cell lines  
3) To develop a zebrafish model, in which the mitochondrial bottleneck can be 
manipulated 
4) To study the effect of a low level of mtDNA copy-number on embryogenesis 
in zebrafish and characterize the underlying processes 
In Chapter 2, we present next-generation sequencing technology and discuss the 
impact it has on identifying causative variants, which can lead to a genetic 
diagnosis in a number of genetic diseases. The potential and limitations of 
different technologies and diagnostic approaches (targeted NGS, whole-exome 
sequencing, RNA-Seq and whole genome sequencing) are being discussed for 
different diseases. As NGS can detect all almost variants in the exome or genome, 
we explored as a proof-of-concept, if genetic modifiers or risk factors can be 
detected, which can explain differences in clinical severity among carriers of the 
same gene defect. Putative genetic risk modifiers were identified in the cancer 
syndrome, Lynch syndrome, by testing a panel of 154 candidate genes (Chapter 
3). A comparable approach can be applied to identify genetic modifiers in 
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mitochondrial diseases.  In Chapter 4 and 5 we applied whole-exome sequencing 
(WES) to identify the primary genetic cause in patients with mitochondrial 
diseases. The diagnosis was based on clinical symptoms, including MRI, and 
deficiencies in OXPHOS complexes in muscle and/or fibroblasts of the patients. 
Evidence for the pathogenicity or these novel variants in partly novel genes was 
provided by complementation assays. In 3 Moroccan families with Leigh syndrome 
we found the same genetic defect in a thiamine transporter gene (Chapter 4), 
resolving a new possible treatable cause of Leigh syndrome. In Chapter 5, we 
describe 3 families with paediatric, mitochondrial cardiomyopathy with early-onset 
brain disease and multiple OXPHOS deficiencies, having novel genetic defects and 
affected genes in mitochondrial-encoded translation proteins. In Chapter 6 we 
explore the role of a reduced mtDNA copy number by knocking down TFAM using 
morpholinos during early zebrafish development. The effect of a reduced mtDNA 
copy number on mitochondrial function and embryonic development was assessed 
and affected pathways were identified by transcriptomics. The general discussion 
(Chapter 7) discusses the impact of next-generation sequencing on the 
diagnostics of mitochondrial disease and the use of zebrafish for studying the 
mechanism of the genetic bottleneck. In Chapter 8, the valorisation chapter, we 
describe the rapid use of NGS, WES and WGS in the clinical practice, and the 
cases, in which identification of the gene-defect has enabled directly gene-based 
therapies.  
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1. Introduction 
Next-generation sequencing (NGS), also called massive parallel sequencing, has 
been developed in the last 2 decades and allows simultaneous sequencing of 
millions of DNA fragments without previous sequence knowledge. This advanced 
technology has been a revolution compared to traditional sequencing methods, in 
which one or a few relatively short fragments of DNA, previously amplified by 
Polymerase Chain Reaction (PCR), could be sequenced per reaction. Due to the 
high costs and intensive work required, traditional sequencing was only performed 
on specific DNA regions or genes and for specific samples. For instance, genetic 
screening for mutations, as in breast/ovarian cancer or Lynch syndrome, was not 
long ago based on first screening of PCR fragments for DNA hetero-duplexes, 
which indicated the presence of a DNA variant. Only the PCR fragments with such 
heteroduplexes would then be sequenced. The limited throughput can be 
exemplified by the duration of the Human Genome Project, which launched in 
1990, required 13 years and billions of dollars to sequence the complete human 
genome. With NGS, today a complete genome can currently be sequenced in a 
few days for less than $1000 per genome. The implications and the impact of NGS 
in characterizing genetic disorders, in understanding the biological processes of 
diseases like cancer and in personalising patient care are unprecedented. In this 
chapter, the major milestones in NGS technology and the technical developments 
and application of NGS in the field of diagnostics, classification, therapeutics, and 
pharmacogenetics will be briefly addressed. 
  
2. NGS—Next-Generation Sequencing Technology 
The Sanger DNA sequencing method, also named chain terminator sequencing, 
was developed in 1977. This method, which was later automated and modified, 
was the gold standard for sequencing until the late 2000’s [1]. In the first decade 
of this century, and number of different approaches for sequencing were 
developed, which evolved into commercially available NGS DNA sequencers. The 
first commercial NGS sequencer, based on pyrosequencing technology, was 
developed in 2004 by 454® and further commercialized  by Roche. Sequencing by 
synthesis (SBS) technology was developed by Solexa and further commercialized by 
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Illumina. Since then, speed and costs of NGS have decreased continuously, with 
a massive decline during the last eight years, and several NGS sequencers with 
different chemistries have been launched into the market (Figure 1). 
Figure 1. 1A) The Nationals Institutes of Health (NIH) reported in 2017 costs per raw 
megabase of DNA sequence and costs per genome. 1B) The pipeline illustrating the 
four major blocks   in next-generation sequencing (NGS) studies. Illumina® 1; Agilent 
Technology® 2;  Nimblegen® 3;  MIP: Molecular Inversion Probe 4, used to amplify in 
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large numbers short specific regions of DNA (SciTools®, Integrated DNA Technologies, 
Coralville, Iowa, U.S.);  ThermoFisher® 5;  Roche® 6;  PacBio®  7. Because of their recent 
development, information about the Qiagen GeneReader® and 10x Genomics® 
technology are not included in this figure. $ Users have reported up to 200,000 pb; * 
To detect low expressed transcripts, >2000× coverage is needed. 
Advantages of NGS sequencers are the high-throughput sequencing capacity of 
large or small genomic regions for many samples in parallel and the fact that they 
do not require previous knowledge of the genome per se. Nowadays, the use of 
NGS almost replaced conventional Sanger sequencing and is a very versatile 
approach for several clinical and non-clinical applications. 
2.1. NGS Technology, Historical Perspective and State-of-the-Art 
A thorough overview of the different NGS platforms and approaches (e.g., Illumina 
(Solexa)® , Oxford Nanopores®, PacBio® or Roche®  is available at the “Next-Gen-
Field-Guide” by Travis Glenn [2]. This synopsis was created in 2011, was last 
adapted in 2016, covering advantages, disadvantages, costs and overall 
performances of the different platforms. Current NGS technology can be divided 
in two major types, i.e., short- and long-read sequencing. For short-read 
sequencing Illumina® is market leader with cheap “sequencing by synthesis” 
(SBS) of reads shorter than 300 bp [3]. The ion semiconductor method (Ion 
Torrent®) is another cheap short-read sequencer [4]. For long-read sequencing 
PacBio® is market leader, involving more expensive “single molecule real-time” 
(SMRT) technology with half of the data in the reads being >50 Kb [5, 6]. The 
Oxford Nanopore Technologies® MinION, using single stranded pore technology, 
also allows to sequence very long molecules (>10 Kb) [7] and at a relatively low 
cost, but with a relatively higher error rate compared to PacBio.  
Short-read sequencing has the lowest costs per Gb and a very high accuracy (low 
final error-rate; 0.1 Kb), and has become the method most frequently used today. 
In contrast, long-read sequencing has a lower accuracy (high final error-rate; >1 
Kb) and a higher costs per Gb. Nevertheless, long-read sequencing presents 
unique advantages for a number of applications. It improves the alignment in the 
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bioinformatics pipeline (e.g., de novo assembly). It is also more suitable for 
familial haplotyping (allele phasing), for the detection of DNA and chromosomal 
structural variations, large chromosomal rearrangements, translocations, and 
repeat sequence and for the characterization of transcript-isoforms from RNA-Seq 
data, allowing the detection and frequency of alternative splice-events. Qiagen 
GeneReader® [8], 10x Genomics® technology [9] and Illumina NovaSeq® 
sequencer [3] represent the latest developments in NGS. Qiagen GeneReader® is 
a versatile system that provides the complete NGS pipeline from library 
preparation by PCR-based targeted exon enrichment to data analysis (see next 
paragraph) but can be coupled to other technologies and sequencers as well. The 
10x Genomics® technology coupled with Chromium System [9] facilitates the 
preparation of libraries suitable for multiple NGS platforms, linking reads into 
extra-long (synthetic) reads for analysis.  
2.2. NGS Strategies 
Different NGS approaches can be used according to the questions to be addressed. 
The initial input material can be genomic DNA (DNA-Seq), messenger or non-
coding RNA (RNA-Seq) or any nucleic/ribonucleic material obtained after specific 
procedures. It can be derived from large number of cells or even from single cells. 
The implementation of NGS technology can be visualised as four major blocks 
(Figure 1B). 
(A.) Libray preparation or sample processing. The material is first 
fragmented mechanically or enzymatically to yield fragments whose 
sizes are compatible with the sequencing technology used (small 
fragments of 200–300 nucleotides for short-read sequencing, longer 
for the long-read sequencing). This material can be enriched to 
analyse a limited number of genetic regions (e.g., disease gene-
panels or microbes [10]) or all coding exons of the human genome 
(approximately 21,000 genes, Whole-Exome-Sequencing, WES). 
These regions are called regions of interest (ROIs). The complete 
genomic DNA can also be sequenced (Whole-Genome-Sequencing, 
WGS),which does not require an enrichment step (see Section 2.2.3). 
An amplification step through PCR with 4–12 cycles is perfomed in 
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most cases. During this step, proper linkers and barcodes, which are 
unique nucleotide tags (6–8 nt), are attached to the DNA fragments, 
which are necessary to link the final sequence to a specific sample or 
individual. DNA barcodes allow pooling of samples together in one 
single flowcell for the sequencing reaction. 
(B.) Sequencing. Most common sequencers have been extensively 
described [2-7] and Figure 1B summarises a few characteristics that 
distinguish them. A review on the different sequencing chemistries 
can be found elsewhere [11]. 
(C.) Initial quality and raw data analyses. General read quality is assessed 
with FastQC [12]. Many pre-processing tools are available for removal 
of bad quality reads, trimming, etc. After mapping, specificity is 
determined, i.e., the fraction (%) of the total number of predefined 
ROIs, which are correctly enriched and sequenced. 
(D.) Variant calling and data interpretation. This last step is dependent on 
the specific application. In this chapter, some methods and 
bioinformatics tools relevant to data interpretation will be presented. 
 
As the focus of the NGS work in this thesis is on detecting pathological variants 
in genes, I will concentrate on strategies to identify these variants. 
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2.2.1. Gene-Panels 
For clinical applications, the use of gene-panels to sequence only a limited number 
of genes of interest has been the first method of choice, because of its cost-
efficiency, its high coverage of the ROIs and its simplicity in the data analyses 
[13]. It also prevents the identification of unsolicited findings, but, as a drawback, 
it will not allow the identification of novel genes. When the number of genes 
sequenced is restricted to the few already analysed in previous diagnostic tests 
using traditional methods, this is normally called targeted re-sequencing.  
Different protocols are available to design and capture panels of genes and other 
ROIs. In most cases, companies providing library preparation kits, offer online 
tools to design the hybridisation probes or the PCR oligos to enrich the desired 
ROIs. Enrichment can be obtained via solid phase hybridisation, in-solution 
hybridisation (most frequently used) or PCR-based enrichment and can be 
followed by amplification via multiplex PCR, rolling-circle amplification (HaloPlex®) 
or amplicon-based-microdroplet-PCR (RainDance® technology) [14]. The latter 
presents the advantage of simultaneously amplifying a large number of targeted 
regions into separate micro drops, thus keeping each amplification separate from 
the others and limiting the disturbance due to primer pair interactions. A cheap 
and flexible method to capture small regions of the genome for NGS analyses is 
the Molecular Inversion Probe (MIP) [15].  
After sequencing, the analysis of raw data is relatively simple [13]. Due to the 
high coverage per nucleotide, the specificity is high and only particular DNA 
regions may be captured inefficiently (due to high GC nucleotide content, for 
instance). Normally, sequencing depth of around 80× is sufficient to detect 
germline variants that are present in a homo- or heterozygous status. In case of 
somatic mutations, a higher coverage is required (>500) since mutations are 
usually present at low levels. 
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2.2.2. WES—Whole-Exome-Sequencing  
Protocols/kits to enrich the library for all exons are available from several 
companies and use the same or similar technologies as mentioned for the 
enrichment of gene-panels. Following sequencing, raw data analysis is performed 
to determine the quality of the sequencing data, checking for issues that may 
have occurred at the level of library preparation and/or sequencing. Both steps 
are crucial to obtain good quality data. A high sequence-on-target yield of more 
than 90% of the ROIs and coverage higher than 20× per nucleotide is necessary 
for sufficient specificity and sensitivity in heterozygous mutation detection. 
Normally, when less than 90% of the ROIs are sequenced but coverage is high, 
sample processing was suboptimal; when the ROIs are sufficiently sequenced 
(>90%) but coverage is low, then the sequencing reaction was suboptimal and 
re-sequencing is required [16, 17]. 
2.2.3. WGS—Whole-Genome-Sequencing 
The holy grail of NGS is obviously whole genome sequencing in order to identify 
all variants present. WGS, or RNA-Seq (see below), are logical follow-up steps, in 
case WES did not reveal a causative variant in families with a high probability of 
carrying a genetic mutation. The major technical advantage of WGS is that the 
library preparation does not require any enrichment or amplification and the 
specificity is theoretically 100% (achieving around 95%–98% in practice) with a 
uniform coverage throughout the input material. Therefore, the possibility to miss 
a disease-causing variant (or any other information) for technical reasons such as 
inefficient probe targeted enrichment, inefficient amplification of a specific ROI or 
PCR amplification artefacts do not apply to WGS [18-20]. However, not a single 
technique can detect all variants in the entire genome and for true complete 
genome analysis, hybrid sequencing using both short-read and long-read 
sequencing is required. 
The most important obstacles in applying WGS on a routine scale are the high 
costs, the complex pipeline for data analyses and data interpretation. However, 
the more the costs of NGS decrease, bioinformatics tools improve and our 
understanding of the function of the non-coding part of the genome increases 
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(also via the development of novel functional assays), the more this approach will 
be implemented. It is foreseeable that in the near future WGS will be performed 
routinely for every diagnostic question as a generic test and ROIs will be 
subsequently selected ad-hoc in silico for each specific application from the raw 
data, in order to find the causative genetic variants [21]. As WGS enables to 
detect chromosomal abnormalities and pathogenic intronic variants it increases 
the number of diagnoses in selected cohorts to 10-35% [20, 21].  
2.2.4 Identification of Disease-Causing Variants using RNA-Seq or Transcriptomics  
Splicing, the process of removal of the introns in the pre-mRNA molecule, is highly 
regulated by the RNA-splicing machinery and depends on specific genetic 
sequences to mark intron/exon junctions. Additionally, epigenetic factors 
(chromatin conformation and histone modifications) have also been implicated in 
the regulation of splicing [22]. Incorrect splicing, which occurs due to the presence 
of genetic variants, mostly in intronic regions, has been implicated as a cause of 
genetic disease, including hereditary cancer syndromes [23-28]. Targeted-
sequencing or WES analysis is mainly limited to the protein-coding region (exons) 
of the genome and to a few intronic nucleotides, which are the most conserved 
splice sites adjacent to the exon, and do not cover the remaining of the introns, 
promoter regions and non-coding RNAs, which are important for gene-expression 
regulation. In addition, computer-based tools and pipeline analyses are less 
accurate in predicting the effect of DNA-variants on gene-expression or RNA 
splicing. Therefore, mutations with a potentially pathogenic effect on RNA 
expression or processing are either not included in the regions of interest during 
WES sequencing or are missed by bioinformatics analysis [29-33]. Sequencing 
the transcriptome by RNA-Seq is therefore a valuable approach to detect variants 
affecting RNA amounts, including mutations in transcription binding sites or 
promotors, or splicing in tissues where the gene is expressed. RNA-Seq allows the 
analysis of the transcriptome at an unprecedented depth [34-37]. Similar to WGS 
and unlike Sanger sequencing, it does not depend on previously known sequences, 
which is of particular relevance when studying the mRNA and its alternative 
splicing events. RNA-Seq can be performed with short-read and long read, single 
molecule sequencers, with the long-read sequencers having the advantage to 
sequence entire RNA molecules covering all variants and splice events (described 
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in Section 2). Combining RNA-Seq with WGS protocols and integrated analyses will 
also aid identification of RNA-editing events and will increase the chance of finding 
the causative DNA variant. RNA-Seq also has some limitations. RNA is less stable 
than DNA and requires higher care in handling and storage of the samples. In 
addition, RNA expression (and processing) is tissue-dependent and the tissue 
available for analysis may not express the gene with the defect.  A number of 
studies has shown the benefit of RNA-Seq in screening splice variants in inherited 
diseases so far. Recently, a publication reported the success of transcriptome 
sequencing to increase mutation-detection rate in undiagnosed mitochondrial 
disorders [38]. This resulted in the identification of causative, non-exonic 
regulatory variants in an additional 10% of patients. One should realize that by 
RNA-Seq only the genes are analysed, which are expressed in the tissue of 
investigation, which might affect the success rate for specific diseases. For 
example, in fibroblasts 2574 (68%) of the 3768 known disease genes reported in 
OMIM are expressed, which include most of the mitochondrial genes. Currently, 
the diagnostic WES -yield varies from 25-50% for rare muscular disorders [39], 
and 39%-69% for mitochondrial disorders [38, 40]. In the 2 papers described 
RNA-Seq-yield adds a 35% for rare muscular disorders [39], and 10% for 
mitochondrial disorders [38].  
 
2.3. Data Analyses and Interpretation 
After raw data analysis has demonstrated sufficient quality, data analyses and 
interpretation needs different pipelines depending on the approach (gene-panel, 
WES, WGS or RNA-Seq) and on the questions to be answered. Figure 2 illustrates 
briefly the major steps for DNA-Seq used in genetic diagnostics to interpret data 
obtained from an Illumina® platform, but which is comparable to other platforms 
used. 
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Figure 2. Data interpretation pipeline. Example of DNA-Seq Bioinformatics Pipeline for 
Illumina®. 1 This step removes duplicate sequences using the Picard program; 2 GATK: 
Genome Analysis ToolKit.
Base-calling is performed using software like the Casava pipeline that produces 
Fast-Q files (raw-initial data), which can then be aligned to the human reference 
genome using Burrows-Wheeler-Alignment tool (BWA). Single base variants can 
be identified using Sequence-Alignment-MAP tools (SAM) and annotated. 
Additional software and scripts match the data from NGS analysis to variants in 
reference databases (RefGene, dbSNP and UCSC genome browser [21]), in order 
to identify variants already annotated and identify new variants present in the 
NGS sample.  This ultimately generates the “variant table” (Figure 2) that 
contains a list of all identified variants with, if available, information compiled from 
other databases such as allele frequency, pathogenicity scores, conservation and 
literature references.
For identifying the genetic cause of a disease in a patient or in a family, the goal 
is to assign clinical significance to the variants identified. Several databases (OMIM
[41], LOVD [42], ClinVar [43]), catalogue known variants with respect to their 
pathogenicity, but for unknown variants pathogenicity has to be determined. A 
variety of tools is available that can be used to predict their effect at the protein 
level, protein activity, RNA splicing and ultimately help assess the presence of 
protein damaging alterations (Alamut, Polyphen, Sift). This analytical process can 
be performed manually for each variant or can be automated. Several guidelines 
are available to assist such classification [44]. The ultimate proof of the 
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pathogenicity of a variant may be functional characterization (or any other genetic 
diseases), requiring specific functional assays (in vitro, in vivo) and/or co-
segregation studies of the variant with the disease among relatives. Similar 
considerations and sorts of analyses apply to studying and deciphering the effects 
of somatic mutations occurring in cancer. 
 
2.4. Conclusions 
Different methods and technologies are currently available to identify the genetic 
cause of diseases, with NGS becoming the prime diagnostic test. NGS has brought 
unprecedented advances in understanding the biology of diseases, with important 
clinical implications. The costs of short-read sequencing have become extremely 
low. Nowadays, WES/WGS (yield 50-60%) and RNA-Seq (yield 35-10%) are 
becoming routine in clinical practice for heterogeneous genetic disorders, but the 
eventual step in diagnostics in the years to come will be WGS/RNA-Seq by short-
read sequencing and later by hybrid sequencing, involving long-read sequencing 
for structural variants and repeat sequences. Technical and bioinformatical 
advances make NGS technology increasingly more powerful. It is crucial that these 
progresses are accompanied by increasing awareness of its strong potential by 
physicians and patients. It is also of fundamental importance that the progress is 
paralleled by strict monitoring the use of these technologies in relation to ethical 
issues, especially as NGS will in future not only be performed to identify the cause 
of disease, but also in the form of the personal genome to guide the life of a healthy 
person. Unfortunately, despite all significant improvements in the diagnosis of 
genetic diseases, the knowledge of the genetic cause has only limitedly led to the 
development of novel, effective therapies, which will be the challenge for the years 
to come. 
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Abstract 
Background: The risk to develop colorectal and endometrial cancers among 
subjects testing positive for a pathogenic Lynch syndrome mutation varies, 
making the risk prediction difficult. Genetic risk modifiers alter the risk conferred 
by inherited Lynch syndrome mutations, and their identification can improve 
genetic counseling. We aimed at identifying rare genetic modifiers of the risk of 
Lynch syndrome endometrial cancer. 
Methods: A family based approach was used to assess the presence of genetic 
risk modifiers among 35 Lynch syndrome mutation carriers having either a poor 
clinical phenotype (early age of endometrial cancer diagnosis or multiple cancers) 
or a neutral clinical phenotype. Putative genetic risk modifiers were identified by 
Next Generation Sequencing among a panel of 154 genes involved in endometrial 
physiology and carcinogenesis. 
Results: A simple pipeline, based on an allele frequency lower than 0.001 and on 
predicted non-conservative amino-acid substitutions returned 54 variants that 
were considered putative risk modifiers. The presence of two or more risk 
modifying variants in women carrying a pathogenic Lynch syndrome mutation was 
associated with a poor clinical phenotype. 
Conclusion: A gene-panel is proposed that comprehends genes that can carry 
variants with putative modifying effects on the risk of Lynch syndrome 
endometrial cancer. Validation in further studies is warranted before considering 
the possible use of this tool in genetic counseling. 
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Introduction 
Lynch Syndrome is caused by mutations in one out of four mismatch repair (MMR) 
genes - MLH1, MSH2, MSH6 and PMS2 - and results in a 25% to 75% lifetime risk 
of colorectal cancer and 60% risk of endometrial cancer in women [1]. 
 
Genetic testing helps estimating the individual risk, plan appropriate care, 
screening and prophylactic treatments. Nevertheless, the risk to develop cancer 
conferred by a MMR mutation is modified by both the environment and genetic 
risk modifiers. The identification of such genetic risk modifiers can improve risk 
prediction and genetic counseling, through the individualization of surveillance 
programs and the evaluation of benefits versus burdens associated with 
prophylactic strategies [1, 2]. 
 
Searching for genetic risk modifiers is a challenge due to their expected small 
effect-size and their non-pathogenicity in the absence of a pathogenic mutation 
[2-4]. Genome-wide-association studies have identified loci and single nucleotide 
polymorphisms (SNPs) with risk modifying effects [5-8]. More recently, Next 
Generation Sequencing (NGS) of the whole genome or combined with gene-panels 
is emerging in genetic diagnostic to detect germ-line variants predisposing to 
cancer [4, 9-11]. 
 
Here, NGS combined with a 154 gene-panel was used to identify rare variants 
(minor allele frequency, MAF, <0.001) acting as gene-modifiers of Lynch 
syndrome MMR mutations. Unlike cancer somatic mutations, which map 
exclusively on tumor suppressors and oncogenes, the carcinogenic effect of germ-
line variants can be indirect [2, 4, 11], hence they can map within but also outside 
the genes classically associated with cancer. A defect in the genome stability 
conferred by a Lynch syndrome MMR mutation can be aggravated by disturbed 
tissue homeostasis. Therefore, as proof of principle for Lynch syndrome related 
endometrial cancer, a panel that included genes controlling the endometrial 
physiology and homeostasis (i.e. hormone signaling) beside those associated with 
cancer was complied. A family based approach was used: the presence of 
candidate genetic risk modifiers was evaluated among 35 patients carrying 
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already a MMR mutation and characterized by either a poor clinical phenotype 
(early age of diagnosis or the diagnosis of multiple cancers) or by a neutral clinical 
outcome (diagnosis with endometrial cancer only and late in life). 
 
Results 
Patients 
Table 1 shows the clinical features of the women enrolled. All were diagnosed 
with endometrial cancer between 31–81 years (mean: 53.1 ± 10.7). Subjects 
belonged to 29 families with a Lynch syndrome mismatch repair (MMR) pathogenic 
mutation, and all women carried the mutation. These mutations will be referred 
to as ‘familial MMR mutations’ (Table 1). One familial MMR mutation 
in MSH6 (c.3729_3732dupATTA – p.(Phe1245Ilefs*31)) was a founder mutation 
common to nine subjects belonging to six families. 
Eleven women were diagnosed with a second Lynch syndrome tumor (two in the 
breast, six in the intestine, three in the ovaries). One woman developed colorectal 
and urinary tract cancers and one was diagnosed twice with colorectal cancer (14 
years apart). Additionally, 14 women developed endometrial cancer at the age of 
49 or earlier. In the following analyses, women diagnosed with more than one 
cancer, or with endometrial cancer before 50 (49 or younger) are defined as 
patients with poor clinical phenotypes (or outcome, n = 23), whereas 14 patients 
who developed only endometrial cancer and after the age of 50 are defined as 
having a neutral clinical phenotype. 
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Estrogen and Cancer related 154 Gene-panel 
The coding sequences and splice regions (10 non-coding nucleotides at each exon 
end) of 154 genes implied in endometrial physiology and carcinogenesis were 
explored by Next Generation Sequencing (NGS). Table 2 overviews the captured 
panel and Supplemental Table S1 gives the complete list of genes and the full set 
of related references. 
 
 
Table 2: Overview of the panel design of 154 estrogen and cancer associated 
genes with the variants identified in 35 subjects analysed 
 
 
Capture plan 
Variants identified 
Total dbSNP deposited* non-dbSNP deposited 
No of 
genes nt (Kb) No 
Missense 
+ non-
sense Silent 
Intron-
exon 
Missense + 
non-sense 
+ ins/del Silent 
Intron-
exon 
ESTROGEN 47 101.407 25 9 4 0 11 0 1 
ligand 
metabolism 
10 13.501 3 0 0 0 3 0 0 
target genes 24 46.847 12 6 2 0 3 0 1 
responsive   
genes 
7 10.539 1 0 0 0 1 0 0 
co-regulators 6 30.52 9 3 2 0 4 0 0 
ONCOGENES 35 112.56 24 3 5 2 8 6 0 
TUMOUR 
SUPPRESS 
63 162.306 40 17 9 0 8 4 2 
OTHER 9 19.395 9 0 3 0 5 0 1 
TOTAL 154 395.668 98 29 21 2 32 10 4 
*Variants deposited in the dbSNP database with MAF <0.001. 
The list of all variants is given in Supplemental Table S3. 
 
Estrogens are important physiological regulators in the endometrium and risk 
factors for cancer [12]. Hence, the capture panel included 47 genes involved in 
estrogen (and progesterone) signaling, comprising genes controlling the 
metabolism and degradation of steroids [12], genes directly targeted by the 
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hormone receptors [13-15], genes responsive to steroids [14, 16] and genes 
encoding for co-regulators controlling the hormone receptor transcriptional 
activity [13-15]. In addition, 35 oncogenes and 63 tumor suppressors were 
captured [10, 17-19]. NGS and Quality Control analyses are described as 
Supplemental Materials (Supplemental Methods, Supplemental Figures S1, 2 and 
Supplemental Table S2). Thirty-seven DNA samples were sequenced but two were 
excluded due to low quality (12–04-079_22 and 12–04-079_25, Supplemental 
Materials and Table 1). As control of NGS and raw data analyses, two samples 
(12–04-079_6 and 12–04-079_15) were randomly selected and subjected to one 
additional and independent library preparation and NGS run and they showed 
100% concordance between called variants. 
Variant Analyses 
Among the 35 patient’s DNA successfully sequenced, 865 independent variants 
deposited in dbSNP database were identified and each subject carried on average 
245 single nucleotide polymorphisms (SNPs; range 207–270). Common SNPs 
were excluded from further analyses, but since rare dbSNP variants can be 
relevant in our search for genetic risk modifiers [20, 21], 52 variants with a minor 
allele frequency (MAF) lower than 0.001 were retrieved (Table 2). Of these, 28 
were missense, one non-sense (stop), 21 were silent and two located in non-
coding intron/exon boundaries. In addition, 46 identified variants were not 
reported in dbSNP, and 34 of these were never deposited before in any database 
(ExAC, Cosmic, LOVD and HGMD were checked; Table 2). Twenty-nine missense, 
one frame-shift non-sense, one in frame deletion and one in frame insertion of 
one amino-acid were identified plus 10 silent variants and four changes located in 
the non-coding regions flanking an exon (Table 2). 
 
In total, 98 rare variants were identified (dbSNP with MAF <0.001 and non-dbSNP 
deposited). Considering only variants affecting the amino-acid sequence, there 
were 57 missense, one amino-acid insertion, one deletion (both in-frame) and two 
non-sense changes. All variants were heterozygous (Supplemental Table S3). 
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Putatively Genetic Risk Modifiers: Risk-Variants 
To predict the functional consequences and potential risk modifying effects, 
variants were curated using defined criteria [20-22], literature, controlling 
manually and in combination with bioinformatics tools such as: Alamut (version 
2.4, Interactive Biosoftware, including SIFT and PolyPhen-2), Uniprot, 
PhosphoSitePlus® (for three-dimensional structure and post-translational 
modifications) [23], NCBI Clinical Variants, ExAC, NHLBI ESP, LOVD, HGMD, 
Cosmic. 
 
Variants outside the MMR genes were analysed first. The 98 rare variants reported 
earlier were considered plus three SNPs with a MAF ≥ 0.001 previously reported 
as pathogenic or disease related. These were: rs57865060, chromosome position 
Chr15:75012998:delT, with predicted protein change CYP1B1:p.(Glu229Lys); 
rs121918303, Chr13:32351535:A > C with predicted protein change 
RXFP2:p.(Thr222Pro); rs56378716, Chr17:56356502: A > G, with predicted 
protein change MPO:p.(Met251Thr). 
 
The resulting 101 variants (Supplemental Table S3) were categorized in five 
groups according to the recommendations of the Dutch and British societies for 
clinical genetics [21]: categories 1 and 2 = no effect; 3 = variants of unknown 
significance – VUS; 4 = likely pathogenic; 5 = pathogenic. Silent and non-coding 
variants were categorized as 1 (none was predicted to affect splicing or other 
regulatory functions). Conservative amino acid changes were considered unlikely 
to affect the protein function (category 2), with the exclusion of four variants that 
had been associated with disease or were predicted to have damaging effects 
(Alamut prediction tool), which were categorized as 3. The remaining class 3 
variants were all non-conservative protein changes. Eight variants were in 
category 4, four of which were pathogenic (class 5) for disorders other than 
endometrial cancer, hence they were considered as class 4 in the present study. 
Two independent investigators (RA and BMJ, of which BMJ is a Clinical Laboratory 
Geneticist with expertise in diagnostics and oncogenetics) performed this curation 
blindly for each other’s results. Supplemental Table S3 gives the curation details 
and the complete variant list. 
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Since genetic risk modifiers have modest effects (see discussion), all variants 
categorized as 3 (provided the presence of a non-conservative amino-acid 
substitution) or higher were considered and resulted in 54 candidate risk-
modifiers. Such variants, referred to as ‘risk-variants’ from now on, were further 
characterized for the following features (Supplemental Table S3): i) the presence 
of cancer somatic (not silent) mutations in the same protein region (i.e. max +/−3 
amino acids from the identified risk-variant; Cosmic database). This was 
considered as an indication that changes in the specific protein region could affect 
function and predisposition to cancer; ii) the interspecies protein domain 
conservation; iii) the presence of the same risk-variant among relatives; iv) the 
occurrence of the risk-variant in relevant protein domains; v) the predicted 
consequences based on Alamut, protein in silico analysis, literature mining or the 
occurrence of other pathogenic variants/SNPs in the same region; vi) we excluded 
that risk-variants could co-segregate with the familial MMR mutation by verifying 
their localization on separate chromosomes (Supplemental Table S3). 
 
The majority of the patients carried one (or more) risk-variant in estrogen related 
genes (19 out of 35 patients, 54%) and 18 risk-variants were unique (i.e. the 
same variants occurring in relatives were counted only once: n = 5). Risk-variants 
in tumor suppressors were observed in 18 patients (49%), and 25 were unique. 
One (or more) oncogene contained nucleotide changes in nine patients (26%), 
and nine were unique. 
 
MMR genes also contained three risk-variants beside the familial mutation and 
these have not been computed in the list of 101 variants given so far (Figure 
1A). Two variants, one in PMS2 -rs116788608, Chr7:6035211:T > C, with 
predicted protein change PMS2:p.(Asp286Gly)- and the second in MSH2 - 
rs41295288, Chr2:47702191:A > G with predicted p.(Asp596Ser)- were on other 
chromosomes than the familial MMR mutation (MSH6) of these subjects. In 
contrast, MSH6 variant with predicted protein change p.(Ala25Ser) 
(rs267608026, Chr2:48010445:G > T) in patient 12–04-079_32 could co-
segregate with the MSH6 familial mutation carried by this subject. Besides these 
three risk-variants, three additional variants in MMR genes with MAF < 0.001 were 
classified in category 2 (Figure 1A).  
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Figure 1: The number of class 3 (or more) risk-variants correlates with poor clinical 
phenotypes. A. Heat map showing the presence of class 3 (or more) risk-variants in each 
subject with neutral phenotype (green, N) or with a poor phenotype (orange, poor; Y = 
young age of endometrial cancer diagnosis; M = cancer at multiple sites). The familial MMR 
mutations (all non-sense but the one carried by subject 12–04-079_38) are indicated 
(3rd column). ‘Additional MRR variants’ (4th column) reports the six rare variants (MAF < 
0.001) found in MMR genes among seven subjects. In particular, MSH6:p.(Arg378Lys) in 
subject 12–04-079_10 has been already described to be in linkage with the familial 
MSH6:p.(Arg482*) mutation detected in the patient [24]. ‘Total’ (5th column) refers to the 
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total number of risk-variants outside the MMR genes identified in each patient. The specific 
risk-variants are reported at the right as gene name and predicted amino-acid change (for 
full chromosomal coordinates/nucleotide change, see Supplemental Table S3), together with 
a color code that indicates the gene function. Variants previously reported as (likely) 
pathogenic (categories 4 and 5) are labeled with a starred ‘P’. B. Kaplan-Meier curves 
showing the occurrence of any poor-clinical phenotype feature (Top chart; first events were 
only considered for statistic), of the diagnosis of endometrial cancer before 50 (Middle 
chart), or of the occurrence of a second tumor (Bottom chart; first events were only 
considered for statistic) in subjects carrying a maximum of one risk-variant (indicated as 
RV) compared to subjects carrying two or more risk-variants outside the MMR gene. The 
statistical p for significance is computed by Log Rank (Mantel-Cox, Test of equality of survival 
distributions for the different levels of risk-variants; SPSS). 
Risk-variants are Associated with Poor Clinical Phenotypes 
The distribution of MMR pathogenic mutations did not vary between women with 
poor and neutral clinical phenotypes (Table 3), but patients with poor clinical 
phenotypes carried more frequently one or more risk-variants outside the MMR 
genes compared with women with a neutral phenotype (Table 3 and Figure 1A). 
 
Table 3: distribution of familial MMR mutations and risk-variants outside the MMR 
genes (class-3 or more, i.e. putatively risk modifiers) among patients with neutral 
and poor clinical phenotypes 
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Total 
subjects 
Neutral tumor 
phenotype 
Poor tumor 
phenotype 
 
No. No. p-value 
14** 23** 
 
Lifespan* 64.2 ± 6.0 66.8 ± 14.1 ns# 
FAMILIAL MMR MUTATIONS 
 No. % No. % p-value 
MLH1 0 0.0 3 13.6 
ns##* 
MSH2 2 15.4 6 27.3 
MSH6 12 92.3 12 54.5 
PMS2 0 0.0 2 9.1 
PRESENCE OF ADDITIONAL 
RISK-VARIANTS*** 
no variant 5 38.5 2 9.1 
0.0471##@ 
one 
variant 
6 46.2 4 18.2 
two 
variants 
1 7.7 5 22.7 
three 
variants 
1 7.7 8 36.4 
four 
variants 
0 0.0 2 9.1 
five 
variants 
0 0.0 1 4.5 
0 or 1 
variant 
11 84.6 6 27.3 
0.0016### 
2 or more 
var. 
2 15.4 16 72.7 
*age of subjects in 2013 was used as lifespan (mean age ± standard deviation in years). 
**13 and 22 subjects were successfully analysed by NGS. 
***risk-variants, i.e. class-3 or higher, in genes other than the MMR were considered. 
#T-test to compare mean values. 
##*Chi square, with 3 degrees of freedom. 
##@Chi square, with 5 degrees of freedom, Pearson’s: 11.225. 
###Fisher exact test, two sided p-value. 
ns = non-significant. 
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Cox-regression analysis confirmed that increasing number of risk-variants was 
associated with a poor clinical phenotype (Supplemental Figure S3). In these 
Kaplan-Meier analyses the curves of subjects with no or one risk-variant overlap 
with each other and are separated from the curves of subjects with two, three or 
more than four risk-variants. Table 3 (rows at the bottom) also shows a highest 
statistical significance by combining these two groups. Because of this net 
distinction between subjects carrying no or one risk-variant versus women 
carrying more than two risk-variants, in subsequent Kaplan-Meier cox-regression 
analyses we combined patients in these two groups (Figure 1B). The presence of 
two or more risk-variants beside the familial MMR mutation was associated with 
the occurrence of poor clinical features. As defined earlier, poor clinical features 
were either a diagnosis of endometrial cancer at a young age (<50), or the onset 
of multiple cancers. Subsequently, these two characteristics were assessed 
separately and the presence of two or more risk-variants was associated with both 
(Figure 1B). The lifespan among patients with neutral and poor clinical 
phenotypes, extrapolated at 2013 (the date of last update of our database), did 
not vary significantly between groups (Table 3, Figure 1B and Supplemental 
Figure S3). 
To exclude that multiple risk-variants could co-occur because of co-segregation, 
we verified that all risk-variants in one subject were located on separate 
chromosomes. This was confirmed for 16 out of the 18 subjects. Subject 12–04-
079_14 carried risk-variants Chr5:112179368:A > G (APC:p.(Asn2693Asp)) and 
Chr5:131915673:G > A (RAD50:p.(Arg224His)) both on chromosome 5 (at a 
distance of about 90 Mb). A second patient (12–04-079_13) carried two risk-
variants in the same gene (NOTCH1). Results did not change by considering these 
four risk-variants as two co-segregating haplotypes. 
 
Three possible risk-variants (category 3 or higher) were identified in MMR genes 
(grey shaded in Figure 1A), which were not considered in the aforementioned 
analyses because a linkage with the MMR familial mutation could not be excluded. 
Nevertheless, when these risk-variants were included, results did not change. In 
fact, two risk-variants that lied certainly in other chromosomes than the MMR 
familial mutation – Chr7:6035211:T > C, predicted protein change 
PMS2:p.(Asp286Gly) and Chr2:47702191:A > G with predicted 
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MSH2:p(Asp596Ser)- occurred in patients with a poor clinical phenotype, whereas 
risk-variant Chr2:48010445:G > T, with predicted change MSH6:p.(Ala25Ser), 
which could be in linkage with the familial mutation, occurred in subject 12–04-
079_32 having a neutral clinical phenotype. 
 
Among 15 subjects there were some 1st and 2nd degree parental relationships and 
they belonged to 7 families. Among the five families in which members had distinct 
neutral or poor clinical phenotypes, there were three families (A, E and F) in which 
the woman with poor phenotype carried two or more risk-variants and carried 
more risk-variants than the relative with a neutral phenotype (Supplemental 
Figure S4). In family B, both members carried three risk-variants but the woman 
with neutral phenotype was significantly younger than the women with poor 
phenotype, and the occurrence of a poor phenotype later in life cannot be 
excluded. 
Protein Characterization in Tumors 
Immunohistochemistry was used to further characterize the protein expression in 
a limited number of endometrial tumor specimens carrying the risk-variants 
(formalin-fixed-paraffin-embedded, FFPE). Risk-variants and relative predicted 
protein change were: Chr10:43604498:C > A, with predicted protein change 
RET:p.(Asn361Lys); Chr15:75012998:delT, CYP1A1:p.(Cys457*); Chr15: 
99465448:C > T, IGF1R:p.(Thr758Met), Chr12:124821523:G > C, 
NCOR2:p.(Ser1964Cys); Chr22: 19951274:delAAG, COMT:p.(Lys159del); 
Chr1:11264 625:T > G, mTOR:p.(Met1313Leu). We will refer from now on to 
these risk-variants using their predicted protein changes. Results on protein 
expression in the Lynch tumors were compared with a panel of sporadic 
endometrial cancers (n = 7) and post-menopausal healthy controls (n = 5). The 
presence of the risk-variant-allele in the Lynch tumors was confirmed by Sanger 
sequence analyses in 12 samples and none showed loss of heterozygosity (LOH, 
listed in Supplemental Table S4). 
 
Since we found a substantial number or risk-variants mapping in the estrogen 
signaling, the expression levels of the estrogen receptor (ER-α) and the Ser-167-
phosphorylated form, induced by growth factors (including mTOR, IGF1R and RET) 
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and associated with ligand-independent activation [25-27], were assessed. ER-α 
and phospho-Ser-167-ER-α levels varied between samples, with highest 
expression in non-cancerous endometrium (both from healthy controls and normal 
tissues adjacent to cancer cells, i.e. peri-tumoural tissue), intermediate levels in 
well-differentiated cancers and lowest levels in high-grade lesions (Supplemental 
Figure S5). The expression of NCOR2, CYP1A1 and COMT, involved in the estrogen 
signaling (see discussion), and the oncogenes mTOR, RET and IGF1R was high in 
normal and cancerous endometrium and varied between samples (Figure 2 and 
Supplemental Figures S5 and S6). 
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Figure 2: Aberrant expression or localization of RET, CYP1A1 and IGF1R in specimens 
carrying the respective risk-variants. A. Immunohistochemical images of tumors bearing the 
common allele (WT) of RET or the risk-variant RET:p.(Asn631Lys). Note the punctuated 
cytoplasmic pattern in the risk-variant carrying tumor indicative of trapping of the receptor 
inside the cell. Scale bar = 100 μm. B. Immunohistochemical images of endometrial 
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specimens bearing the common allele (WT) of CYP1A1 (control post-menopausal 
endometrium and Lynch syndrome endometrial cancer: left images). Right images, CYP1A1 
expression on tumor specimen bearing the p.(Cys457*) risk-variant, showing one area with 
loss of expression (arrowhead). Scale bar = 100 μm. C. Canonical consensus and the five 
glycosylation sequences (glycosylation site indicated by red asterisk) in the IGF1R plus the 
consequent disruption of this consensus caused by risk-variant 
IGF1R:p.(Thr768Met). D. Immunohistochemical images of tumor specimens with common 
allele (WT) of IGF1R or with risk-variant p.(Thr758Met). Scale bar = 100 
μm. E. Representative confocal laser scanning microscopic (CLSM) images and fluorescence 
quantification of the membrane/cytoplasmic fractions of IGF1R in tumor with common allele 
or with p.(Thr758Met) IGF1R. The box plot represents the distribution of four independent 
samples for common allele and four areas of sample 12–04-079–23 [carrying the 
p.(Thr758Met) risk-variant]. Asterisk indicates a p-value < 0.05, Wilcoxon-Mann-Whitney 
Rank Sum Test. F. Representative immunohistochemical images (top) and quantification of 
the percentage of nuclei positive to phospho-Ser-167-ER-α among endometrial cancer with 
wild type IGF1R (the grey bar indicates the mean ± SD of seven Lynch syndrome tumor 
specimens) and with IFG1R:p.(Thr758Met) (black bar, mean ± SD of four independent areas 
of the tumor from subject 12–04-079–23, bearing the variant). Asterisk indicates a p-value 
< 0.05 compared to common allele (t-test). Scale bar = 100 μm. 
The identified risk-variant p.(Asn361Lys) in the RET tyrosine kinase receptor has 
been previously described in Hirschsprung disease. Asn361 is a N-linked 
glycosylation site necessary for correct membrane localization of the receptor and 
mutated RET remains trapped in the endoplasmic reticulum [28]. 
Immunohistochemistry on sample 12–04-079_7, carrying RET:p.(Asn361Lys), 
clearly shows an aberrant RET cytoplasmic localization compared with controls 
where RET is located at the plasma membrane (Figure 2A). 
 
The frame-shift change in CYP1A1 at position 457 is predicted to replace the 
cysteine heme-binding site [29] with a stop codon thus disrupting the catalytic 
site and causing premature protein termination. Partial and localized loss of 
CYP1A1 expression was observed in the tumor carrying this risk-variant (Figure 
2B). 
 
Risk-variant p.(Thr758Met) in the tyrosine kinase receptor IGF1R is predicted to 
abolish the N-linked glycosylation at residue Asn756 (Figure 2C). Glycosylation 
is needed for correct receptor processing, membrane localization and signal 
transduction [30]. Specimen 12–04-079_23 carrying this risk-variant showed a 
decreased membrane immuno-localization of the IGF1R (Figure 2D), which was 
confirmed with confocal laser scanning microscopy (CLSM; Figure 2E). This 
observation was concomitant with the highest percentage of phospho-Ser-167-
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ER-α staining (Figure 2F), one of the downstream target of the IGF1R kinase 
activity, suggestive of a sustained intracellular activation. 
 
Discussion 
Genome-wide approaches [5, 6, 31]have identified modifiers of the cancer risk 
conferred by pathogenic Lynch syndrome mutations, but additional genetic 
modifiers are predicted to exist. For instance, genome-wide studies cannot detect 
rare variants [32] whose risk modifying contribution remains largely 
undetermined. To identify rare genetic modifiers of the risk of Lynch syndrome-
related endometrial cancer, we have screened a panel of 154 genes among a 
cohort of 35 Lynch syndrome related endometrial cancer patients. Fifty-four 
variants with putative risk modifying action were selected (risk-variants), which 
occurred in 40 genes and the presence of two or more risk-variants was associated 
with poor clinical phenotypes (Figure 1). This result is in line with genome-wide 
studies that have shown that risk modifying alleles exert larger risks in carriers of 
multiple variants compared with single-variant carriers [6]. 
 
The rationale used to design the 154 gene-panel and the criteria used to select 
putative risk modifiers derived from recent understandings in cancer biology. 
Cancer somatic mutation landscapes have shown that while somatic driver 
mutations inactivate tumor suppressors or activate oncogenes, germ-line 
predisposing variants have more subtle effects and do not necessarily give a direct 
growth advantage or cancer phenotype [11]. For these reasons, the designed 
gene-panel included not only cancer associated-genes but also genes that are 
broadly involved in the endometrial physiology, like those encoding for proteins 
controlling the estrogen signaling. In line with this model suggesting a distinction 
between germ-line predisposing versus somatic driver mutations [11], no (germ-
line) risk-variant was identified among the genes that are most frequently 
mutated at the somatic level in endometrial cancer, such 
as PTEN, PIK3CA, CTNNB1, KRAS (all included in the panel). When endometrial 
cancer somatic mutation landscape (COSMIC database [10]) was aligned to the 
risk modifiers identified in the present study, MTOR was the first common gene 
ranking 130th among somatic mutations. STK11 and ATM appeared as risk 
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modifiers in our screen and are frequently mutated somatically [9] but not in 
endometrial cancer (COSMIC database [10]). 
 
Well-established criteria were used to cluster variants in categories 1–5 [20, 22, 
33]. In addition, we considered that genetic modifiers are expected to have little 
or no influence in the general population (modest effect-size), while influencing 
the cancer-risk in predisposed subjects, i.e. in subjects carrying a penetrant 
cancer mutation [2]. Hence, we considered as putative risk modifiers all variants 
having a likely-pathogenic or pathogenic effect (category 4/5) but also those with 
‘unclear significance’ (category 3), provided that the were missense leading to 
non-conservative amino-acid substitution. In this context, the recognition of the 
role of rare missense changes in cancer susceptibility is growing [34]. Lower 
categories (2 and 1, unlikely to have any effect at the protein level) were excluded. 
 
Genes such as NOTCH1 (cell-fate determination), NCOR2 and NCOA2 (controlling 
the activity of ER-α), COMT (detoxification pathway and estrogen degradation), 
and classical oncogenes (the tyrosine kinase receptors NTRK1 and IGF1R) or 
tumor suppressors (APC, BRCA2, EPHB2 and CDH1, the latter being already 
identified as a risk modifier locus in genome-wide studies [6]) carried more than 
one independent risk-variant, indicating that they are hit frequently. In addition, 
the pathways where risk-variants were found underscored some signalings in 
which genetic modifier can be found: the STK11/TSC1/mTOR cascade; the 
estrogen signaling at ER-α transcriptional control (NCOR2, NCOA2 - both with 
multiple risk-variants - and PPARGC1A); or at ligand metabolism level, with risk-
variants identified in CYP1A1, COMT and CYP1B1, phase I and II detoxifying 
enzymes degrading also estrogens via the formation of catechol-compounds. The 
CYP1A1 locus was reported previously as risk modifier for Lynch syndrome 
colorectal cancer, although data were not confirmed in independent studies [5] 
and common variants in CYP1A1 and in other genes controlling the estrogen 
metabolism have been associated with sporadic endometrial cancer [35]. 
 
Although it was not possible to assess the segregation of the identified risk-
variants with the disease within the families in our cohort (DNA from unaffected 
relatives with matched life-span was not available), poorer phenotypes tended to 
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segregate with a higher number of risk-variants among the small number of 
patient-relatives included in our cohort (Supplemental Figure S4). 
 
Further immunohistochemical characterization of a limited number of risk-variants 
showed association with protein changes. The estrogen degrading protein CYP1A1 
showed localized loss of expression in the tumor carrying CYP1A1:(p.Cys457*). 
Tyrosine receptors including RET and IGF1R have important crosstalk’s with the 
estrogen signaling and are relevant to the endometrial physiology [27, 36]. 
Variant RET:p.(Ans361Lys) impairs RET correct membrane localization [28], and 
was indeed associated with aberrant cytoplasmic immunoreactivity in this study. 
Glycosylation of IGF1R is reported to be important for cellular localization, 
response to anti-IGF therapy and signaling activation [30]. Variant 
IGF1R:p.Thr758Met, predicted to disrupt one N-linked glycosylation site, was 
associated with diminished membrane IGF1R localization and increased 
phosphorylation of ER-α, one of the downstream IGF1R kinase targets. 
The IGF gene locus (coding for the ligand of IGF1R) has been reported as a genetic 
risk modifier for Lynch syndrome [5]. 
 
In conclusion, we propose a gene-panel that contains potential genetic risk 
modifiers of Lynch syndrome related endometrial cancer in our population. Risk-
variants that are likely pathogenic have been identified and assessing their 
segregation with the disease phenotypes can be relevant to the family members 
and the subjects assisted at our center. 
 
For implications outside the families of the present investigation, the development 
of gene-panels in diagnostics is technically desirable compared to complete 
genome sequencing because it allows achieving sufficient coverage, cost 
effectiveness and simplicity in analyses [11, 20]. Therefore, it is intriguing to 
validate these data in independent populations and examine how this panel will 
translate to other ethnicities. The fact that a number of risk modifiers identified 
here correspond to loci that were previously characterized in genome-wide 
investigations is encouraging. Additionally, it is possible to improve our panel 
design by including genes recently identified as risk modifiers in genome-wide 
studies [6, 37]. 
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Material and Methods 
 
Ethical Statement 
Investigation has been conducted in accordance with the ethical standards, 
according to the Declaration of Helsinki and according to national and international 
guidelines. Protocols have been approved by the authors’ institutional medical 
ethical committee (see below for details). 
Patient Population 
Thirty-seven Dutch Caucasian women from 29 families who developed hereditary 
endometrial cancer and carried a germ-line mismatch repair (MMR) gene mutation 
were enrolled (Table 1). Women were counseled at the Maastricht or Leiden 
Medical Centers (2011–2013) because of a Lynch syndrome family history, a 
Lynch syndrome mutation or a Lynch Syndrome diagnosis (Bethesda criteria). 
Genomic DNA was used for Next Generation Sequencing (NGS) analyses. All 
women had given consent to use their DNA for research. The local medical ethical 
committee approved the protocol (METC 12–04-079). 
 
Archival formalin-fixed-paraffin-embedded (FFPE) tissues of 12 women’s tumor 
specimen were retrieved from the hospitals that performed the hysterectomy and 
they were used for DNA analyses, loss of heterozygosity (LOH; n = 12) and 
histology/immunohistochemistry (n = 8). Seven sporadic endometrial cancers 
and five postmenopausal healthy controls were randomly selected from our tissue-
bank [12] and used as control for immunohistochemistry (local medical ethical 
committee tissue-bank protocol approval: METC-14–04-003). 
 
Gene-panel and NGS 
Coding sequences plus intron/exon boundaries of 2012 regions from 154 genes 
(396kB; Table 2, Supplemental Table S1) and 57 off-target control regions 
(84kB) were designed and captured with Haloplex platform (Agilent Technologies, 
Ratingen, Germany). Illumina HiSeq NGS (Illumina, San Diego, USA) was used 
for sequencing and reads were aligned against the reference genome 
(GRCh37/hg19). Variants were called using NextGene (Softgenetics, State 
College, USA), SureCall software packages (Agilent Technologies, Ratingen, 
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Germany) plus manual checking, which resulted in 0% false positives (confirmed 
by Sanger analyses) and in the successful detection of all re- sequenced 
pathogenic MMR mutations suitable to be detected (Supplemental Methods). 
Sanger sequencing was performed using BigDye Termination v.1.1. (Life 
Technologies, Bleiswijk, Netherlands). Detailed descriptions of the gene-panel 
design, capture, library preparation, NGS, variant calling and quality controls are 
given in Supplemental Methods. The dbSNP142 - The National Center for 
Biotechnology Information (NCBI) was used to identify deposited polymorphisms 
and variants. 
Immunohistochemistry, Confocal Laser Scanning Microscopy (CLSM) and 
LOH 
Standard protocols [12, 38] and antibody manufacturer’s instructions were used 
for immunohistochemistry. Antigens were retrieved with tris-EDTA buffer. 
Antibodies used: estrogen receptor-α (ERα; monoclonal D-5, 1:100; Dako, 
Glostrup, Denmark), IGF1R (1:400; monoclonal; Novus Biologicals, Littleton, 
USA), CYP1A1 (1:1000; polyclonal; Sigma-Aldrich, St. Louis, USA), COMT (1:100; 
polyclonal; Sigma-Aldrich, St. Louis, USA), Phospho-ERα ser167 (1:50; 
monoclonal; Cell Signaling Technology, Danvers, USA), RET (1:500; polyclonal; 
Sigma-Aldrich, St. Louis, USA). Chemate Envision and 3,3-diaminobenzidine 
(Dako, Glostrup, Denmark) were used to visualize antibody binding. 
Immunoscores were assessed by two independent investigators (DB and RA) as 
described [12]. Protocols for SMRT, Phospho-S6 Ribosomal protein-ser235/236 
and mTOR staining are given in Supplemental Figure S6. 
 
Confocal laser scanning microscopy (CLSM) was performed on 4 μm thick FFPE 
tissue sections. Anti IGF1R (1:250; monoclonal; Novus Biologicals, Littleton, 
U.S.A.) followed by rabbit-α-mouse IgG-FITC (1:100, Dako, Glostrup, Denmark) 
were used. CLSM was performed with Leica CTR 4000/CTC SPE and the Application 
Suite/advance fluorescence software (Leica Microsystems B.V., Rijswijk, 
Netherlands). Image-J program (v 1.48, National Institutes of Health, USA) was 
used for image analyses. For LOH, an expert pathologist (VdVKK) identified the 
tumor regions from histological sections of FFPE materials, which were resected 
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for genomic DNA isolation (QIAamp DNA FFPE tissue kit, Leusden, Netherlands) 
and Sanger sequencing. At least two separate tumor regions were analysed. 
Statistical Analyses 
Kaleidograph (v 4.1, Synergy Software, Reading, USA), SPSS (v 22, IBM 
Corporation, Armonk, USA) and the online Simple Interactive Statistical Analysis 
(SISA) were used as indicated in the text. 
URLs 
Genebrowsers 
Ensembl Genome Browser: http://www.ensembl.org; 
NCBI: http://ncbi.nlm.nih.gov; University of California Santa Cruz: UCSC 
Genome Browser: http://genome.ucsc.edu. 
 
Variant Analyses 
dbSNP database Human Build 142: http://ncbi.nlm.nih.gov; Exome Aggregation 
Consortium: ExAC, v 0.3, (Cambridge, MA, USA; February 
2015): http://exac.broadinstitute.org/; Exome Variant Server, NHLBI GO Exome 
Sequencing Project (ESP, release ESP6500SI-V2, March-2015), Seattle, 
USA: http://evs.gs.washington.edu/EVS; Leiden Open Variation Database: LOVD 
3.0: lovd.nl; The Human Gene Mutation Database: HGMD (Cardiff 
University): http://www.hgmd.cf.ac.uk; Genome of Netherlands project, release 
5: http://www.nlgenome.nl [39]; Catalogue Of Somatic Mutations In Cancer: 
Cosmic (Sanger Institute): http://cancer.sanger.ac.uk; 
PhosphoSitePlus®: http://www.phosphosite.org [23]. 
 
Gene Ontology, Expression Information 
NCBI: http://ncbi.nlm.nih.gov; UniProt 
Knowledgebase: http://www.uniprot.org/uniprot; GeneCards (v 3.12.354 March 
2015, Weizmann Institute of Science): http://www.genecards.org. 
 
Statistics 
SISA: http://www.quantitativeskills.com/sisa/. 
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Supplementary Data 
Customized gene-panel 
Customized gene-panel A panel of 154 endometrial physiology and cancer related 
genes was compiled based on literature and own experience [10, 12-19]. Genes 
involved in estrogen and progesterone signaling, involved in the metabolism of 
steroid hormones plus oncogenes and tumor suppressors were included. For the 
complete gene-panel description and full set of references see Supplemental Table 
S1. The coding sequences plus intron/exon boundaries based on GenBank and 
CCDS records were captured (The National Center for Biotechnology). Captured 
sequences were designed with Haloplex Design Wizard Tool (Agilent Technologies, 
Ratingen, Germany) using Illumina100 as library type. The designed panel 
consisted of 396kB from 2012 target regions. As control for off target DNA, 57 
additional regions mapping in introns or inter-genic DNA sequences were captured 
as well (84kB). Parameters were optimized to the latest targeted exome capture 
platform Haloplex (Agilent Technologies, Ratingen, Germany) and Illumina HiSeq 
NGS (Illumina, San Diego, CA, USA). 
Next-generation sequencing - NGS 
Genomic DNA was quantified, assessed for quality by Qubit measurement (Life 
Technologies, Bleiswijk, Netherlands) and for degradation on 1.5% agarose gel. 
As positive control for the sequencing reactions, the gDNAcontrol from Agilent was 
used, and consisted of material from a single Caucasian subject isolated from an 
early passage lymphoblastic cell line. Target DNA sequences were captured with 
Haloplex Target Enrichment System (Agilent Technologies, Ratingen, Germany) 
and barcoded libraries were made according to the manufacturer’s protocol. 
Library quality and DNA content were evaluated on a 2100 Bioanalyzer using the 
High Sensitivity DNA Kit (Agilent Technologies, Ratingen, Germany). Library 
clusters were generated using the TruSeq® PE Cluster Kit V3 according to the 
manufacturer’s protocol (Illumina, San Diego, CA, USA) and the paired-end library 
was sequenced in 2 × 100 cycles paired-end sequencing by synthesis (SBS) using 
a TruSeq™ SBS Kit v3 on a HiSeq2000 (Illumina, San Diego, CA, USA). Base 
calling was done by using Casava 1.8 (Illumina, San Diego, CA, USA) and 
sequence reads were aligned against the human reference genome assembly 
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GRCh37/hg19 (UCSC Genome Browser on Human Feb. 2009). Total target region 
size was 480052 base pairs (bp) and after sequencing a total of covered target 
regions of 98.4% could be analyzed (472542 bp). 
Quality assessment 
Quality assessment of sequencing reactions Quality Control (QC) analysis on 
coverage was performed by Surecall (Supplemental Figure S1). A threshold for 
read depth was set of at least 50 times, and for coverage at 90% of the original 
regions of interest. Two samples did not match these criteria and were excluded 
(12–04-079_22 and 12–04-079_25, Supplemental Figure S1  and Table I). 
Sample 12–04-079_31 was of borderline sufficient quality with a depth of 50 times 
for about 80% of the regions of interest. This sample was retained because the 
familial MMR mutation could be retrieved and Sanger sequencing confirmed the 
validity of the additional variants found. The remaining 34 samples were covered 
more than 50 times in every nucleotide position, over 95% of the region of 
interests were covered and could be analyzed. Each region was covered on 
average 2309 times. Supplemental Figure S2 gives the average coverage per 
region in our samples, and Supplemental Table S2 reports the coverage 
information per patient per region of interest. 
Variant calling and validation 
NextGene software package (Softgenetics, State College, PA, USA) on unique 
reads with basic settings and SureCall (Agilent Technologies, Ratingen, Germany) 
were used for raw data analyses. Alignment and variant calling were performed 
on unique reads with default settings, using a filter set on the region of interest 
file provided by the Agilent-Haloplex report. To adjust the settings for variant 
calling, over 70 variants were analyzed by Sanger sequencing (not shown). After 
this preliminary optimization of variant calling, we further optimized the variant 
calling pipeline by integrating results from Nextgene and SureCall software’s. This 
strategy resulted in a highly stringent selection of variants with low false positive 
rate. To further decrease the false positive rate, called variants were manually 
controlled by excluding those occurring at the 5′or 3′ prime end of the sequence 
reads and those having an insufficient quality (Phred score less than 25). This 
pipeline was suitable to call single or few bases aberrations (substitutions, small 
Germ-line Variants Identified by Next-Generation Sequencing
83
3
 
insertions and deletions) and gave 0% false positive as confirmed by additional 
Sanger analyses (Supplemental Table S4, column ‘number validated samples’). 
Among the previously sequenced (at genetic counseling) pathogenic mutations in 
MMR genes, 12 out of the 14 familial MMR mutations consisting of few nucleotide 
alterations were retrieved. These mutations were distributed in 27 subjects and 
the presence was confirmed in all (see also Table I). Two out of 14 familial MMR 
mutations consisting of few nucleotide alterations could not be retrieved because 
located on regions that were poorly covered in the two DNA carrier samples (12–
04079_30 and 12–04-079_38). Beside these 14 mutations, five additional familial 
MMR mutations were identified at counseling in six samples (12–04-079_13, 18, 
29, 23, 27 and 35) but they consisted of relatively large chromosomal 
rearrangement that could not be retrieved by our pipeline (Table I). In addition, 
among the variants outside the MMR genes, 19 that were non-deposited in the 
dbSNP database were selected for Sanger sequencing and their presence was 
validated in all 21 subjects carrying the variant. Also, the presence of seven 
identified polymorphisms deposited in dbSNP was validated in the 22 subjects’ 
DNA carrying the polymorphic allele. Sanger sequencing was performed using the 
BigDye Termination v.1.1. (Life Technologies, Bleiswijk, Netherlands) as 
recommended. Prior to sequence reactions and analyses, DNA regions were 
amplified by PCR (Taq polymerase, Fermentas, Burlington, CA, USA) using 
primers listed in Supplemental Table S4 (forward primers were used for Sanger 
sequence reactions). 
Supplementary data due to many presented columns in Excel processed via 
download link: 
https://www.oncotarget.com/index.php?journal=oncotarget&page=rt&op=suppF
iles&path[]=5694&path[]=18434 
Supplementary Table S1: List of captured genes 
Supplementary Table S2: Coverage data per region per sample 
Supplementary Table S3: List of all selected variants (outside MMR genes) 
identified in 35 subjects 
Supplementary Table S4: List of primers used for Sanger sequencing analyses 
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Supplemental Figures S1-S6
Supplementary Figure S1: Quality control. Quality Control analysis on coverage was 
performed by using Surecall as described in the main manuscript text. A threshold for read 
depth was set of at least 50 times (x axes), and a threshold for coverage at 90% (y axes) 
of the original regions of interest. The two samples that did not match this criteria cluster 
clearly separate from the rest (12–04-079_22 and 12–04-079_25). Sample 12–04-079_31 
was of borderline sufficient quality.
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Supplementary Figure S2: Average coverage of the captured regions. Average coverage 
of the 2069 captured regions covering the 154 genes. The samples with low quality (12–
04-079_22 and 25) are excluded. Mean reads (plus maximum and minimum) per each 
region in each sample are given in Supplemental Table S2, which gives also the 
correspondence between region number (on the x axes) and captured gene exon (with 
chromosomal coordinates).
Supplementary Figure S3: Kaplan-Meier analyses of any poor clinical phenotype event: 
diagnosis of endometrial cancer below 49 years and/or diagnosis of a second cancer. 
Kaplan-Meier analysis of the occurrence of any event classified as poor-clinical-phenotype 
(either diagnosis of endometrial cancer at 49 years or earlier, or the diagnosis of a second 
tumor other than the endometrial one) among subjects carrying no risk-variants, one, 
two, three or more than four risk-variants beside the MMR gene familial mutation. Overall 
comparisons: statistic computed with SPSS; d.f. = degrees of freedom; Sig = value for 
statistical significance. The table at the bottom shows the overall distributions of the 
events among the difference categories. * lifespan was extrapolated at 2013. Log-Rank 
(Mantel-Cox) for statistical significance is shown for the occurrence of any poor phenotype 
event (shown also as Kaplan-Meier graph, top left), and for the early diagnosis of 
endometrial cancer or the diagnosis of a second tumor separately. Data in the Kaplan-
Meier graph (top left) show that subjects carrying no or one risk-variant beside the MMR 
N
um
be
r o
f r
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ds
 
No. risk-variants lifespan* total Any poor-phenotype event
EC before 50 
years Second tumour
p = ns n n % n % n %
0 66 ± 5 7 3 42.9 0 0.0 2 28.6
1 65 ± 7 10 4 40.0 3 30.0 2 20.0
2 65 ± 7 6 5 83.3 4 66.6 3 50.0
3 64 ± 12 9 7 77.8 4 44.4 5 55.5
4-5 64 ± 23 3 3 100.0 2 66.6 1 33.3
overall 65 ± 11 35 21 60.0 13 37.1 13 37.1
Log-Rank 0.004 0.02 0.08
ev
en
ts
 (i
n 
pr
op
or
tio
n)
   
age at diagnosis of first event (years)
Chi-square d.f. Sig.
Log-Rank
(Mantel-Cox) 8.167 1 0.004
Breslow
(Generalized
Wilcoxon)
6.883 1 0.009
Tarone-Ware 7.361 1 0.007
Number of risk-variants beside 
the MMR familial mutation
No risk-variant
One risk-variant
Two risk-variants
Three risk-variants
Four or more risk-variants
+   Censored 
Overall comparisons
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mutation cluster separately from subjects carrying two or more risk-variants. In the main 
text, analyses were performed by categorizing subjects in those carrying no or one risk-
variants and those carrying more than two risk-variants beside the MMR mutation. 
 
 
Supplementary Figure S4: Clinical phenotypes and genetic characterization of relatives. 
The seven families (15 subjects) for which DNA from relatives was screened. Among the 
five families in which members have distinct cancer phonotypes (A, E, F, B and C), in 
three (A, E and F), the member with poor clinical phenotype carries more risk-variants 
than the one with neutral phenotype. In Family B, both members carry three risk-variants 
and the woman with neutral phenotype is relatively young compared to her relative, 
characterize by a poor cancer phenotype. Members if family C (one poor and neutral) 
carry no risk-variants. The remaining two families comprise women who had all a poor 
cancer phenotype. All members of these families carries at least one risk-variant. 
Superscripts refer to dbSNP accession, when applicable: (1) rs142007602; (6) 
rs56328701; (7) rs121918303; (11) rs180869630;(14) rs35962982; (15) rs118203400; 
(16) rs149242330;  (18) rs149475426; (19) rs142155101. 
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Supplementary Figure S5: Estrogen signaling and protein expression in tumor specimens. 
A. Representative immunohistochemical images showing expression of the estrogen 
receptor (ER-α) and the phosphorylated form at Ser-167 in normal endometrium adjacent 
to tumor tissues (peri-tumoral), low-grade and high-grade Lynch syndrome endometrial 
cancer. ‘s’ marks the stromal component, ‘e’ the epithelial glandular cells. Stroma is 
abundant in post-menopausal endometrium and decreases in cancer. In high-grade 
lesions the cytological differentiation between stromal and epithelial cells is less evident. 
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Red-arrowheads on the images at the right indicate one area of low-grade cancer with 
clearly well-differentiated epithelial cells. Bar = 100 μm. B. Quantification of ER-α (black) 
and phosphoSer-167-ER-α (grey) in Lynch syndrome endometrial cancer (n = 8), 
sporadic endometrial cancer (n = 7) and post-menopausal controls (n = 5). Immuno-
scores range: 0–15. Mean values ± standard deviations (SD) are shown. C. Quantification 
(range 0–15) of the immunohistochemical expression of COMT, NCOR2, CYP1A1, RET, 
IGF1R, mTOR. Expression levels are shown for the group of Lynch syndrome tumors, the 
group of sporadic tumors, the controls (black bars) and the specimen bearing the 
indicated risk-variant (grey bars). Black bars are the mean values ± SD of the different 
subjects (Lynch syndrome specimens without the variant, n = 7; sporadic cancers, n = 
7; controls, n = 5). Grey bars are the mean values ± SD of four independent areas of the 
tumor from the indicated subject bearing the risk-variant.
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Supplementary Figure S6: Analysis of tumor material by immunohistochemistry. 
Immunohistochemical stainings for CYP1A1, COMT, mTOR (and downstream signal 
protein S6) and NCOR2. Overall, immunohistochemical analysis (including those for RET 
and IGF1R in Figure 2 and Supplemental figure 5) shows high expression levels of these 
proteins (and the downstream signaling activation in case of mTOR) in the endometrium 
and in endometrial cancer, proofing that they play a role in endometrial physiology. A. 
(top series). Immunohistochemical images of a tumor and a normal endometrium 
specimens bearing the wild type CYP1A1 or the tumor with risk-variant 
CYP1A1:p.Cys457fr*, showing the expression of the protein CYP1A1. (bottom series). 
Immunohistochemical images of a tumor and a normal endometrium specimens bearing 
the wild type COMT or the risk-variant COMT:p.Lys159del, showing the expression of the 
protein COMT
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Abstract 
Leigh syndrome is an early onset, often fatal progressive neurodegenerative 
disorder caused by mutations in the mitochondrial or nuclear DNA. Until now, 
mutations in more than 35 genes have been reported to cause Leigh syndrome, 
indicating an extreme genetic heterogeneity for this disorder, but still only 
explaining part of the cases. The possibility of whole exome sequencing enables 
not only mutation detection in known candidate genes, but also the identification 
of new genes associated with Leigh syndrome in small families and isolated cases. 
Exome sequencing was combined with homozygosity mapping to identify the 
genetic defect in a Moroccan family with fatal Leigh syndrome in early childhood 
and specific MRI abnormalities in the brain. We detected a homozygous nonsense 
mutation (c.20C>A; p.Ser7Ter) in the thiamine transporter SLC19A3. In vivo 
overexpression of wild-type SLC19A3 showed an increased thiamine uptake, 
whereas overexpression of mutant SLC19A3 did not, confirming that the 
mutations results in an absent or non-functional protein. Seventeen additional 
patients with Leigh syndrome were screened for mutations in SLC19A3 using 
conventional Sanger sequencing. Two unrelated patients, both from Moroccan 
origin and one from consanguineous parents, were homozygous for the same 
p.Ser7Ter mutation. One of these patients showed the same MRI abnormalities as 
the patients from the first family. Strikingly, patients receiving thiamine had an 
improved life-expectancy. One patient in the third family deteriorated upon 
interruption of the thiamine treatment and recovered after reinitiating. Although 
unrelated, all patients came from the province Al Hoceima in Northern Morocco. 
Based on the recombination events the mutation was estimated to have occurred 
1250-1750 years ago. Our data shows that SLC19A3 is a new candidate for 
mutation screening in patients with Leigh syndrome, who might benefit from high 
doses of thiamine. Especially Moroccan Leigh patients should be tested for the 
c.20C>A founder mutation in SLC19A3. 
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Introduction 
Leigh syndrome (MIM256000) is a progressive neurodegenerative disorder 
characterized by focal, bilateral lesions in one or more areas of the central nervous 
system, including basal ganglia, thalamus, cerebellum, brainstem and spinal cord. 
Leigh syndrome is an early onset mitochondrial disorder with extensive genetic 
heterogeneity and can be caused by mutations in the mitochondrial DNA (mtDNA) 
and many nuclear genes. The most common cause of Leigh syndrome is a defect 
in one of the subunits or assembly factors of the oxidative phosphorylation 
complexes (complexes I, II, IV, V and coenzyme Q) [1]. Additionally, mutations 
in components of the pyruvate dehydrogenase complex and in the gene encoding 
the leucine-rich PPR motif containing protein have been described [2-4]. In total, 
mutations in at least 35 genes have been reported to cause Leigh syndrome. 
Although for example 25-75% of Leigh patients with complex IV deficiency 
harbour mutations in the complex IV assembly factor SURF1 [5], no clear 
candidate gene can be selected in the majority of patients despite small 
phenotypic differences. Because of the extreme genetic heterogeneity of this 
disorder, gene specific mutation detection is a time consuming and expensive 
approach. Additionally, the limited genotype-phenotype correlations, the small 
size of families and large number of isolated cases make classical family based 
approaches, like linkage analysis, less applicable. Recently, new sequencing 
techniques have been developed enabling the sequencing of large packages of 
candidate genes, the whole protein-coding region (exome) or even the whole 
genome at higher rate and at lower costs [6]. Especially exome sequencing has 
become a valuable tool for identifying the genetic cause for different disorders. 
Over the last 3 years, exome sequencing enabled the identification of over 30 new 
genes involved in Mendelian diseases [7].  
Here we describe a new candidate gene for Leigh syndrome identified by whole 
exome sequencing in combination with homozygosity mapping in a 
consanguineous Moroccan family with Leigh syndrome and specific abnormalities 
on MRI. 
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Patients and Methods 
Patients 
Family a is a Moroccan family with three healthy children and three deceased 
children, due to Leigh syndrome, born from healthy consanguineous parents 
(Figure 1). The deceased children died 1 month after birth due to respiratory 
insufficiency. Patient II:1 was born at 41 weeks gestation without complications. 
He was admitted to the hospital for his opisthotonic posture, inconsolable crying 
and roving eye movements after 1 month of age. After 2 to 3 weeks he began 
experiencing seizures. To reduce the seizures, phenobarbital was prescribed. He 
was a hypotonic boy with hyperreflexia in the extremities, including positive 
Babinski sign. Later he developed feeding difficulties. His blood tests showed a 
slightly increased lactic acid of 3.8 mmol/l and an alanine level which was in the 
upper normal range. Urine culture revealed a hemolytic streptococcus group B. 
Biochemical analysis of respiratory chain complex activities in fibroblasts was 
normal. His brain CT scan demonstrated various hypodense areas, most 
pronounced in the basal ganglia. After 1 month and 7 days he died of Leigh 
syndrome, mainly due to apneas and Cheyne-Stokes type of breathing. The fifth 
child of this family (patient II:5) was born at a gestational age of 40 weeks. After 
almost 5 weeks of age he presented with convulsions, nystagmus, hypotonia with 
positive Babinski sign and sun-set phenomenon. His convulsions responded well 
to phenobarbital. Soon after presentation a brain MRI was performed, which 
demonstrated abnormal signal intensity in the basal ganglia, thalamus, brainstem 
and cerebellum (Figure 2a). Brain MRS showed a lactate peak in the basal 
ganglia. These findings were similar to the clinical course of his brother and 
therefore carnitine, riboflavin and vitamin E were prescribed.  Blood tests revealed 
disturbance of liver function with a gamma GT of 114 U/l, ASAT 109 U/l, ALAT 70 
U/l, an increased lactic acid of 4.4 mmol/l and pyruvate of 247 µmol/l. In 
cerebrospinal fluid increased levels of leucine and isoleucine were found. 
Biochemical analysis on muscle and skin biopsy showed no clear decreased 
activity of the respiratory chain complexes. After 1 month of age he died of 
respiratory failure. The youngest son (patient II:6) was born at a gestational age 
of 41 weeks without complications and showed an identical disease course as his 
brothers. He was first admitted to the hospital at 3 weeks of age with feeding 
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difficulties, opisthotonic posture and roving eye movements. Clinical examination 
showed hypotonic extremities and symmetric hyperreflexia with positive Babinski 
sign. Blood tests revealed a slightly increased lactic acid of 3.4 mmol/l. 
Neurotransmitters in cerebrospinal fluid showed lowered levels of HVA and HIAA. 
Brain specific proteins MBP, GFAP and fosfo-tau were increased in liquor. Metabolic 
urine tests showed slightly increased levels 2-ketoglutaric acid, 2-hydroxy-glutaric 
acid, glutaric acid, succinate and 2-ketoadipic acid. Biochemical analysis on skin 
biopsy revealed a slightly decreased activity of complex IV. Later he began 
experiencing breathing difficulties. Treatment was started with carnitine, vitamin 
E, riboflavin and CoQ10. The patient died due to a progressive abnormal breathing 
pattern at 6 weeks of age.  
Family b is a consanguineous Moroccan family with seven children (Figure 1) of 
which two girls died after 4 weeks of age due to a progressive neurologic 
deterioration caused by Leigh syndrome. When patient II:1 was admitted to the 
hospital, she was irritable, cried inconsolably and presented with jitteriness. She 
had drinking difficulties and frequent green defecation. Her extremities were 
hypertonic with clonic triceps surae reflexes including a positive Babinski sign. 
Shortly after hospitalization she became respiratory insufficient with progressive 
neurological symptoms. Her EEG was normal. Her brain CT scan showed 
symmetric hypodense areas in pons, mesencephalon, vermis and thalamus. 
Medication existed of phenobarbital. Before she died, she was hypotonic with 
hyperreflexia in the extremities. Patient II:5 had sucking difficulties and could not 
open her eyes for 3 days. Because of the progressive disease course of her older 
sister, she was admitted to the hospital for observation. At presentation she had 
an abnormal breathing pattern and increasing convulsions confirmed by EEG. The 
epileptic activity was treated with phenytoin. Clinical examination showed 
hyperreflexia in the extremities including a positive Babinski sign. Apart from that, 
the extremities were hypertonic with an axial hypotonia.  Lactic acid was found 
slightly increased in liquor as well as in blood. Her MRI demonstrated abnormal 
signal intensity in basal ganglia, thalami, mesencephalon and brainstem. The 
lesions were bilateral and symmetrical. After 1 month her clinical condition 
deteriorated rapidly. She began experiencing a Cheyne-Stokes respiration, which 
eventually led to her death. 
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Figure 1. Pedigrees of 3 Moroccan families with Leigh syndrome showing the haplotype in 
the region surrounding the mutation 
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Moroccan family c consists of nine children, of which six died due to a Leigh-like 
syndrome (Figure 1). All children were born to healthy non-consanguineous 
parents. The children who were clinically investigated had a very similar disease 
course and features. Three of the children died at 1 month of age, one at three 
years, one at fifteen years and one at 20 years of age. 
The proband, patient II: 3, was born at a gestational age of 39 3/7 weeks. Besides 
meconium in the amniotic fluid there were no further complications. Because his 
brother died of a progressive encephalopathy he was hospitalized for observation 
during the first month of live. At 1 month of age he appeared to be alternating 
hypo- and hypertonic and irritable. His clinical picture and failure to thrive posed 
the possibility of a mitochondrial disease. Oxidative phosphorylation was 
measured in a fresh muscle biopsy of the patient. Polarographic measurements 
were performed in isolated muscle mitochondria by a Clarke electrode as 
previously described [8] with pyruvate + malate, succinate + rotenone and 
ascorbate + TMPD. Oxygen consumption in the isolated mitochondria of the 
patient with pyruvate as the substrate was only 12 % of normal oxygen 
consumption and with succinate and ascorbate as substrate 50% of normal 
oxygen consumption. When normalized for citrate synthetase, oxygen 
consumption with pyruvate was 25% compared to normal and the oxygen 
consumption with succinate and ascorbate was normal. Biochemical measurement 
of Complex I and IV activities in the muscle homogenate were normal.  Almost 
the same biochemical result was found in proband II:7 with normal activities of 
the respiratory chain complexes and a lowered oxygen consumption of 25% 
compared to normal with pyruvate + malate. The activities of pyruvate 
dehydrogenase and α-ketoglutarate dehydrogenase measured in the muscle 
homogenate in vitro, after addition of thiamine pyrophosphate, were increased 
respectively to 441% and 156% compared to controls. In the 1990’s treatment 
with vitamin cocktails for mitochondrial disease was recommended. The boy (II:3) 
was treated with thiamine and riboflavin, which were later discontinued because 
he was developing well. Shortly after this change of treatment regimen he became 
hyperactive and irritable again, so treatment with these vitamins was resumed 
and the irritability disappeared. The following year he experienced three periods 
with relapses presented with an opisthotonic posture, inconsolable crying, and 
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loss of motor functions. His brain CT scan showed hypo-intense lesions in the 
thalami and basal ganglia, suggestive for Leigh disease. A metabolic analysis for 
a wide range of metabolic disorders was normal. Biotin was added to his standard 
medication. At the age of eleven, he presented with a status epilepticus for which 
he was treated with sodium valproate and phenytoin. When he was twelve, he 
was severely mentally retarded. In that same year a gastrostomy was performed 
because of swallowing difficulties. The patient eventually died due to respiratory 
insufficiency and an abnormal breathing pattern at the age of 20. Patient II:9 was 
born at a gestational age of 42 weeks without complications. Soon after birth, 
treatment was started with riboflavin, thiamine and carnitine. At 1 month of age 
he became hypertonic and cried inconsolably. After one year he presented with 
seizures. His EEG demonstrated a severely distorted picture with epileptogenic 
phenomena. Therefore he received phenobarbital combined with carbamazepine. 
At six years of age severe psychomotor retardation was confirmed and he began 
experiencing reflux and spasticity. Brain MRI at six years of age revealed abnormal 
intensities in the putamen, thalami, nucleus dentate, and to a lesser extent in the 
globus pallidus (Figure 2b). At the age of eight, a percutaneous endoscopic 
gastrostomy was performed because of his feeding difficulties. A few years later, 
at the age of eleven, he strongly deteriorated and could hardly make any contact 
with his environment. The following years he had recurrent respiratory tract 
infections. The performed muscle biopsy showed COX negative fibres. Biochemical 
measurements of the OXPHOS complexes in patient II:9 revealed no enzyme 
deficiency and the oxygen consumption measured with glutamate or succinate as 
substrate was normal. The many respiratory tract infections proved fatal and he 
died at the age of fifteen.  
Control Population 
Blood samples were collected from 230 unrelated newborns’ umbilical cords. They 
originated from different regions of Morocco and the Moroccan origin of their 
parents and grandparents was confirmed. Informed consent for DNA analysis was 
obtained from the parents. Genomic DNA was extracted from 3 ml blood using the 
salting-out method. 
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Figure 2. Brain MRIs (T2 weighted images, axial view). a) Upper row, patient II-5 of family 
an at age 1 month. Image B1 Cerebellum and brain stem show minor changes. B2 
Increased signal intensities in putamen and mediocaudal and ventrolateral thalamic 
nuclei. The caudate nuclei are spared. Image B3 shows an abnormal intensity and swelling 
of the rolandic area. b) Lower row, patient II-9 of family c at the age of 6 years. A1 
Infratentorial increased signal intensities in the periaquaductal and cerebellar region. 
Image A2 and A3: Supratentorial loss of white matter increasing in antero-posterior 
direction with subcortical cysts. Relatively sparing of directly periventricular situated white 
matter. Thin corpus callosum. Pathologic hyperintensity of the putamen (white arrow) 
and less so of the globus pallidi and thalamic nuclei (black arrow).  
 
 
Methods 
Homozygosity Mapping 
Homozygosity mapping was performed with the Affymetrix GeneChip Human 
Mapping 250 K NspI SNP array using peripheral blood DNA of patients II:5 and 
II:6 from family a. The DNA was processed and labelled according to the 
manufacturer’s instructions. Genotypes were generated by the Affymetrix 
GeneChip Genotyping Analysis Software (GTYPE). Homozygous regions were 
determined by the online tool ‘HomozygosityMapper’ [9].  
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Whole Exome Sequencing and Analysis 
The exome was captured for patient II:6 of family a according to the TruSeq Whole 
Exome Enrichment for Paired-end Sequencing Preparation Guide (Illumina). In 
short, 1 µg of genomic DNA was fragmented using a Covaris S2, with settings 
optimal for an average fragment peak size of 200-300bp. Fragments were end-
repaired, ligated to specific adapters with a single index after the addition of a 3’-
A. Subsequently the fragments were size selected for approximately 400bp on 
agarose gel and pre-PCR amplified (10 cycles) to yield a total amount of 500ng 
for the hybridization step. The DNA library was mixed with the capture probes of 
the targeted exome regions. The hybridization steps were performed as follows 
95°C for 10 minutes, 18 cycles of 93°C for 1 minute, decreasing 2°C per cycle, 
and 58°C for 16-20hrs. Streptavidin affinity was performed to capture targeted 
regions of interest. Additionally three washes were applied to remove non-specific 
binding from the beads. Next, the enriched library was eluted from the beads. A 
second round of hybridization and subsequent washing was done to increase 
enrichment of the targeted regions. A post-PCR (10 cycles) was performed to 
amplify the enriched DNA library. Quantification and quality determination of the 
library was done on a 2100 Bioanalyzer using the High Sensitivity DNA Kit 
(Agilent). Clusters were generated using the cluster generation kit V5.0 according 
to the manufacturers protocol (Illumina) and the paired-end library was 
sequenced using 2x150 cycles V5.0 paired-end by sequencing by synthesis (SBS) 
on a Genome Analyzer ІІx system (Illumina). 
Basecalling was done using Casava 1.6 (Illumina). Sequence reads were aligned 
against the human reference genome (UCSC hg19) using BWA 0.5.9. Single base 
variants were identified using samtools 0.1.16 and annotated using an in house 
developed annotation python/R script that matched variants to the RefGene and 
dbSNP132 hg19 tracks from the UCSC genome browser. The data obtained was 
filtered for genes containing at least two alleles with a nonsynonymous variant or 
variant leading to premature stop codons, which had an allele frequency of <0.01 
or were absent in dbSNP132 and the 1000genomes data (1000 Genome Project 
Consortium, 2010) and present in the homozygous candidate regions.  
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SLC19A3 Sequencing and Mutation Specific Restriction Assay 
Specific intronic primers were designed for amplifying the exons and flanking 
introns of SLC19A3 (Supplementary table 1). PCR was performed in a 10 µl 
reaction volume using Amplitaq Gold Master Mix (manufacturer) with 8% glycerol, 
2 pmol of each primer and 5 ng DNA. The cycle conditions were: 96°C for 5 min, 
followed by 33 cycles of 94°C for 30 seconds, 60°C for 45 seconds, and 72°C for 
45 seconds with a final elongation step of 72°C for 10 minutes. PCR products were 
directly sequenced with the PRISM Ready Reaction Sequencing Kit (Perkin-Elmer 
Life Sciences) on an ABI3730 DNA Analyzer (Applied Biosystems). A mutation-
specific restriction assay was developed to screen controls for the c.20A>G 
mutation. A 5 µl PCR product of exon 2 was digested with MseI for 2.5 hours at 
37°C. The mutation results in the gain of a restriction site presenting a fragment 
of 138 bp instead of 187 bp, which was visualized on an agarose gel.  
Defining the SLC193A Mutation Haplotype 
All patients and relatives and 230 Moroccan controls were genotyped for six 
polymorphic markers (D2S2354, D2S159, D2S401, D2S439, D2S362 and 
D2S2297) flanking the SLC19A3 gene. Primers were fluorescently labelled. 
Amplicons were amplified in a 50 µl reaction volume using Bioline Taq polymerase. 
The cycle conditions were: 94°C for 5 min, followed by 33 cycles of 94°C for 1 
min, 58°C for 1 min, and 72°C for 1 min 30 seconds with a final elongation step 
of 72°C for 7 minutes. Subsequently the size of the amplicons was determined on 
an ABI3730 DNA Analyzer (Applied Biosystems) according to manufacturer’s 
instructions. Analysis was conducted using the Peak ScannerTM Software 1.0 
(Applied Biosystems). The following formula was used to assess the age of the 
c.20C>A mutation in generations (G):  G = log δ / log (1-θ), with δ = LD  = (Pd-
Pn)/(1-Pn). The measure δ refers to the linkage disequilibrium (LD) between the 
mutation and the nearest recombinant markers, in our case, D2S2354 and 
D2S439 (Figure 1). Pd is the frequency of the ancestral STR allele among 
chromosomes carrying the SLC19A3 mutation and Pn is the frequency of the 
ancestral STR allele among chromosomes not carrying the mutation. θ refers to 
the recombination fraction between marker and genes [10]. 
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Thiamine Transport Assay 
An expression construct containing the SLC19A3 open reading frame was obtained 
from Open Biosystems (SLC19A3 in pCMV-SPORT6). The mutation was introduced 
using site-directed mutagenesis with forward primer (5’-
GATTGTTACAGAACTTAACTAAGCAGTTCCTGG-3’ and reverse primer 5’-
CCAGGAACTGCTTAGTTAAGTTCTGTAACAATCC-3’). The presence of the mutation 
was verified by sequencing. HEK293 cells were cultured in DMEM containing 10% 
Fetal Calf Serum at 37°C. For overexpression experiments, cells were seeded in 
6-well plates and transfected using Lipofectamine 2000 with expression constructs 
containing either wild-type or mutant SLC19A3 or an empty vector. The 
transfection efficiency was checked by qPCR of SLC19A3 RNA and SLC19A2 RNA 
of the wild-type and mutant transfected cell lines. Both the mutant and wild-type 
SLC19A3 were highly expressed (data not shown). Transfected HEK293 cells were 
incubated with different concentrations of 3H-thiamine in Krebs Ringer Buffer 
(KRB; 133 mM NaCl, 4.93 mM KCl, 1.23 mM MgSO4, 0.85 mM CaCl2, 5 mM 
glucose, 5 mM glutamine, 10 mM HEPES, 10 mMMES pH7.4) for 20 minutes at 
37°C. Low concentration of radiolabeled thiamine (15 nM) was used to favour 
high-affinity, low capacity uptake, whereas a high concentration (10 µM) was used 
to favour low-affinity, high capacity uptake. The reaction was stopped with ice-
cold KRB and samples were dissolved in 0,5M NaOH and neutralized with 0,5M 
HCl. A fraction of the sample was used for protein quantitation and the remainder 
was subjected to liquid-scintillation counting. Non-specific uptake was determined 
by repeating the experiment at 0°C and subtracted from the results. The results 
are calculated as pmol or fmol thiamine uptake/min mg protein.  
Results 
Homozygosity mapping was performed for patients II:5 and II:6 (family a) with 
the Affymetrix GeneChip Human Mapping 250K NspI SNP array. Both patients 
were homozygous for an overlapping region on chromosome 2 (220-234Mb) and 
chromosome 13 (80-101Mb). In these regions a total of 258 genes were present, 
but no obvious candidate gene. As a next step for identifying the genetic defect, 
the whole exome of patient II:6 was sequenced. An average coverage of 52x was 
established and in total 17,848 coding variants were detected. After filtering for 
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nonsynonymous variants and variants leading to premature stop codons, which 
had an allele frequency of <0.01 or were absent in SNP databases but present in 
the homozygous candidate regions, only SLC19A3 contained two mutated alleles. 
The patient was homozygous for a substitution in SLC19A3 (c.20C>A) which 
resulted in a premature stop codon (p.Ser7Ter). The presence of the mutation 
was confirmed by Sanger sequencing (Figure 3).  
 
Figure 3. Mutation spectrum family a. All are reverse sequences.  
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The patients’ affected brother was homozygous for the mutation, whereas both 
parents and the healthy siblings I:2, II:3 and III:4 were heterozygous. The 
mutation was not present in 460 Moroccan control alleles. Measurement of the 
pyruvate dehydrogenase activity in muscle of patient II:5 showed no activity in 
the absence of thiamine pyrophosphate (TPP) as co-factor whereas the activity 
was normal in the presence of TPP supporting a thiamine deficiency (Table 1). 
Sequence analysis of SLC19A3 in 17 additional patients with Leigh syndrome 
revealed the same homozygous c.20C>A mutation in two patients of Moroccan 
origin, from different families (Figure 1; families b and c). One patient (family b) 
showed the same MRI abnormalities as the patients of the first family and was 
born from consanguineous parents. 
Table 1. Pyruvate dehydrogenase activity 
  PDH complex activity -TPP PDH complex activity +TPP 
Control  2.8 ± 0.4 7.2 ± 2.2 
Patient II:5, Family A 0  8.2  
Pyruvate dehydrogenase activity in muscle normalized to CS 
PDH = Pyruvate dehydrogenase; TPP = thiamine pyrophosphate 
 
The parents of the other patient (family c) were not related. This family had 
previously been tested for linkage using the Human Mapping 10K GeneChips for 
genotyping and Merlin for linkage analysis. Although not statistically significant, 
genomic regions on several chromosomes segregated with the disease (maximum 
LODscore 1.58) including a region from 222 to 231Mb on chromosome 2 in which 
SLC19A3 is located. Segregation analysis of the mutation in this family showed a 
perfect genotype-phenotype association. Unfortunately no material was available 
for segregation analysis in family b.  
As all three families carried the same mutation and originated from Morocco, 
markers surrounding the mutation were genotyped to test for a common 
haplotype. The markers D2S2354, D2S159, D2S401, D2S439, D2S362 and 
D2S2297, located within 0.3-1.8Mb of SLC19A3, were used to determine the 
haplotype of this region (Figure 1). A shared genotype was detected for all 
patients for markers D2S159 and D2S401. Possible recombination events in the 
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regions between markers D2S2354 and D2S159 and markers D2S401 and 
D2S439 resulted in a 0.74-1.35 Mb shared region between all affected individuals 
which includes SLC19A3. Additionally, 230 Moroccan controls were genotyped for 
these markers to determine the allele frequencies in the Moroccan population. 
These frequencies were used for the calculation of the linkage disequilibrium (LD) 
between the SLC19A3 mutation and the recombinant markers D2S22354 and 
D2S439 which were δ = 0.542125 and δ = 0.664317 respectively. Taken into 
account the genetic distances between the mutation and these two markers, the 
c.20C>A mutation in SLC19A3 was estimated to have occurred between 50 and 
70 generations ago. Assuming 25 years per generation, this would mean that the 
mutation arose about 1250 to 1750 years ago.  
To confirm a causal role for this mutation in the biochemical and clinical 
phenotype, we performed thiamine uptake assays in HEK293 cells overexpressing 
either wild-type or mutant SLC19A3 (Figure 4). Low and high concentration of 
radiolabeled thiamine was used, testing both high-affinity, low capacity uptake 
and low-affinity, high capacity uptake. A clear increase (approx. 4-fold) in 
thiamine uptake was observed in cells transfected with wild-type SLC19A3, 
confirming its function as functional thiamine transporter. In contrast, cells 
expressing mutant SLC19A3 do not show enhanced thiamine uptake when 
compared to mock-transfected cells, demonstrating that the mutation results in 
an absent or non-functional protein. 
Low and high concentration of radiolabeled thiamine was used, testing both high-
affinity, low capacity uptake and low-affinity, high capacity uptake. A clear 
increase (approx. 4-fold) in thiamine uptake was observed in cells transfected 
with wild-type SLC19A3, confirming its function as functional thiamine 
transporter. In contrast, cells expressing mutant SLC19A3 do not show enhanced 
thiamine uptake when compared to mock-transfected cells, demonstrating that 
the mutation results in an absent or non-functional protein. 
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Figure 4. Thiamine transport assay. Thiamine uptake in HEK293 cells overexpressing empty 
vector (mock), wild-type (wt) or mutant (mutant) SLC19A3 in the presence of (a) a low 
concentration of radiolabeled thiamine (15nM) or (b) a high concentration of radiolabeled 
thiamine (10µM). Mock and mutant transfected cells take up only a marginal amount of 
thiamine while wild-type SLC19A3 overexpressing cells take up 4 times more thiamine. Error 
bars indicate the standard deviation. 
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Discussion 
By combining whole exome sequencing with homozygosity mapping we identified 
a homozygous nonsense mutation in SLC19A3 (c.20C>A; p.Ser7Ter) causing 
Leigh syndrome in a Moroccan consanguineous family. Because candidate regions 
after homozygosity mapping contained far too many genes for systematic 
sequence analysis and no obvious candidate gene, whole exome sequencing was 
performed yielding an average coverage of 52x and 17848 coding variants. 
Variants were filtered in various steps to exclude those unlikely to be pathogenic. 
In the first step, nonsynonymous variants and variants leading to premature stop 
codons were selected as these are most likely to affect protein function. In the 
next step, variants which are present in different SNP databases like dbSNP132 
and 1000 genomes [11][55] and have an allele frequency >0.01 were 
excluded. Subsequently only genes with homozygous variants were selected 
based on the autosomal recessive inheritance and consanguinity in the family. 
Finally, only the variants located within the homozygous candidate regions were 
considered candidates. This strategy revealed only one strong candidate, a 
homozygous nonsense mutation in SLC19A3, a gene previously reported to be 
involved in neurological disorders. The sequence of SLC19A3 in 17 additional Leigh 
patients was analysed and lead to the detection of the same homozygous c.20C>A 
in two unrelated patients of Moroccan origin. The brain MRI from patient II:5 of 
family b and patient II:9 of family c showed the same pattern of involvement of 
putamen, thalamus and cerebellar region as patient II:5 of family a suggesting 
the same disease. Marker analysis of the region surrounding the mutation in the 
three families showed a 0.74-1.35 Mb shared region between all affected 
individuals. This combined with the fact that the three families originated from the 
same province Al Hoceima in Northern Morocco supports the presence of a founder 
effect. Calculations to assess the age of the mutation revealed that the mutation 
occurred 1250-1750 years ago.   
Metabolic investigations in all families indicated a mitochondrial defect due to 
possible deficiency of the respiratory chain, the pyruvate dehydrogenase, the 2 
ketoglutaric acid dehydrogenase or the branched chain ketoacid dehydrogenase. 
A defect in the respiratory chain was excluded by the biochemical enzyme 
measurements. The normal oxygen consumption with glutamate and defective 
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oxygen consumption with pyruvate indicated a defect in pyruvate dehydrogenase. 
However, the pyruvate dehydrogenase activity measured in the presence of 
thiamine pyrophosphate was found to be either normal or increased, indicating 
there is no genetic defect of the pyruvate dehydrogenase complex but a defect of 
a cofactor. The cofactor which could explain the increase in the different 
metabolites such as lactate, pyruvate, 2- ketoglutaric acid, leucin and isoleucin is 
thiamine pyrophosphate, the active form of thiamine, indicating a possible defect 
in thiamine, thiamine transport or in the synthesis of thiamine pyrophosphate. 
SLC19A3 is one of the two thiamine transporters present in the plasma 
membrane.  In our patients, no functional SLC19A3 is predicted to be present, 
due to the premature stop codon, preventing the transport of thiamine in the 
cytoplasm by SLC19A3. Mutations in SLC19A3 have previously been associated 
with neurological disorders like, biotin responsive basal ganglia disease (BBGD) 
[12, 13], Wernicke’s-like encephalopathy [14] and epileptic spasm in early 
infancy, severe psychomotor retardation and progressive atrophy [15]. Our 
results identified Leigh syndrome with specific MRI abnormalities as a new 
neurological disease phenotype associated with mutations in SLC19A3. It has 
been suggested that loss-of-function mutations are associated with the BBGD 
phenotype [15]. However, our patients had Leigh syndrome caused by a 
homozygous nonsense mutation which does not support this hypothesis. 
Moreover, the c.980-14A>G mutation described by Debs et al in BBGD patients 
does probably not result in a complete skipping of exon 4 as wild-type transcript 
was still detectable in patients which indicates there is a decreased amount of 
protein rather than a complete absence [13]. Additionally, the BBGD families show 
typically striatal necrosis with caudate neurodegeneration which was not observed 
in any of our families, not even in the severely affected patients. Mutations in 
SLC19A2, the other thiamine transporter, have been described to cause 
megaloblastic anemia [16-18]. The affected tissues in SLC19A2 or SLC19A3 
deficiency correlate with the difference in expression of both thiamine 
transporters.  
Thiamine is imported into the cytosol by either SLC19A2 or SLC19A3 and 
converted into the active form, thiamine pyrophosphate (TPP), by thiamine 
pyrophosphokinase 1 (TPK1). TPP is an important cofactor in the cytosol for 
Exome Sequencing Reveals A Novel Moroccan Founder Mutation in SLC19A3
111
4
 
transketolase and in the mitochondria for pyruvate dehydrogenase (PDH), 2-
ketoglutarate dehydrogenase (2-KGDH) and branched chain α-keto acid 
dehydrogenase (BCKDH).  As SLC19A3 is the low affinity high capacity 
transporter, this will most likely lead to a deficiency of the cofactor TPP and of the 
TPP dependent processes. Whereas the other thiamine transporter, SLC19A2, is a 
high affinity low capacity transporter with a different tissue expression pattern. It 
is highly unlikely SLC19A2 can compensate the absence of a functional SLC19A3. 
Thiamine, or vitamin B1, is not synthesized by humans or other animals and is 
required in the diet as the thiamine reserves only last for 20 days. Absence of 
thiamine in the diet or due to alcohol consumption leads to Beri-Beri or Wernicke-
Korsakoff syndrome. Overlapping symptoms with Leigh syndrome are hypertonia, 
hypotonia, muscle weakness, dystonia, apneu, epilepsy, feeding problems, 
nystagmus and deafness. 
A central role for thiamine deficiencies or thiamine transport defects in Leigh 
syndrome and related neurological disease can be further deduced from the 
clinical phenotypes associated with mutations in TPK1, the mitochondrial thiamine 
transporter (SLC25A19) and the TPP dependent processes. Whereas patients with 
mutations in TPK1 presented with variable degrees of ataxia, psychomotor 
retardation, progressive dystonia and lactic acidosis [19], mutations in SLC25A19 
have been described in patients with bilateral striatal necrosis and chronic 
progressive polyneuropathy [20]. Mutations in PDHA1 and PDHB, both encoding 
subunits of the E1 component of the PDH and sharing a TPP binding site, have 
been reported to cause Leigh syndrome [21, 22]. Finally, mutations have been 
identified in different subunits of the BCKDH in patients with maple syrup urine 
disease [23]. Remarkably, all mutations in proteins involved in the thiamine 
metabolism, with the exception of SLC19A2, result in severe neurological 
symptoms demonstrating the importance of thiamine in brain development. 
Previous studies have shown that SLC19A3 expression is dependent on biotin 
levels. The phenotype in BBGD patients is likely the result of insufficient thiamine 
transport which can partly be restored by overexpression of SLC19A3 via high 
doses of biotin. This supports our hypothesis that mutations in BBGD patients lead 
to a decreased amount or activity of SLC19A3 instead of a completely non-
functional protein. Besides biotin, also administration of high doses of thiamine 
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has been reported to improve the clinical phenotype [14]. In this study it is 
suggested that the efficiency of high doses of thiamine indicates that dysfunction 
of SLC19A3 may induce expression of SLC19A2 increasing intracellular thiamine 
transport.  The only patients in our families who survived childhood (patients II:3 
and II:9 of family c) had been treated with a cocktail of vitamins, including 
thiamine and biotin. As it is highly unlikely that overexpression of the mutated 
SLC19A3 gene will be beneficial, this treatment might have induced a partially 
compensating up-regulation of SLC19A2, which could be sufficient for patients 
carrying this nonsense mutation to survive childhood.  For patients with TPK 
mutations, TPP has been suggested as a therapeutic option [19]. This might also 
be an option for patients with SLC19A3 mutations. However, as stated by Mayr et 
al., the effectivity and safety of TPP as a drug still needs to be demonstrated and 
it is unclear whether TPP can cross the blood brain-barrier [19]. In summary, we 
identified a nonsense mutation in SLC19A3 in a consanguineous Moroccan family 
with Leigh syndrome, expanding the spectrum of neurological disorders associated 
with mutations in SLC19A3 and pathways affected in Leigh syndrome. Our results 
further indicate that mutational screening of SLC19A3 should be considered in 
patients with mitochondrial disorders and neurological symptoms, especially in 
specific parts of Morocco. Finally, these patients might benefit from high doses of 
biotin or, more likely, thiamine which would make this a partly treatable form of 
Leigh syndrome. 
Acknowledgements 
We would like to warmly acknowledge the late neurologist Prof. dr. Herman F.M. 
Busch (Aug 21, 1929-Jan 21, 2005; Erasmus MC Rotterdam, The Netherlands), 
who has been involved in the clinical investigations, and L.M. Hussaarts for 
excellent technical support.  
 
Funding 
The work is supported by the Alma in Silico project, which is financed by the 
Interreg IV European funds, The Walloon Region, The North Rhine Westphalia, 
The Flemish Community, The Belgian Province of Limburg and The Dutch Province 
of Limburg, as well as by the Universities of Maastricht and Liège, by the Prinses 
Beatrix Fonds (grant W.OR11-24) and the Stichting Metakids. 
Exome Sequencing Reveals A Novel Moroccan Founder Mutation in SLC19A3
113
4
 
References 
1. Tucker, E.J., A.G. Compton, and D.R. Thorburn, Recent advances in the 
genetics of mitochondrial encephalopathies. Curr Neurol Neurosci Rep, 
2010. 10(4): p. 277-85. 
2. Matthews, P.M., et al., Molecular genetic characterization of an X-linked 
form of Leigh's syndrome. Ann Neurol, 1993. 33(6): p. 652-5. 
3. Grafakou, O., et al., Leigh syndrome due to compound heterozygosity of 
dihydrolipoamide dehydrogenase gene mutations. Description of the first 
E3 splice site mutation. Eur J Pediatr, 2003. 162(10): p. 714-8. 
4. Mootha, V.K., et al., Identification of a gene causing human cytochrome c 
oxidase deficiency by integrative genomics. Proc Natl Acad Sci U S A, 
2003. 100(2): p. 605-10. 
5. Pequignot, M.O., et al., Mutations in the SURF1 gene associated with Leigh 
syndrome and cytochrome C oxidase deficiency. Hum Mutat, 2001. 17(5): 
p. 374-81. 
6. Metzker, M.L., Sequencing technologies - the next generation. Nat Rev 
Genet, 2010. 11(1): p. 31-46. 
7. Ku, C.S., N. Naidoo, and Y. Pawitan, Revisiting Mendelian disorders 
through exome sequencing. Hum Genet, 2011. 129(4): p. 351-70. 
8. Scholte, H.R., et al., Oxidative phosphorylation in human muscle in 
patients with ocular myopathy and after general anaesthesia. Biochim 
Biophys Acta, 1990. 1018(2-3): p. 211-6. 
9. Seelow, D., et al., HomozygosityMapper--an interactive approach to 
homozygosity mapping. Nucleic Acids Res, 2009. 37(Web Server issue): 
p. W593-9. 
10. Risch, N., et al., Genetic analysis of idiopathic torsion dystonia in 
Ashkenazi Jews and their recent descent from a small founder population. 
Nat Genet, 1995. 9(2): p. 152-9. 
11. A map of human genome variation from population-scale sequencing. 
Nature, 2010. 467(7319): p. 1061-73. 
12. Zeng, W.Q., et al., Biotin-responsive basal ganglia disease maps to 2q36.3 
and is due to mutations in SLC19A3. Am J Hum Genet, 2005. 77(1): p. 
16-26. 
13. Debs, R., et al., Biotin-responsive basal ganglia disease in ethnic 
Europeans with novel SLC19A3 mutations. Arch Neurol, 2010. 67(1): p. 
126-30. 
14. Kono, S., et al., Mutations in a thiamine-transporter gene and Wernicke's-
like encephalopathy. N Engl J Med, 2009. 360(17): p. 1792-4. 
15. Yamada, K., et al., A wide spectrum of clinical and brain MRI findings in 
patients with SLC19A3 mutations. BMC Med Genet, 2010. 11: p. 171. 
16. Labay, V., et al., Mutations in SLC19A2 cause thiamine-responsive 
megaloblastic anaemia associated with diabetes mellitus and deafness. 
Nat Genet, 1999. 22(3): p. 300-4. 
Chapter 4
114
 
17. Raz, T., et al., The spectrum of mutations, including four novel ones, in 
the thiamine-responsive megaloblastic anemia gene SLC19A2 of eight 
families. Hum Mutat, 2000. 16(1): p. 37-42. 
18. Scharfe, C., et al., A novel mutation in the thiamine responsive 
megaloblastic anaemia gene SLC19A2 in a patient with deficiency of 
respiratory chain complex I. J Med Genet, 2000. 37(9): p. 669-73. 
19. Mayr, J.A., et al., Thiamine pyrophosphokinase deficiency in 
encephalopathic children with defects in the pyruvate oxidation pathway. 
Am J Hum Genet, 2011. 89(6): p. 806-12. 
20. Spiegel, R., et al., SLC25A19 mutation as a cause of neuropathy and 
bilateral striatal necrosis. Ann Neurol, 2009. 66(3): p. 419-24. 
21. Schiff, M., et al., Leigh's disease due to a new mutation in the PDHX gene. 
Ann Neurol, 2006. 59(4): p. 709-14. 
22. Quintana, E., et al., PDH E(1)beta deficiency with novel mutations in two 
patients with Leigh syndrome. J Inherit Metab Dis, 2009. 
23. Nobukuni, Y., et al., Heterogeneity of mutations in maple syrup urine 
disease (MSUD): screening and identification of affected E1 alpha and E1 
beta subunits of the branched-chain alpha-keto-acid dehydrogenase 
multienzyme complex. Biochim Biophys Acta, 1993. 1225(1): p. 64-70. 
 
 
 
 
 
 
  
Exome Sequencing Reveals A Novel Moroccan Founder Mutation in SLC19A3
115
4
 
Legends of supplemental figures 
  Supplementary Table 1. PCR primers for SLC19A3 
 PCR primers  5’ → 3’  
Gene-
Exon 
Forward Reverse 
Produ
ct 
size 
(bp)* 
SLC19A
3-Ex2 
CAACAGAGCGACCCTCC AATCAGGCTCACTGAGTTTAAT 386 
SLC19A
3-Ex3A 
ATGTTTCTCCGTAATGCGAATAA ACCGACCCTGCTGTGTA 432 
SLC19A
3-Ex3B 
GGCCTACTACGCCTACATATACA AACGTCCACAGTCACATTG 421 
SLC19A
3-Ex3C 
GAAGAGCAGAAACCCACATC CCGTGACTTTCATTCTTGAC 434 
SLC19A
3-Ex4 
ATTTATCTTTCAGAATTACCCGA
G 
GTTGGCTTAGTTGTGTCTAATT
T 
448 
SLC19A
3-Ex5 
GCTGGAGGTGGGTGACA 
TTTTAATTGCTTAACCAAGGAA
CTC 
354 
SLC19A
3-Ex6 
TCAGTTACCCCATAATCCAAGC CAAAGCATGTCAAGTTATGGCA 381 
* Extended with M13-sequence (For:TGTAAAACGACGGCCAGT and 
Rev:CAGGAAACAGCTATGACC) 
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Abstract 
This study aims to identify gene defects in paediatric cardiomyopathy and early-
onset brain disease with oxidative phosphorylation (OXPHOS) deficiencies. We 
applied Whole-Exome Sequencing in 3 patients with paediatric cardiomyopathy 
and early-onset brain disease with OXPHOS deficiencies. The brain pathology was 
studied by MRI analysis. In consanguineous patient 1 we identified a homozygous 
intronic variant (c.850-3A>G) in the QRSL1 gene, which was predicted to cause 
abnormal splicing. The variant segregated with the disease and affected the 
protein function, which was confirmed by complementation studies, restoring 
OXPHOS function only with wild-type QRSL1. Patient 2 was compound 
heterozygous for two novel affected and disease causing variants 
(c.[253G>A];[938G>A]) in the MTO1 gene. In patient 3 we detected one unknown 
affected and disease causing variants (c.2872C>T) and one known disease 
causing variant (c.1774C>T) in the AARS2 gene. The c.1774C>T variant was 
present in the paternal copy of the AARS2 gene, the c.2872C>T in the maternal 
copy. All genes were involved in translation of mtDNA-encoded proteins. Defects 
in mtDNA-encoded protein translation lead to severe paediatric cardiomyopathy 
and brain disease with OXPHOS abnormalities. This suggests that the heart and 
brain are particularly sensitive to defects in mitochondrial protein synthesis during 
late embryonic or early postnatal development, probably due to the massive 
mitochondrial biogenesis occurring at that stage. If both the heart and brain are 
involved, the prognosis is poor with a likely fatal outcome at young age. 
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Introduction 
In this study we searched for the genetic defect in paediatric patients with severe 
cardiomyopathy and early-onset brain disease with deficiencies in oxidative 
phosphorylation (OXPHOS). This is often lethal at a very young age. The affected 
hearts were mostly thick-walled and diagnosed as hypertrophic cardiomyopathy 
(HCM). The brain pathology was investigated with MRI. Additionally, muscle, liver, 
and developmental abnormalities were observed, this is not uncommon for 
OXPHOS diseases as the OXPHOS systems consists of 5 enzyme complexes, which 
generate ATP, the prime source of cellular energy, and OXPHOS defects often 
affect multiple organs and more particularly those organs with a high energy 
requirement. Overall, OXPHOS diseases have a prevalence of about 1 in 85000. 
Genetically, 13 of the structural proteins of the OXPHOS complex are encoded by 
the mtDNA, which has a genetic code different from the nuclear DNA and therefore 
also contains the necessary tRNA and rRNA genes to generate mtDNA encoded 
proteins [1]. The vast majority of the OXPHOS proteins, but also the proteins 
involved in replication, transcription and translation of the mtDNA, in assembly of 
the OXPHOS complexes, and in mitochondrial quality control are encoded by 
hundreds of nuclear genes. This implies that these disorders can have a dual 
genetic origin [2]. The extreme variability of the clinical manifestations and the 
high number of genes potentially precludes genotype-phenotype correlations and 
complete, unbiased approaches, like whole exome sequencing, have become the 
preferred and successful strategy to reveal the underlying genetic cause.  
 
We performed Whole-Exome Sequencing (WES) in 3 patients from unrelated 
families, one consanguineous and two non-consanguineous, in which mtDNA 
defects were excluded as cause. We filtered the consanguineous family for 
homozygous variants affecting protein function in regions of homozygosity, 
whereas for the non-consanguineous families first a targeted analysis of 412 
mitochondrial disease genes and functionally or structurally related genes was 
performed [3]. When negative, this was followed by an analysis of all genes 
captured and sequenced. For both approaches an autosomal recessive disease 
model was used [4-8]. In each family a severe defect in a different gene was 
identified causing the disease, but all 3 genes were involved in translation of 
mtDNA-encoded proteins.  
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Material and Methods 
 
Patients with Paediatric Cardiomyopathy, Early-Onset Brain Disease and 
OXPHOS Deficiency  
 
Patient I (Family I)  
Patient 2.2, the female proband of a consanguineous Turkish couple, was 
prenatally diagnosed with hypertrophic cardiomyopathy using fetal 
echocardiography (Ultrasound) and postnatally confirmed by electrocardiography 
(ECG). From birth she developed encephalopathy, failure to thrive, and lactic 
acidosis. Magnetic resonance imaging (MRI) of the brain at 5 months showed 
diffuse cerebral atrophy with T2 weighed imaging including hyper-intensive 
abnormalities in globus pallidus and putamen and also infratentorial in the dorsal 
brain stem, medulla oblongata and mesencephalon, which is characteristic for 
Leigh syndrome (Figure 1, the female patient 2.2).  
 
Figure 1. MRI of the brain data from patient I.2.2 1A.T1 weighted sagittal image: small 
corpus callosum, atrophy of the cerebellar vermis, abnormal intensity dorsal pons and 
mesencephalic region (arrow). 1B. Axial T2 weighted images showed subdural effusions, 
diffuse atrophy, frontal>occipital and hyperintensities in dorsal mesencephalon (arrow) in 
figure. 1C. Hyperintensities in the dorsolateral part of the putamen (arrow). All three figures 
showed Leigh syndrome. 
 
MRI spectroscopy of the white matter showed high lactic acid peak, and elevated 
biochemistry data for choline/creatine ratio, consistent with demyelination. She 
died at the age of 6 months. Her brother (2.1), with a comparable phenotype, 
died in utero and both were prenatally diagnosed with hypertrophic 
cardiomyopathy using fetal echocardiography (Ultrasound). Patient 2.2 was also 
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prenatally diagnosed with a growth delay and a head lag. This head lag in infants 
is showing a developmental delay in head and neck muscle control. In conclusion 
the pregnancy of 2.1 and 2.2 was not a normal development in contrast to 2.3 
and 2.4. Their parents, a second sister (2.3), and the youngest brother (2.4) were 
healthy (Figure 2A).  
 
Figure 2. Pedigree of 3 families with paediatric cardiomyopathy and Leigh (Family A) or 
Leigh-like syndrome (Family B and C) with multiple OXPHOS deficiencies. 2A. Patient I.2.1 
and I.2.2 from a consanguineous marriage carried a homozygous splicing defect in QRSL1 
gene (NC_000006.11(NM_018292.4)). 2B. Patient II.2.1 showed two novel variants in the 
MTO1 gene (NM_001123226.1). 2C. Patient III.2.1, III.2.2, and III.2.3 showed two variants 
in the AARS2 gene (NM_020745.3). 
 
The relative activities of OXPHOS enzyme complexes in muscle tissue biopsy of 
patient 2.2 were normalized to Citrate Synthase (CS); CI=41%, CII=68%, 
CIII=70%, CIV=71%, CV=40%. Skin fibroblast (2.2) OXPHOS data showed 
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CI=43%, CII=81%, CIII=86%, CIV=54%, CV=64%. This indicates a complex I 
and V deficiency in muscle and a complex I, IV and V deficiency in fibroblasts. 
Patient 2 (Family II) 
Patient 2.1 was diagnosed with a severe paediatric, hypertrophic cardiomyopathy 
(HCM) by ECG and died at the age of 1.5 year. He was the only child of non-
consanguineous Dutch healthy parents (Figure 2B) during a normal pregnancy. 
He showed diffuse cerebral atrophy with intraventricular septa on the MRI, 
characteristic for brain disease, and high levels of alanine and lactic acid, 
suggesting a mitochondrial disorder. The relative activities of OXPHOS enzyme 
complexes in muscle biopsy material of patient 2.1 were normalized to CS; 
CI=11%, CII=128%, CIII=25%, CIV=11%, CV=61%, showing a severe 
deficiency of complex I, III and IV. Skin fibroblast data showed a decreased 
activity of CI=50%, unfortunately CII, CIII, CIV, CV were not determined. 
Patient 3 (Family III) 
Patient 2.1 was born dysmature and was diagnosed at birth with severe 
hypertrophic cardiomyopathy (HCM) by ECG, and encephalomyopathy, persistent 
hypotonia, lung hypoplasia, and also high levels of lactic acid.  Two other male 
siblings showed a similar phenotype and all three affected siblings died within 2 
weeks after birth (2.2 within 1 day, 2.1 within 4 days, and 2.3 within 16 days) 
(Figure 2C). The Dutch healthy parents were unrelated. Patient 2.1 and 2.2 
patients were described as a spontaneous twin pregnancy and no complications 
before planned section Caesarea. Nevertheless, after birth patient 2.2 showed 
immediately lung hypoplasia and died after 2 hours post-mortem. No further 
information of patient 2.3 was available. Muscle biopsy (2.1) taken directly after 
birth showed many COX negative fibers with no other abnormalities. Postmortem 
brain pathology (2.1) confirmed the postmortem MRI and showed degeneration 
of the fasciculus gracilis and cuneatus with some vacuolization of the substantia 
nigra, characteristic for Leigh-like syndrome. The HCM was also confirmed during 
the postmortem heart pathology (2.1). The heart tissue was observed by 
transmission electron microscopy (TEM) and showed abnormal mitochondria, 
which were less in amount and large in size (Data not shown). The relative 
Genetic Defects in mtDNA-encoded Protein Translation
123
5
activities of OXPHOS enzyme complexes in muscle tissue biopsy of patient 2.1 
were normalized to CS; CI=27%, CII=120%, CIII=11%, CIV=6%, CV=48%. Skin 
fibroblast data showed activities of CI=45%, CII=67%, CIII=119%, CIV=97%, 
CV=107%.  In muscle all complexes showed a decreased activity, except complex 
II, whereas in fibroblasts only complex I was decreased.  
Homozygosity Mapping 
Homozygosity mapping was performed using the Affymetrix GeneChip Human 
Mapping 250K SNP array (Affymetrix, Santa Clara, US) using peripheral blood 
DNA of consanguineous parents and siblings (Family I). The DNA was labelled and 
processed according to the manufacturer’s instructions. Genotypes were 
generated by the Affymetrix Genotyping Analysis Software (GTYPE). Homozygous 
regions were determined by the online tool Homozygosity 
Mapper,(http://www.homozygositymapper.org/).  
Whole-Exome Sequencing and Analysis 
Genomic DNA was isolated from peripheral blood leukocytes using the DNeasy 
Blood & Tissue kit (Qiagen, Hilden, Germany). The quality of the genomic DNA 
was determined on a NanoDrop (Wilmington, USA) and by Agarose gel 
electrophoresis and finally quantified with PicoGreen on a Qubit fluorometer 
(Invitrogen, Bleiswijk, The Netherlands). A total of 4µg starting material was used, 
which was further purified with a DNA Clean & Concentrator TM (ZymoResearch, 
BaseClear Diagnostics, Leiden, The Netherlands). The genomic DNA was 
fragmented to 150-200bp lengths by shearing on a Covaris S2 (Covaris Inc, 
Massachusetts, US). The exome was captured with the SureSelect Human All Exon 
V4 plus UTR’s kit (Agilent, Technologies, Amstelveen, The Netherlands) for Paired-
End Illumina Sequencing platforms (Illumina, Eindhoven, The Netherlands) using 
the standard SureSelect protocol (version 1.3). Quality was controlled on a 
Bioanalyzer 2100 (Agilent). Basecalling was performed using Casava 1.8 
(Illumina). Reads were aligned to the human reference genome (UCSC hg19) 
using Burrows-Wheeler-Alignment tool (BWA) version 0.5.9. Single base variants 
were identified using Sequence-Alignment-MAP tools (SAM) version 0.1.16 and 
annotated according an in-house annotation Python/R script that matched 
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variants to the RefGene, GenCode v19, and dbSNP144 hg19 tracks from the UCSC 
genome browser. Variants between the proband and the reference sequence were 
annotated and listed in an Excel file for further analyses. Two filtering strategies 
were applied. In the consanguineous patient I.2.2 homozygous variants from 
homozygosity regions were analysed. In the non-consanguineous patients II.2.1 
and III.2.1, first a diagnostic panel of 412 mitochondrial genes was analysed for 
compound heterozygous variants, and if negative all captured genes would be 
analysed.  
 
All variants were filtered for a predicted functional effect (nonsense, missense, 
INDELs and splice site variants) and frequency (<1% or absent in sequence 
databases (dbSNP144, Exome Variant Server (EVS), Exome Sequencing Project 
(ESP), Exome Aggregation Consortium (ExAC) and in-house patient database). 
Possible splice site variants were analysed with Maximum Entropy Modeling of 
Short Sequence Motifs (MaxEnt), Neural Networks Berkeley Drosophila Genome 
Project (NNSPLICE) and Human Splicing Finder (HSF). Missense variants were 
classified, using SIFT (http://sift.jcvi.org/) and PolyPhen-2 
(http://genetics.bwh.harvard.edu/pph2/). Additionally, in the consanguineous 
patient I.2.2, novel genes carrying variants were prioritized for their likelihood of 
being involved in mitochondrial disease using Weighted Gene Expression Tool and 
database (WeGET: http://weget.cmbi.umcn.nl). Shortly, remaining variants were 
analysed for their co-expression with genes encoding mitochondrial proteins 
(mitochondrial system) in mammalian tissues. A weighted average of co-
expression with mitochondrial system was calculated for all genes containing rare 
variants affecting protein function. A higher contribution was assigned to datasets 
that showed congruent expression (concomitant up- and down-regulation) of the 
mitochondrial system itself. The variants affecting the protein function and could 
be the cause of the disease in the patient were submitted to the gene variant 
database. Links were described as: 
1) www.lovd.nl/QRSL1, (QRSL1; #00100428: patient I.2.2), 2) 
www.lovd.nl/MTO1, (MTO1; #00100427: patient II.2.1), and 3) 
www.lovd.nl/AARS2, (AARS2; #00100426: patient III.2.1). Relevant variants 
were sequenced with gene specific primers with an M13 tail and the BigDye 
Terminator v1.1 Cycle Sequencing kit (Applied Biosystems, Bleiswijk, The 
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Netherlands) on an ABI 3730 DNA Analyzer. Data were processed using Sequence 
Scanner v1.0 from Applied Biosystems. 
 
cDNA Analysis and Complementation Assay of QRSL1 
All primers used are listed in Table 1. RNA was isolated from patient and neonatal 
dermal human fibroblast cells (NDHF control cells) using Total RNA Isolation Kit 
according to the manufacturer’s manual (Roche Nederland B.V., Almere, The 
Netherlands). Copy DNA (cDNA) synthesis was performed by the qScript cDNA 
Synthesis Kit (Quanta Biosciences, Gaithersburg, MD, USA) using 1µg of RNA 
input. Standard PCR steps: 1) 5 min 94⁰C, 2) 1 min 94⁰C, 3) 1 min 58⁰C, 4) 1.5 
min 72⁰C, 5) 7 min 72⁰C, repeat step 2-4 34 cycles and cooling down to 4⁰C. 
QPCR mRNA expression protocol were designed to generate a cDNA fragment 
across the site of the QRSL1 variant.  QRSL1 mRNA expression was measured by 
the 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, 
USA) and was based on a primer pairs at exon 7 (209bp amplicon), intron 7- exon 
8 (169bp amplicon, splice position), exon 8 (202bp amplicon) and exon 9 (162bp 
amplicon) of the QRSL1 transcript (NM_018292.4). QRSL1 expression was 
corrected for the TBP housekeeping gene (TATA box–binding protein, 
NM_003194.4, primer set in exon 5, 89bp amplicon). Sensimix Sybr Hi-Rox 
(Bioline, Taunton, MA, USA) was used for cDNA amplification under the following 
conditions: 2 min 50⁰C, 2 min 95⁰C, followed by 40 cycles of 15 s 95⁰C 
(denaturation) and 1 min 60⁰C (annealing and extension). Non-specific primer 
annealing was excluded by analysis of a primer dissociation curve which was 
obtained by the following PCR steps: 15 s 95⁰C, 15 s 60⁰C, 15 s 60⁰C, cooling 
down to 4⁰C. For patient 1 QRSL1 mRNA expression was calculated using the 
standard 2 - ΔΔ Ct method towards a TBP housekeeping gene, and compared to 
healthy control NDHF cells. The mutant spliced cDNA 
(NC_000006.11(NM_018292.4):c.850-3A>G) resulted in a percentage wild-type 
rest level of the normal spliced cDNA in exon 8.  Mutant and wild-type PCR 
fragments were cloned using the pGEM T Easy cloning system (Promega, Madison, 
USA). Wild-type QRSL1 was expressed using QRSL1 cDNA (NM_018292.4) 
pcDNA3.1_DYK clone (Genscript, Piscataway, US). All wild-type and mutant 
(patient 1 cDNA) QRSL1 constructs were also cloned in a pUltra-Chili Lentiviral 
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(Addgene, Cambridge, US) with special restriction enzymes sites primers (with an 
overhang generating restriction sites for BamHI (GGATCC) and XbaI (TCTAGA). 
 
Table 1. Primers 
Primers Forward Reverse 
QRSL1_M13_F 
TGTAAAACGACGGCC
AGTCCCAACCAGATC
TCCAATCTTT 
  
QRSL1_M13_R   CAGGAAACAGCTATGACCCCATATTCGATGCCACTTCTGA 
QRSL1_exon6_F TGTGCCAGGAATCTTAACCAGA   
QRSL1_exon9_R   ACATGGCTTCAGTGGACACATC 
Pultra_QRSL1_F CCTTCTAGAATGGATTACAAGGATGACGAC   
Pultra_QRSL1_R   GCCGGATCCTTATCATTACTGTTTTAGAGA 
QRSL1_pcDNA3.1_XbaI_F 
CTTTCTAGAATGCTG
GGCCGGAGCCTCCG
AGAA 
  
QRSL1_pcDNA3.1_BamHI_R   GCCGGATCCTTACTGTTTTAGAGAGAC 
QRSL1 QPCR_Exon 7_F TGTGCCAGGAATCTTAACCAGA   
QRSL1 QPCR_Exon 7_R   ACTGGGAAGCATGAATGGTTTA 
QRSL1QPCR_Intron 7_Exon 8_F TCCAGCCTAGGTGACAGAGTGA   
QRSL1 QPCR_Intron 7_Exon 8_R   ACATGGCTTCAGTGGACACATC 
QRSL1 QPCR_Exon 8_F ACCAAAGGTCCTGAAGTACAGATTT   
QRSL1 QPCR_Exon 8_R   ATTACTTTGGCCCCCTCAGACT 
QRSL1 QPCR_Exon 9_F GGCCTGATTTTAGCCAAAACTTTAC   
QRSL1 QPCR_Exon 9_R   GAATTCTTCCTCTCACCACATCA 
TBP QPCR_Exon 5_F CACGAACCACGGCACTGATT   
TBP QPCR_Exon 5_R   TTTTCTTGCTGCCAGTCTGGAC 
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Metabolic Complementation Experiments 
 
Human fibroblasts were grown in media containing either glucose or galactose as 
the main carbohydrate source and the acidification rate (ECAR) or the oxygen 
consumption rate (OCR) was determined with the Seahorse device (Seahorse 
Biosciences, Massachusetts, US), according to the protocol of the manufacturer. 
Fibroblasts of patient I.2.2 and a control were transduced with wild-type and 
mutant (without exon 8) cDNA, cloned in a QRSL1-pUltra-Chilli Lentiviral vector 
[9]. The results for mitochondrial respiration are normalized to control fibroblasts, 
transduced with wild-type cDNA. 
 
Results 
 
Patient I 
For patient I.2.2 a total of 41,338 variants were detected in the WES data, of 
which 366 were homozygous variants mapping in the regions of homozygosity 
(ROH). Variants that affected protein function were determined by in silico protein 
prediction tools, resulting in 24 of low frequency, damaging candidate variants 
(Supplementary table 4). The genes involved were prioritized for their likelihood 
of causing mitochondrial disease using Weighted Gene Expression Tool and 
database (WeGET). Based on this prioritization list we started our analysis with 
the QRSL1 gene, located in the ROH of chromosome 6, which carried a 
homozygous intronic variant A>G (NC_000006.11(NM_018292.4):c.850-3A>G 
(p.?), NP_060762.3), (Figure 2A). The QRSL1 variant possibly leads to abnormal 
splicing, based on 3 splicing predictions (Maximum Entropy Modeling of Short 
Sequence Motifs (MaxEnt): -100.0%, Neural Networks Berkeley Drosophila 
Genome Project (NNSPLICE): -98.6% and Human Splicing Finder (HSF): -1.1%), 
which showed that the normal splice acceptor site was slightly reduced and an 
acceptor site 3 bps downstream could be used. Functional splicing validation was 
required and segregation analysis showed that both affected siblings (I.2.1 and 
I.2.2) were homozygous for the variant. The parents (I.1.1 and I.1.2) were 
heterozygous, as was the unaffected brother (I.2.4). The unaffected sister (I.2.3) 
did not carry the variant (Figure 2A).  
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PCR amplification of the QRSL1 cDNA using primers spanning the site of the 
variant, followed by sequence analysis revealed three different PCR fragments of 
439bp, 330bp and 243bp for the mutant, whereas the wild type control cDNA 
showed only one band of 439bp (Figure 3A, B).  
 
 
Figure 3. Analysis of splice defects in QRSL1 cDNA in patient I.2.2. 3A. QRLS1 cDNA of 
patient I.2.2 with variant A>G (NC_000006.11(NM_018292.4):c.850-3A>G) showed three 
cDNA fragments. 3B. Sequence analysis confirmed 3 different splicing events of intron 7 and 
8, resulting in fragments of 439bp (wild-type), 330bp and 243bp. 3B. Percentage wild-type 
cDNA in patient I.2.2 compared to controls. The wild-type of patient I.2.2 cDNA (c.850-
3A>G) resulted in a wild-type significant rest (*) level of 40% of the normal spliced cDNA 
in exon 8 (p<0.05 by student T-test), three splice events for QRSL1 exon 8 in 3C.  
 
Additional denaturing 10% UREA PAGE gel confirmed the presence of 3 different 
fragments, excluding the possibility of one band being a hetero-duplex (Data not 
shown). Sequence analysis showed that in the PCR fragment of 243bp exon 8 was 
completely absent (NM_018292.4:r.850_1042del), leading to a frameshift and 
premature stop codon at exon 9. In the PCR fragment of 330bp, exon 8 was partly 
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retained (37 amino acids of a total of 64 (NM_018292.4:r.850_931del), therefore 
missing 27 amino acids) and an exonic splice acceptor was used at position 
NM_018292.4:r.933 (c.933A). This also caused a frameshift and premature stop 
codon at position NM_018292.4:r.887* (c.887C). The 439bp fragment was the 
normally spliced cDNA fragment. Quantitative PCR analysis showed that wild-type 
cDNA was about 40% of the amount observed in control fibroblast (Figure 3C).  
 
Metabolic complementation measurements in fibroblasts of patient I.2.2 showed 
defects in glycolysis and OXPHOS. For a complementation test wild-type and 
mutant QRSL1 cDNAs was cloned in a pUltra-Chili Vector and subsequently used 
to transduce the fibroblasts of patient I.2.2 NDHF cells were negative controls. 
Patient cells transduced with wild-type cDNA QRSL1 showed a 61% OXPHOS 
activity (42% increase compared with non-transduced patient cells). The control 
cells showed a 51% OXPHOS activity when transduced with variant 1 (exon 8 was 
completely absent) cDNA QRSL1 (Figure 4). Polybrene was added to enhance the 
expression after transduction, but in addition to that a minor cytotoxic effect was 
observed in all cells for all conditions. 
 
 Figure 4. Complementation of QRSL1 defects in fibroblasts with 2 different vectors. 
Transduction with QRSL1 cDNA without exon 8 showed a significant decrease of 49% ATP 
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production in control cells. A significant increase of 42% ATP production in patient (I.2.2) 
and patient (I.2.2) plus transduced wild-type cDNA QRSL1 was observed. Both conditions 
were significant results (p<0.05) by student T-test. The standard deviation was measured 
at four independent time points after transduction (Wild-type or mutant) and non-
transduced (Control or Patient I.2.2). The results for mitochondrial respiration are 
normalized to control fibroblasts, transduced with wild-type cDNA.  
 
Patient II 
In patient II.2.1 we detected 4540 variants in the 412 mitochondrial genes, of 
which the MTO1 gene, containing two novel variants (NM_001123226.1, 
NP_001116698.1), Alanyl-tRNA Synthase 10, Supplementary table 5), was the 
most likely candidate based on function and genotype-phenotype correlation [16, 
17]. The patient carried a G>A substitution (NM_001123226.1:c.253G>A) in exon 
2, changing p.(G85R), and a G>A substitution (NM_001123226.1:c.938G>A) in 
exon 5, changing p.(R313Q), both of which were damaging by in silico predictions 
of Polyphen (probably damaging, score 0.95) and Sorting Intolerant From Tolerant 
(SIFT-deleterious, score 0.001). The first variant was not present in the in-house 
and ExAC database, whereas the second variant (rs number 371179032) had a 
very low allele frequency (1/1211348, AF=8.241E-6) in the ExAC database. Both 
variants were located in functional protein domains of MTO1, which were highly 
conserved, based on protein BioGraph annotated predictions. Each parent (II.1.1 
and II.1.2) was heterozygous for one of the variants (Figure 2B). 
 
Patient III 
In patient III.2.1 we detected 4917 variants in the 412 mitochondrial genes, of 
which we identified two unknown variants and one known variant in the AARS2 
(NM_020745.3, NP_065796.1, Alanyl-tRNA synthetase) gene (Supplementary 
table 6). Based on the HCM and Leigh-like phenotype, the AARS2 (Alanyl-tRNA 
synthetase) gene was the best candidate gene from the list (Supplementary table 
6). The first variant was a G>A substitution (NM_020745.3:c.1774C>T) in exon 
13 (rs138119149 with a frequency of 0.001), causing a substitution of p.(R592W) 
with a damaging score based on Polyphen (probably damaging score 0.97) and 
SIFT (deleterious score 0.002).  The first variant was listed in ExAC: rs138119149 
(33/121110, AF=0.0002725). The second variant was a G>A nonsense variant 
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(NM_020745.3:c.2872C>T) in exon 22 had no rs number and was not present in 
the in-house or ExAC databases, p.(R958*). The unaffected father was 
heterozygous for the G>A (c.1774C>T) substitution in exon 13 and the unaffected 
mother was heterozygous for the nonsense variant c.2872C>T in exon 22 (Figure 
2C). 
Discussion 
Cardiomyopathy is a disease of the heart muscle, interfering with efficient 
contraction and often leading to heart failure. According to the definition of the 
American Heart Association (AHA), cardiomyopathies can be either primary 
limited to the heart or can be a secondary result of other illnesses [10], Table 2. 
In 3 families with paediatric cardiomyopathy, brain disease, and multiple OXPHOS 
deficiencies we identified the causative variant by WES. Given the genetic 
heterogeneity of OXPHOS disorders with more than 1400 nuclear genes potentially 
involved, WES is the best suitable unbiased approach for finding the underlying 
genetic cause [11]. We started with an autosomal recessive disease model and in 
case of consanguinity as in patient I.2.2, we focused on homozygosity regions.  
The second patient from a consanguineous marriage carried a homozygous 
splicing defect (NC_000006.11(NM_018292.4):c.850-3A>G, NP_060762.3) in the 
QRSL1 gene, leading to 2 mRNAs with a premature stop codon and a strong 
reduction of the normal mRNA.  A complementation assay confirmed a causative 
role in the complex I deficiency and pathology. Therefore, we did not proceed with 
other candidate genes on the list. During the course of our studies a paper was 
published, reporting the first disease-causing variants in the QRSL1 gene. A 
homozygous variant (NM_018292.4:c.398G>T (p.(G133V)) was presented in a 
consanguineous family with two affected siblings (Patient Y and Z in Table 3) 
including hypertrophic cardiomyopathy (HCM) [12].  Also, a compound 
heterozygosity for the variants (NM_018292.4:c.350G>A (p.(G117E) and 
NM_018292.4:c.398G>T (p.(G133V)) was reported in another non-HCM patient 
(Patient AA in Table 3) with interstitial pneumonia and mitochondrial respiration 
deficiencies [12]. These data confirmed the involvement of QRSL1 in paediatric 
cardiomyopathy with OXPHOS deficiency.  
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The clinical manifestations vary, and based on the limited data, a strong red uction 
in QRSL1 seems more severe than the amino acid changes reported, although 
data on the brain phenotype are lacking (Tables 2, 3). QRSL1 (or GatA) is part 
of a heterotrimeric enzyme complex GatCAB; GatA, GatB (PET112L), and GatC 
(GATC). GatA (QRSL1) plays a role as a mitochondrial amido-transferase, 
recognizing Glu-tRNA (Gln) and converts Glu to Gln. An accumulation of Glu-tRNA 
previously showed defects of mitochondrial mammalian translation processes and 
respiration [13]. The QRSL1 defect can explain the observed defects in glycolysis 
and OXPHOS. This is supported by earlier data on the role of mitochondrial 
translation and glutaminyl-mt tRNAGln in mouse cells, which demonstrated that 
mgatA produced a strong mitochondrial translational aminoacylation defect [14]. 
In Drosophila, null mutants of GatA gene, the homolog of QRSL1, caused larvae 
to grow slowly and die before pupariation [15]. As one (I.2.1) of the siblings of 
family 1 died in utero this could reflect a similar developmental defect. Both 
studies support the essential role for glutaminyl-mt tRNAGln in mitochondrial 
protein synthesis and OXPHOS. 
 
In patient II.2.1 we identified two novel variants in the MTO1 gene, which is 
involved in mitochondrial tRNA modification. MTO1 catalyzes the 5-
carboxymethylaminomethylation of the uridine base in mitochondrial tRNA-Gln, 
tRNA-Glu, and tRNA-Lys, usually together with MTO2 (TRMU). A disease-causing 
role of MTO1 in mitochondrial patients with hypertrophic cardiomyopathy (Table 
2, 3) has been described before [16, 17]. The two variants 
(NM_012123.3:c.1282G>A (p.(Ala428Thr) and NM_012123.3:c.1858dup 
(p.(Ala620Lysfs*8)) in siblings patients P and Q showed early-onset lethal HCM, 
but normal brain anatomy (Table 3). An unrelated third consanguineous patient 
R with NM_012123.3:c.1282G>A (p.(Ala428Thr) showed HCM without lethality, 
and also normal brain development. In two consanguineous families (lethal male 
siblings T/U and non-lethal female siblings V/W) a homozygous variant 
(NM_012123.3:c.1232C>T (p.(Thr411Ile)) was reported causing early-onset HCM 
including abnormal brain morphology by MRI. Our two novel variants in MTO1 
gene in patient II.2.1 (Table 3, patient X) displayed a similar early-onset HCM, a 
diffuse cerebral atrophy with an intraventricular septa, and multiple OXPHOS 
deficiencies, and lethality at 19 months. 
Genetic Defects in mtDNA-encoded Protein Translation
139
5
 
In patients III.2.1, III.2.2 and III.2.3 we identified two variants in the AARS2 
gene: NM_020745.3:c.1774C>T (p.(R592W) , and NM_020745.3:c.2872C>T 
(p.(R958*). AARS2 consists of three functional domains; the N-terminal catalytic 
domain, the Editing domain and the C-terminal (C-Ala domain). The AARS2 gene 
belongs to the class-II aminoacyl-tRNA synthase family and the protein is 
functional as a dimer. The first variant (c.1774C>T) on the paternal allele are in 
the editing domain of the AARS2 gene. The editing domain removes incorrectly 
charged amino acids and the first (c.1774C>T) variant is previously reported as a 
disease-causing variant associated with HCM and a poor prognosis [18, 19].  The 
second novel stop (c.2872C>T) variant on the maternal allele is located in the c-
terminus (C-Ala domain) for the AARS2 gene and most likely leads to nonsense-
mediated decay of the transcript. The presence of a reduced amount of the protein 
and the presence of 2 detrimental amino acid substitutions in the other allele 
could, especially in dimers like AARS2, explain the more severe disease 
manifestation, of paediatric cardiomyopathy, Leigh-like syndrome, and multiple 
OXPHOS deficiencies. One of the patients in literature (patient D in Table 3) was 
compound heterozygous for the same missense mutation in combination with a 
frameshift mutation (NM_020745.3:c.[647dup];[1774C>T]), 
(p.[(C218Lfs*6)];[(R592W)]). The frameshift variant (p.(C218Lfs*6)) probably 
leads to nonsense-mediated decay of the transcript. Both variants resulted in 
cardiomyopathy and lethality after 3 months of birth [19-21]. 
 
Different variants affecting protein function have been reported for the AARS2 
gene resulting in HCM, leukodystrophy, and ovarian failure [20, 21] and a 
genotype-phenotype correlation is needed for novel variants in genes. Structural 
modeling of tissue-specific mitochondrial alanyl-tRNA synthetase (AARS2) defects 
was previously reported to predict different effects on aminoacylation activity level 
for the protein [21]. The study showed a clear correlation between the amino acid 
change (p.(R592W)) and the severity of the predicted aminoacylation activity of 
AARS2 linked to cardiomyopathy. In case of a significant residual amount of 
mischarged aminoacids, the predicted activity of aminoacylation resulted in a 
brain disease phenotype. Strikingly, none of the missense variants in 
leukodystrophy patients were reported in the editing domain in contrast to the 
cardiomyopathy patients [21]. Nevertheless, several missense variants were 
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described outside the editing domain (N-terminal catalytic and C-terminal (C-Ala 
domain) and caused a cardiomyopathy phenotype [18, 19, 21]. Further insights 
in protein modeling and in vivo studies (e.g. mice or zebrafish) can further 
elucidate the role of translation defects during mitochondrial protein synthesis. 
 
In all three patients, paediatric cardiomyopathy, early-onset brain disease, and 
multiple OXPHOS deficiencies were present. Our data, together with other reports, 
indicates that the heart is sensitive to severe defects in mitochondrial translation 
during prenatal development (Table 2).  The heart muscle consists for 30% of 
mitochondria, which have a critical role in the structure alignment of heart muscle 
fibres and, in supplying the heart with sufficient energy.  Adequate mitochondrial 
translation is essential for both processes, especially during development when 
the heart differentiates from early embryonic cells by massive proliferation of the 
mitochondria. It is therefore likely that the disturbed translation causes structural 
problems (hypertrophic cardiomyopathy) in combination with OXPHOS defects in 
the prenatal and neonatal heart. Evidence supporting this hypothesis can be 
derived from other cardiomyopathy disease causing variants in mitochondrial 
translation, like the tRNAGly NC_012920.1:m.9997T>C, tRNAHis 
NC_012920.1:m.12192G>A, tRNALys NC_012920.1:m.8344A>G, tRNALeu 
NC_012920.1:m.3243A>G and NC_012920.1:m.3302A>G, tRNAIle 
NC_012920.1:m.4317A>G, tRNATrp NC_012920.1:m.5545C>T, and tRNAVal 
NC_012920.1:m.1644G>A. Furthermore, other defects in nuclear genes involved 
in mitochondrial protein synthesis are reported to cause pediactric 
cardiomyopathy e.g. mitochondrial ribosomal subunits (MRPL3, MRPL44), tRNA-
modifiers (GTPBP3), and RNA processing enzyme (ELAC2) [21, 22]. 
Cardiomyopathy can be the sole manifestation, but it can also be part of a broader 
syndromic spectrum. However, not all defects in genes involved in mitochondrial 
translation lead to hypertrophic cardiomyopathy, as apart from the AARS2 gene 
none of the tRNA synthetases genes affect the heart, but rather the brain, liver, 
and peripheral nervous system (Table 2). The number of variants involved in 
translation of mitochondrial proteins, is yet too low to define whether this is gene-
specific or variant-specific, except for the AARS2 gene where a genotype-
phenotype correlation has been established. 
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Figure 5. Mitochondrial Biogenesis. A schematic overview of the pathways involved in 
mitochondrial biogenesis, including the translation processes, affected in our patients. 
The reported genes are highlighted. 
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In conclusion, our study showed disease-causing variants in the nuclear 
aminoacyl-tRNA synthetase genes (AARS2, MTO1, QRSL1), causing paediatric 
cardiomyopathy, brain, and multiple OXPHOS deficiencies (Figure 5). As the 
expression can be variable, it would be worthwhile to investigate the brain, even 
if the patient only presents with cardiomyopathy, as this is important for 
prognosis.  Our data are in line with a key role of mitochondria in cardiovascular 
genetics and disease [23]. 
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Abstract 
  
High mitochondrial DNA (mtDNA) copy numbers are essential for oogenesis and 
embryogenesis and correlate with fertility of oocytes and viability of embryos. To 
understand the pathology and mechanisms associated with low mtDNA copy 
numbers, we knocked down mitochondrial transcription factor A (tfam), a 
regulator of mtDNA replication, during early zebrafish development. Reduction of 
tfam using a splice-modifying morpholino (MO) resulted in a 42%±17% decrease 
in mtDNA copy number in embryos at 4 days post fertilization. Morphant embryos 
displayed abnormal development of the eye, brain, heart and muscle, as well as 
a 50%±22% decrease in ATP production. Transcriptome analysis revealed a 
decrease in protein-encoding transcripts from the heavy strand of the mtDNA, and 
down-regulation of genes involved in haem production and the metabolism of 
metabolites, which appear to trigger increased rRNA and tRNA synthesis in the 
nucleoli. However, this stress or compensatory response appears to fall short as 
pathology emerges and expression of genes related to eye development are 
severely down-regulated. Taken together, this study highlights the importance of 
sufficient mtDNA copies for early zebrafish development. Zebrafish is an excellent 
model to manipulate the mtDNA bottleneck and study its effect on embryogenesis 
rapidly and in large numbers of offspring.  
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Introduction 
Mitochondria are responsible for producing the majority of cellular energy in the 
form of ATP. Depending on the tissue type and energy requirement, a cell can 
contain up to thousands of mitochondria, each having multiple copies of 
mitochondrial DNA (mtDNA). Of all cell-types, mtDNA copy numbers are the 
highest in oocytes, ranging between 100,000 and 400,000 copies in mammals, 
such as rodents, cows and humans, and up to 16,5 million copies in zebrafish [1]. 
The high mtDNA copy number in oocytes is established by an initial reduction 
during embryogenesis, called the mitochondrial bottleneck, followed by clonal 
expansion of the mtDNA during oogenesis appears to be important for successful 
fertilization and embryogenesis [2]. In mice, the oocyte mtDNA copy number 
should be sufficient for normal development until implantation at day 4, and it has 
been demonstrated that oocytes with less than 50,000 mtDNA copies fail to 
resume development after implantation [3, 4]. This negative correlation between 
mtDNA copy number and developmental competence of embryos has also been 
suggested for human oocytes [5].   
 
Mitochondrial transcription factor A (TFAM), a protein of the high mobility group 
box-family, is a key activator of mtDNA replication and transcription [6] and is 
crucial for the regulation of mtDNA copy number [7]. A direct relation between 
the mtDNA copy number and the total TFAM protein level has been demonstrated 
in mice embryos with a heterozygous or homozygous disruption of the Tfam gene 
[8]. Homozygous TFAM knockout (KO) mouse embryos displayed a strong mtDNA 
depletion with severely reduced functioning of the electron transport chain (ETC) 
and died after gastrulation and implantation, while heterozygous KO TFAM mice 
had moderately reduced mtDNA levels and respiratory chain deficiency, which was 
strongest in the developing heart [7]. These studies demonstrated the importance 
of a sufficient mtDNA copy number during oogenesis and embryogenesis, but the 
mechanism by which a reduced mtDNA copy number affects embryogenesis is 
currently unknown. 
 
Studying embryonic development in zebrafish overcomes ethical and practical 
obstacles associated with the use of human or mouse embryos. Zebrafish are 
vertebrates, >70% of human genes have at least one zebrafish orthologue, and 
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the major tissues and organs are the same. Zebrafish are transparent during early 
development and have a high number of offspring. Organs develop within 5 days 
post fertilization and gene knockdown during early embryogenesis can be 
performed by injection of morpholino antisense oligonucleotides (MOs) [9]. 
Previously, we showed that the mitochondrial bottleneck during early 
development is highly conserved between zebrafish and mammals [10]. In 
addition, the zebrafish Tfam protein is functionally homologous to its human 
counterpart and is expressed ubiquitously from the earliest stages of development 
[11]. In this study, we performed tfam knockdown during zebrafish 
embryogenesis in order to reduce the mtDNA copy number during early 
development. In this way, we created an animal model with a tuneable mtDNA 
bottleneck, which allows us to assess the effect of differences in mtDNA copy 
number on OXPHOS function and embryonic development and to determine the 
underlying mechanisms. 
 
Material and Methods  
Zebrafish Maintenance and Procedures  
Zebrafish (Danio rerio) were housed and raised in the zebrafish facility of the 
University of Liège as described before [12]. To retrieve eggs, wild-type adult 
male and female zebrafish were separated within the same breeding tank by a 
plastic divider the day before breeding. This separation was removed the next day 
after the light was turned on in order to allow natural mating and eggs were 
collected after spawning. Eggs were collected in Petri dishes containing 1x E3 
medium for zebrafish at 28°C (580 mg/l NaCl, 27 mg/l KCl, 97 mg/l CaCl2·2H2O, 
163 mg/l MgCl2·6H2O and 0.0001% methylene blue (Sigma-Aldrich), pH 7.2) [12]. 
Embryos were microscopically staged according to the embryonic development as 
described before [13]. Unless stated otherwise, all reagents used in this study 
were obtained from Thermo Fisher Scientific. 
 
Tfam Knockdown Experiments  
Antisense morpholino oligonucleotides (MO) were purchased from Gene Tools and 
micro-injected into one or two-cell stage embryos. A splice modifying MO was 
used, targeting the boundary of exon 2 and intron 2-3 of the zebrafish tfam gene 
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(Ensemble: ENSDART00000092009, tfam splice-MO: 5’- 
CGGCAGATGGAAATTTACCAGGATT-3’). For controlling the effect of the MO 
injection, an equal concentration of a standard control-morpholino (Ctrl-MO: 5'-
CCTCTTACCTCAGTTACAATTTATA-3') was used in separate embryos of the same 
batch during each experiment. All MOs were dissolved in 1x Danieau buffer (58 
mM NaCl, 0.7 mM KCl, 0.4 mM MgSO4, 0.6 mM Ca(NO3)2, and 5.0 mM HEPES pH 
7.6) and 0.5% rhodamine dextran (Thermo Fisher) was added to the MO solution 
upon injection. At 1 hpf, 1 nl was injected into each embryo using microinjection 
[14]. The next day, distribution of the rhodamine dextran dye was checked using 
fluorescence stereomicroscopy to verify proper injections. Only those embryos in 
which the rhodamine dextran dye was visible were used for follow-up 
investigations. 
 
Quantitative and Qualitative Analysis of Tfam RNA  
Total RNA of 2 – 4 dpf zebrafish embryos was extracted using Trizol reagent and 
purified using the RNeasy Mini Kit (Qiagen), according to manufacturer’s 
instructions. cDNA synthesis was performed with 500 ng RNA in the presence of 
first strand buffer, 0.75 µg oligo-dT, 0.75 µg random hexamer-primer, 50 nmol 
dNTPs (GE Healthcare Life Sciences), 1 U RNAse inhibitor (RNAsin, Promega) and 
5 U reverse transcriptase for 60’ at 42ºC, followed by 5’ at 95ºC. The effect on 
tfam splicing was assessed using RT-PCR amplification of 25 ng cDNA in a PCR 
mix contained under standard conditions, using 0.6 µM forward primer, 0.6 µM 
reverse primer (Supplementary Table S1). PCR conditions were 5’ denaturation at 
94°C, 35 cycles of 1’at 94°C, 1’ at 58°C and 1,5’ at 72°C, followed by 7’ at 72°C. 
The PCR product was sequenced by conventional Sanger sequencing. tfam gene 
expression was quantified by comparing the RNA expression ratio of Tfam RNA to 
18S RNA. Per reaction, 2.5 ng cDNA was amplified in a 10 µl reaction containing 
1x Sensimix Sybr Hi-Rox reagents (Bioline) and 375 nM of both forward and 
reverse primer (Supplementary Table S1). Real-time PCR was performed on an 
ABI7900HT using the following settings: 10’ 95°C, 40 cycles of 15” 95°C and 1’ 
60°C. The statistical analysis was performed by a Student’s t-test. p-values <0.05 
were considered significant. 
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Quantification of mtDNA Copy Number 
To determine mtDNA copy number, embryos were individually collected in sterile 
tubes and directly frozen without water. For DNA isolation, embryos were thawed 
and lysed for 4 hours at 55ºC in lysis buffer containing 75 mM NaCl, 50 mM EDTA, 
20 mM HEPES, 0.4% SDS and 200 µg proteinase K (Sigma) while vortexing 
repeatedly. DNA precipitation was performed overnight at -20ºC after adding 420 
µl isopropanol. Following centrifugation, the DNA pellet was washed with 70% 
ethanol and dissolved in Tris-EDTA buffer. The relative mtDNA abundance was 
quantified by measuring the steady-state amount of mitochondrial ND1 and 
nuclear B2M. Per reaction, 20 ng DNA was used in a 10 µl reaction containing 1x 
Sensimix Sybr Hi-Rox reagents (Bioline) and 375 nM of both forward and reverse 
primer (Supplementary Table S1). Real-time quantification was performed on an 
ABI7900HT as described before. Statistical analysis was carried out using one-
way analysis of variance (ANOVA) followed by the Bonferroni multiple comparisons 
test. P-values <0.05 were considered significant. 
 
Imaging Zebrafish Embryos 
Zebrafish embryos were fixed at 4°C with paraformaldehyde for 4 hours and 
standard paraffin serial sections of 4 µm thickness were prepared for 
immunostaining and hematoxylin-eosin (HE)-staining.  Immunohistochemistry 
was performed following a microwave heat-induced antigen retrieval step for four 
times 5’ at 650 Watt (in Tris-EDTA, pH=9.0) and was analysed with the Dako 
REALTM EnVisionTM Detection System, Peroxidase/DAB, Rabbit/Mouse, using a 
Dako automated immunostaining instrument and protocols according to the 
manufacturer (Agilent, Santa Clara). Antibodies and conditions used are listed in 
Supplementary Table S1. HE-staining was performed to reveal the underlying 
embryonic structures. Paraffin slides were embedded in Entellan (Merck) and 
protected by cover slips (Knittel Glass). Microscopic images were taken by using 
the Nikon Eclipse E80 Imaging System (Nikon) at different magnifications. The 
orientation of fish was determined according to the Zebrafish Bio-Atlas [15]. 
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Oxygen Consumption Rate 
At 4 dpf, chorion-free living fish embryos with a heartbeat and active swimming 
behaviour upon touching were selected and collected individually. The oxygen 
consumption rate (OCR) (pmol/minute) was measured every minute for 15 
minutes in a Seahorse XF24 system (Agilent/Seahorse Biosciences), according to 
the islet protocol of the manufacturer with 2 fish per well of a 24-well plate. Five 
minutes after starting the assay, 80 µM of Oligomycin (Sigma-Aldrich) was added 
and 60 µM for Antimycin & Rotenone (Sigma-Aldrich) in the injecting assay 
medium (1x E3 medium) was added 10 minutes after start. The OCR level at basal 
respiration (pmol/min) was calculated using the OCR values at the start 
respiration level (time-point 5 minutes) minus antimycin/rotenone (AMA) level at 
time-point 10 minutes. Maximal ATP production (pmol/min) was determined as 
start respiration level minus oligomycin (OMY) level at time-point 15 minutes. The 
statistical analysis was performed by a Student’s t-test. p-values <0.05 were 
considered significant. 
 
Gene Expression and Pathway Analysis  
For gene expression studies, tfam splice-MO and control-MO injected embryos and 
non-injected control embryos at 4dpf, were individually collected in sterile tubes. 
Selection criteria were the same as for the OCR measurements. RNA from single 
embryos was isolated using the MagMax-96 for microarray kit (Ambion) and 200 
ng RNA was labelled (Cyanine 3-CTP and Cyanine 5-CTP), fragmented and 
hybridized using the Low Input Quick Amp Labeling Kit, Two-colour (Ambion), 
according to manufacturer’s instructions. After labelling, amplified cRNA samples 
were purified using the RNeasy Mini kit (Qiagen) and Cyanine 3 and Cyanine 5 
dye concentration, RNA absorbance ratio (260/280nm) and cRNA concentration 
were quantified using the nanodrop 2000C (Thermoscientific). Only samples with 
a yield >0.825 µg and a specific dye activity >6.0 pmol/µg were used for 
fragmentation and hybridization. For fragmentation, 825 ng labelled cRNA was 
used and the final volume was adjusted to 41.8 µl with RNAse-free water, followed 
by the hybridization procedure, as described by the manufacturer (Ambion). Dye-
swap hybridizations (2+2) were performed on microarray slides (4x44K zebrafish 
V3, Agilent) using gasket slides and a hybridization chamber and incubated for 17 
h at 65ºC and 10 rpm in the hybridization oven (Agilent Technologies). Slides 
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were washed with Triton X-102, freshly added to the Wash Buffers. Microarray 
slides were scanned using a DNA Microarray scanner with Surescan High-
Resolution Technology (Model 2565CA, Agilent). All microarray data is deposited 
in the GEO database, accession GSE146696. 
 
The arrays contained 45,220 probes. Each probe identifier was transformed to 
Ensembl gene IDs (ENSDARG). This resulted in 36,156 probes containing a non-
empty transcript ID of which 19,459 were unique transcripts and kept for the 
analysis. All transcripts were analysed using a multivariate Gaussian linear 
regression (  where  is the mean,  is the covariance matrix 
 ,  is the variance, and  is both the extra 
component of variance across subjects and the common covariance among 
responses on the same subject) including slide differences (Slide), dye swap 
(Dye), background level (Bg), injection (Inj) and a random effect. The inference 
criterion used for comparing the models is their ability to predict the observed 
data, i.e. models are compared directly through their minimized minus log-
likelihood. When the numbers of parameters in models differ, they are penalized 
by adding the number of estimated parameters, a form of the Akaike information 
criterion [16]. For each transcript, a model containing the relevant covariates 
mentioned above (E(y) =Slide+Dye+Bg+Inj) was fitted in order to obtain a 
reference AIC. Then a model containing the treatment group (Trt) was fitted 
(E(y)=Slide+Dye+Bg+Inj+Inj:Trt). The transcript under consideration was found 
to be differentially expressed if the AIC of this second model decreased compared 
to the model not containing the treatment. These statistical analysis were 
performed using the freely available program R [17] and the publicly available 
libraries 'rmutil' and ‘growth’ [18]. An unbiased Gene-ontology analysis and 
visualization of microarray data on biological pathways was performed using 
PANTHER (Protein Analysis THrough Evolutionary Relationships) with the Danio 
rerio (Dr_Derby_Ensembl_80) gene product/protein database [19, 20]. 
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Differentially expressed genes (DEGs) were mapped to unique Entrez Gene IDs 
and to Gene Ontology (GO) classes, using the PANTHER Overrepresentation Test 
(Released 2018-02-03) enrichment method of PANTHER version 13.1.  
 
Results 
Tfam Knockdown Leads to Reduced mtDNA Content and Reduced Mitochondrial 
Function  
To establish decreased mtDNA copy number, we microinjected an antisense 
splice-MO targeting tfam-mRNA in zebrafish embryos. Using RT-PCR and Sanger 
sequencing of cDNA from tfam splice-MO-injected 4 dpf embryos (n= 6/group), 
we showed that the tfam splice-MO causes a 128 base-pair deletion of exon 2 
(c.84_211del), predicted to cause a frameshift and a premature stop codon 
(p.(Cys29Hisfs*36)) (Figure 1A, Supplementary Figure S1). Quantitative PCR 
analysis of tfam exon 5 and exon 6-7 showed respectively 59%±2% and 60%±5% 
decrease in expression in tfam splice-MO injected embryos at day 4 (mean±SD, 
n= 6/group). qPCR analysis of tfam exon 2 expression showed a reduction of 
80±3% at day 4 in zebrafish (n= 6/group) injected with 2 ng tfam splice-MO 
compared to the Ctrl-MO (Supplementary Figure S2). This indicates that ~60% of 
tfam RNA is subjected to nonsense-mediated decay and that of the residual ~40% 
tfam RNA, only half is exon 2-containing wild-type RNA (only 20% of normal tfam 
amount). Next, we assessed the mtDNA copy number in non-injected, Ctrl-MO 
injected and tfam splice-MO injected embryos (n= 20 in each 2 ng group, and n= 
16 in each 4 ng group). At 4 dpf, a significant, 42%±17% (mean±SD) decrease 
in the mtDNA copy number was observed in embryos injected with either 2 ng or 
4 ng tfam splice-MO (Figure 1B). In contrast, no significant differences in mtDNA 
copy number were apparent between groups at 2 dpf (Supplementary Figure S3). 
To assess if decreased mtDNA copy number also affected mitochondrial capacity, 
we measured the oxygen consumption rate (OCR) at 4 dpf. As shown in Figure 
1C, both the OCR of the basal respiration and the ATP production were 
significantly decreased in the 2ng tfam splice-MO treated zebrafish (n=10) 
compared with the 2ng control-MO treated group (n=9) (p<0.05) by respectively 
40%±25% and 50%±22% (mean±SD). 
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Figure 1. Knockdown of TFAM in zebrafish embryos. Zebrafish embryos injected with 
indicated amount of either Control-morpholino (Ctrl-MO) or tfam splice-morpholino 
(TFAM-MO) at 1 hpf and analysed at 4 dpf. (A) tfam splice-morpholino (MO) at the 3’ 
splice site of exon 2 causes deletion of exon 2, which predicts a frame-shift and premature 
stop codon (p.(Cys29Hisfs*36)) (figure is not on scale). (B) The relative copy number 
assessed by mitochondrial ND1 / nuclear B2M ratio. Data are normalized to the NIC 
embryos (n= 7). Bars indicate mean values with SD, n= 20 per 2 ng injected condition 
and n= 16 per 4 ng injected condition. P-values are calculated using ANOVA followed by 
Bonferroni’s Multiple Comparison Test to assess copy number, * P-value < 0.05, ** P-
value < 0.01. (C) The oxygen consumption rate (OCR) measured by Seahorse XF24 in 
order to assess basal respiration and maximal ATP production capacity at 4 dpf using 2ng 
MO. The statistical analysis was performed by using a student t-test (P < 0.05), n= 10 
per tfam condition and n= 9 per ctrl condition.
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Tfam Knockdown Causes Brain, Eye, Heart, and Muscle Abnormalities  
At 4 dpf, morphant embryos displayed morphological abnormalities compared to 
control embryos. The macroscopic phenotype included overall oedema, curved 
tails, necrotized yolk sacs and small eyes (Supplementary Figure S4). Fish injected 
with 4 ng tfam splice-MO were more severely affected than 2 ng tfam splice-MO 
(n=100 injected per condition), as they had a higher count for oedema, curved 
tails, necrotized yolk sac, small eyes, and developmental delay. The percentage 
of dead embryos was <1% when injecting 2 or 4 ng of tfam MO-injections at 4 
dpf (Supplementary Figure S4). In contrast, injection of 6 ng of tfam splice-MO 
showed >70% of embryonic lethality due to severe developmental complications. 
Macroscopic inspection of tfam splice-MO injected embryos showed that all 
observed pathologies manifested at 3 or 4 dpf, whereas development was 
apparently normal at 2 dpf.  These morphological changes parallel the decrease 
in mtDNA copy number that is observed at 4 dpf, but not at 2 dpf (Figure 1B, 
Supplementary Figure S3). Since the decrease in mtDNA content was comparable 
with 4 ng tfam splice-MO, the dosage of 2 ng tfam splice-MO was used in all 
following experiments, reducing the risk of non-specific observations. 
 
Microscopic evaluation of zebrafish (n=13 per condition) with reduced mtDNA 
copy number using 2ng tfam splice-MO showed impaired development compared 
to control embryos (Figure 2). Brain size was decreased with no or less well-
developed cerebellum (Figure 2B) and eyes smaller and the different layers less-
well organized compared to controls (Figure 2D). Also, the organization of the 
myotomic area was less compact with the skeletal muscle fibres being thinner and 
disorganized (Figure 2F). Finally, morphant fish displayed marked pericardial 
oedema, alongside with a dilated non-looped heart (Figure 2H).  
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Figure 2. Microscopy of zebrafish embryos following TFAM knockdown. Image (A-H):
Microscopic analysis following serial HE-staining of zebrafish embryos at 4 dpf, which 
were injected at 1 hpf with either  2 ng Tfam splice-MO or 2 ng Ctrl-MO, n= 13 each 
condition. (B) The cerebellum was missing in the phenotype or  a delayed development
of this cerebellum in these fish. (D) The eyes were smaller and the eye layers were less 
developed. (F) A muscle phenotype was clearly visible in the dorsal fin, especially in the 
myotomic area, which was less compact in these somatic muscles. (H) The fish displayed 
a marked pericardial oedema (red arrow). They did not develop a normally looped heart 
as in Ctrl-MO (G), but the hearts were dilated in the phenotypes (H).
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Genes and Pathways Altered by Tfam Knockdown 
To characterize the underlying pathogenic processes due to tfam knockdown and 
subsequent decrease in mtDNA copy number, we compared global gene 
expression profiles at 4 dpf of zebrafish injected with 2 ng of either tfam splice-
MO (n= 12) or Ctrl-MO (n= 12). A group of non-injected control zebrafish was 
also included (n=9) to control for the injection effect in the microarray analysis 
and allow identification of transcripts altered in the tfam splice-MO zebrafish 
compared with the Ctrl-MO zebrafish. A total of 19,459 transcripts were present 
on the array (Supplementary Table S2), of which 16,631 (85.5%) had a signal 
intensity higher than twice the background signal in both conditions or a signal 
that was at least three times higher than the background signal in either the group 
of tfam splice-MO or Ctrl-MO zebrafish. Of these, 3,158 transcripts (19.3%) were 
differentially expressed between the two groups with a fold change (FC) >50%. 
Expression of 2,063 transcripts (64.3%) was increased (FC ≥1.50), while 
expression of 1,145 transcripts (35.7%) was decreased in the tfam splice-MO 
injected embryos (FC ≤0.67)). In order to identify significantly altered pathways 
by using gene ontology analysis, Protein ANalysis THrough Evolutionary 
Relationships (PANTHER) was used. The microarray contained 19,459 transcripts, 
of which 17,395 could be annotated (89.4%) and were included in the PANTHER 
analysis. A total of 18 significantly enriched GO biological processes (FDR <0.05) 
were identified and these were manually grouped into five groups including the 
underlying GO terms, namely: tRNA processing, ribosome biogenesis, RNA 
surveillance and catabolism, drug metabolism, and visual perception (Table 1, 
Supplementary Table S4). As the RNA-related processes differ for nuclear and 
mtDNA genes and for that reason should not be considered as one group, we also 
listed the mitochondria-related processes, characterized by mitochondria-related 
GO terms (Table 2, Supplementary Table S5). Most of the mitochondria related 
GO terms were small, comprising less than 50 measured genes, but sufficient 
number of genes were interrogated to conclude that these processes were not 
significantly enriched by the mtDNA reduction. However, as expression of mtDNA 
encoded proteins, which is regulated by TFAM, was not covered in a GO term, we 
checked the expression of the 8 mtDNA protein encoding genes manually. The 8 
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mtDNA proteins encoding transcripts of the H-strand were significantly decreased, 
whereas the single L-strand transcript was unaltered (Supplementary Table S3). 
The remainder four protein encoding transcripts of the H-strand were not present 
on the array (atp6, atp8, cox 3, and cytb). 
 
Table 1. Significantly altered GO biological process terms. 
Description 
Measured 
(n) 
Changed (n)  
Fold 
Enrich
ment 
FDR 
tRNA processing     
GO:0006396  RNA processing 426 
106 
(Cm=15,Cn=91) 
1.52 2.4E-02 
→ GO:0034660 ncRNA metabolic 
process 
260 
88 
(Cm=30,Cn=58) 
2.06 5.2E-06 
     → GO:0006399tRNA metabolic 
process 
118 
44 
(Cm=22,Cn=22) 
2.27 1.4E-03 
          → GO:0009451RNA 
modification 
88 
32 
(Cm=9,Cn=23) 
2.21 2.6E-04 
→ GO:0034470 ncRNA processing 197 
72 
(Cm=14,Cn=58) 
2.22 4.3E-06 
      → GO:0008033tRNA processing 73 
27 
(Cm=7,Cn=20) 
2.25 3.8E-02 
Ribosome biogenesis     
GO:0022613 Ribonucleoprotein 
complex biogenesis 
239 
69 
(Cm=14,Cn=55) 
1.76 1.0E-02 
→ GO:0042254 Ribosome biogenesis 162 
60 
(Cm=14,Cn=46) 
2.25 4.3E-05 
      → GO:0006364 rRNA processing 105 43(Cm=6,Cn=37) 2.49 2.0E-04 
RNA surveillance and catabolism     
GO:0071025 RNA surveillance 9 9 (Cm=0,Cn=9) 6.09 2.3E-02 
→ GO:0071027 Nuclear RNA 
surveillance 
8 8 (Cm=0,Cn=8) 6.09 3.4E-02 
     → GO:0071028 Nuclear mRNA 
surveillance 
8 8 (Cm=0,Cn=8) 6.09 3.6E-02 
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Description 
Measured 
(n) 
Changed (n)  
Fold 
Enrich
ment 
FDR 
          → GO:0034475 U4 snRNA 3'-
end processing 
8 8(Cm=0,Cn=8) 6.09 3.2E-02 
→ GO:0016075 rRNA catabolic 
process 
11 9(Cm=0,Cn=9) 4.98 3.6E-02 
Drug metabolism     
GO:0042737 Drug catabolic process 85 
33 
(Cm=2,Cn=31) 
2.36 1.1E-02 
Visual perception     
GO:0007601 Visual perception 83 
31 
(Cm=2,Cn=29) 
2.27 2.3E-02 
→ GO:0050953 Sensory perception 
of light stimulus 
88 
31 
(Cm=2,Cn=29) 
2.14 3.5E-02 
GO terms biological process with FDR < 0.05 were considered to be significantly changed. 
Cm are changed genes that are linked to mitochondria; Cn are changed genes linked to 
the nucleus; FDR is False Discovery Rate. 
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Table 2. Mitochondria-related GO biological processes 
Description 
Measured 
(n) 
Changed 
(n)  
Fold 
Enrichment 
GO:0007005 mitochondrion organization 152 15 0.60 
GO:0007007 inner mitochondrial membrane 
organization 
20 2 0.61 
GO:0007008 outer mitochondrial membrane 
organization 
1 0  
GO:0006390 mitochondrial transcription 8 2 1.52 
GO:0032543 mitochondrial translation 27 8 1.80 
GO:0006626 protein targeting to mitochondrion 32 1 0.19 
GO:0070585 protein localization to 
mitochondrion 
32 1 0.19 
GO:0042775 mitochondrial ATP synthesis 
coupled electron transport 
41 7 1.04 
GO:0006119 oxidative phosphorylation 46 9 1.19 
GO:0033108 mitochondrial respiratory chain 
complex assembly 
25 2 0.49 
GO:0015986 ATP synthesis coupled proton 
transport 
20 1 0.30 
GO:0006979 response to oxidative stress 70 9 0.78 
GO:0006839 mitochondrial transport 73 6 0.50 
GO:1990542 mitochondrial transmembrane 
transport 
44 3 0.41 
GO:0008053 mitochondrial fusion 12 3 1.52 
GO:0000266 mitochondrial fission 16 1 0.38 
GO:0000422 autophagy of mitochondrion 27 2 0.45 
GO:0000002 mitochondrial genome 
maintenance 
6 1 1.01 
GO:0009117 nucleotide metabolic process (DNA 
replication) 
282 46 0.99 
The false discovery rate (FDR) was > 0.0.5 for all processes.  
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Discussion 
A high mtDNA copy number is critical for normal embryonic development. A key 
regulator of the mtDNA copy number is TFAM, as TFAM initiates mtDNA replication 
by its capability to wrap, bend and unwind the mtDNA [8], a function conserved 
in zebrafish [21]. In order to study the effect of a decreased mtDNA copy number 
during zebrafish embryonic development, we performed tfam knock-down using 
a splice-morpholino (MO). We demonstrated that the tfam splice-MO induced 
skipping of exon 2, leading to a frameshift and a premature stop codon 
(p.(Cys29Hisfs*36)) (Figure 1A) and to nonsense mediated decay. RNA 
expression of normal tfam is reduced to 20% of control values. At 3 and 4 dpf, 
morphant zebrafish have a decreased mtDNA copy number and are less well 
developed. This correlates with the previous observations that in wild-type 
zebrafish larvae an increase in mtDNA copy number only becomes apparent 
between 2 and 3 dpf [10] indicating that, in the absence of mtDNA replication, 
mtDNA copy number and OXPHOS capacity becomes critically low at 3-4 dpf, as 
an increase is required for embryonic tissue differentiation and organogenesis. 
This is a critical phase of development, when there is a high energy demand and 
a metabolic switch from glycolysis to OXPHOS takes place [22, 23]. This necessity 
is illustrated by the aberrant eye and muscle development, pericardial oedema 
and reduced brain size that were observed in morphant zebrafish (Figure 2). The 
heart and the brain are the first organs to develop [24] and therefore the first to 
be affected by OXPHOS defects. Moreover, as in a normal heart >30% of the 
cardiac muscle volume is occupied by mitochondria, the deficit of mtDNA (and 
subsequently mitochondria) also hampers proper alignment of the muscle fibres 
in the developing heart, creating structural problems as well [25]. In homozygous 
Tfam KO mice, OXPHOS was abolished due to a severe mtDNA depletion, causing 
a complete failure of organogenesis and embryonic death [7]. Heterozygous KO 
mice were viable, but showed an OXPHOS deficiency in the developing heart and 
a dilated cardiomyopathy and conduction block later in life [7, 26]. The severity 
of our model seems to fit somewhere in between, as wild-type tfam levels are 
around 20% of control level at the day of analysis. Noticeably, MOs establish only 
a transient knockdown, which is not the case for a homozygous or heterozygous 
knockout of the gene, prohibiting a proper comparison later in life.  
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In order to unravel the biological processes that were altered, we performed global 
gene expression profiling and subsequent gene ontology (GO) analysis (Table 1, 
Figure 3). Despite the observed reduction in OXPHOS function, the gene ontology 
term comprising mitochondrial respiratory chain components was not significantly 
changed, neither were critical mitochondrial processes (Table 2). However, gene 
expression was decreased of 8 out of the 9 mtDNA protein encoding transcripts, 
all encoded by the H-strand, whereas the one transcript on the L-strand was 
unaltered. This most likely this reflects a switch or preferable transcription from 
the Light-Strand Promoter (LSP) that is induced by low amounts of tfam and which 
also primes H-strand replication [27], but which in our case fails to increase 
mtDNA copy number due to the persisting lack of tfam. 
 
The GO term drug catabolism was significantly changed, comprising several 
downregulated genes linked to mitochondrial function, including embryonic 
haemoglobin production. As haem is produced by mitochondria [28], this could be 
explained by the decreased amount of mtDNA and subsequently mitochondria at 
the onset of definitive haematopoiesis, initiating between 1 to 2 dpf [29-32]. 
Obviously, deficiencies in haematopoiesis during development might have 
downstream effects as well. Other mitochondria-related genes of this GO term 
were decreased, such as oxct1a, oxct1b, members of cyp450 family 2 and gpx1a, 
which are related to the metabolism of fatty acids and ketone bodies, exogenous 
drug catabolism and hydrogen peroxide degradation in the mitochondria. The 
decrease in mtDNA copy number and subsequent mitochondrial dysfunction 
appears to result in enrichment of GO terms related to rRNA synthesis, ncRNA 
processing, and ribosomal assembly (Table 1), and the vast majority of genes in 
these GO terms was upregulated (Supplementary Table S4). In addition, the GO 
term tRNA processing was also significantly enriched. In general, expression of 
genes belonging to these GO terms is increased, including a number of genes that 
are linked to mitochondrial function, like mto1 (1.64), trmt10c (1.55) and elac2 
(1.61) [33-35]. Increased tRNA synthesis was also observed by Torrent et al. 
upon applying diverse stress conditions to Saccharomyces cerevisiae, 
demonstrating the regulation of tRNA abundance upon cellular stress [36]. 
However, future research is needed to identify if the observed activation nucleolar 
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processes is caused by mitochondrial stress or is a reaction to compensate for the 
reduction in mitochondrial transcripts. The resulting disbalance between 
mitochondrial transcripts and proteins and nuclear encoded proteins that migrate 
into the mitochondria might be a factors as well. Also, gene expression of 8 out 
of 9 exosome components, belonging to GO term ribosomal biogenesis, were 
significantly upregulated in tfam splice-MO zebrafish. Like increased rRNA and 
tRNA expression, upregulation of the exosome components seems to be a 
compensatory or stress-induced mechanism, as exosomes contain and shuttle 
mRNA, and are important in intercellular communication and developmental 
patterning [37-39]. Future assessment of the zebrafish exosome composition is 
needed to provide further insight into this novel mechanism by which decreased 
mtDNA copy number affects exosome signalling and composition. 
Since clear morphological abnormalities were apparent in tfam splice-MO zebrafish 
at 4 dpf (Figure 2), the nucleolar activation upon mitochondrial deficiency was 
obviously insufficient to compensate. At gene expression level in tfam splice-MO 
zebrafish at 4 dpf, GO terms related to vision and sensitivity to light were 
significantly changed. Retinal development is critical between 32 and 74 hpf and 
normally largely completed at 4dpf [40]. This window coincides with the decrease 
in mtDNA copy number in tfam splice-MO zebrafish, explaining the down-
regulation observed. These extremely down-regulated eye genes are mainly 
involved in processes and response to light stimulus (Supplementary Table S4), 
like pde6c (0.05) and gnat2 (0.09). Zebrafish mutants of these genes respectively 
cause retinal and retinal pigment epithelial disease and cone-rod dystrophy [40, 
41]. Additional down-regulated opsins genes related to the photoreceptor function 
are listed in our zebrafish data (Supplementary Table S4). The lack of significant 
changes in pathways linked to cardiac, muscle or brain development, suggests 
that although pathology clearly manifested, we are still observing the processes 
preceding the pathology and not those resulting from it in the pathway analysis. 
In addition to defective eye development, a number of temporally expressed 
developmental genes are downregulated in tfam splice-MO zebrafish at 4 dpf, such 
as chitinase (Chia) 1, 2, 3 and 4. Expression of chia.1, chia.2 and chia.3, which 
belong to the GO term drug metabolism, normally drastically increases at 4 and 
5 dpf, while chia.4 is more stably expressed. Chitinases are suggested to play a 
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role in early embryo immunity and chitinase inhibition has been shown to cause 
development disruption in zebrafish, characterized by hampered trunk and tail 
formation [42]. 
Figure 3. Schematic overview of alterations in tfam splice-MO zebrafish at 4dpf. The arrow 
indicates if a process is upregulated (green) or down-regulated (red). Altered gene 
expression processes and genes are shown in italic. The mitochondrial DNA figure is 
adapted from (Amorim et al. (2019)).
In conclusion, inhibition of tfam expression during early zebrafish development 
leads to a decrease in mtDNA copy number, OXPHOS capacity, and mtDNA 
encoded transcripts and haem production, affecting the oxygen supply in the 
developing embryo. This triggers a compensation mechanism or stress response 
in the nucleoli at the level of rRNA and tRNA biogenesis and translation initiation, 
but this compensation mechanism falls short, as pathology emerges (Figure 3). 
The results of this study in zebrafish are comparable to other animal models, 
thereby validating our model, but they also take it a step further due to the clear 
advantages of the zebrafish model, being a high number of offspring, a rapid 
development and an optical clarity during development combined with easy 
genetic interventions. Being able to tune the mtDNA content, we can now 
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manipulate the mtDNA bottleneck and study in sufficient numbers the effects on 
processes, like organogenesis, fertility and mtDNA mutation rate.  
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Supplementary Table S1. Overview of 
primers and antibodies used in this study 
Primers Forward Primer (5’-3’) 
Reverse 
Primer (5’-3’) 
18S RNA AGCGTGCGGGAAACCACGAG 
AAGCCGCAGG
CTCCACTCCT 
Tfam Exon 2 
TGTGTAGCTCCAGCGATAAA
GA 
ATGTATGCTGT
CAGGGGTCTCT 
Tfam Exon 5 CCCAAGGAGCACCTTCAACA 
TTGCCTGCGTA
GTAGTTCCC 
Tfam Exon 6-7 CGCTTGAGCGACACACAAAA 
GTGCTCCTCCC
ACGATTTGA 
Tfam Exon 1 CTTTTGTTCGGTGGTCAACA 
Tfam Exon 3 
CTTTTGTTCGG
TGGTCAACA 
Tfam Exon 4 
TCCGAATGGCT
TTTCTTTTG 
Tfam Exon 5 
CGGACTTTATC
GTCCTCTGC 
ND1 
CCACTTAATTAACCCCCTAGC
C 
ATGTTTGTGGG
GGTAGACCA 
B2M 
CGCCTGAAAACTACGTTCTAC
AC 
ACTTTCGGAGT
GGCTGAAAA 
Antibody Company Dilution Incubation 
Primary-anti-
MF20-mouse 
DSHB, Myosin Heavy Chain 
Pro 1:20 dilution 
4°C incubation 
overnight 
Primary-anti-
Zebrin I-mouse 
DSHB, Aldolase C like 
Protein 1:100 dilution 
4°C incubation 
overnight 
Secondary-anti-
mouse/rabbit 
Dako REAL EnVision 
Detection System 
Peroxidase/DAB Ready to use 
room-temperature 
incubation for 30 
minutes 
Table S2. Analysed transcripts analysed in microarray analysis (use download link) 
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primers and antibodies used in this study 
Primers Forward Primer (5’-3’) 
Reverse 
Primer (5’-3’) 
18S RNA AGCGTGCGGGAAACCACGAG 
AAGCCGCAGG
CTCCACTCCT 
Tfam Exon 2 
TGTGTAGCTCCAGCGATAAA
GA 
ATGTATGCTGT
CAGGGGTCTCT 
Tfam Exon 5 CCCAAGGAGCACCTTCAACA 
TTGCCTGCGTA
GTAGTTCCC 
Tfam Exon 6-7 CGCTTGAGCGACACACAAAA 
GTGCTCCTCCC
ACGATTTGA 
1 TTTT TTCGGTGGTCAACA 
Tfam Exon 3 
CTTTTGTTCGG
TGGTCAACA 
Tfam Exon 4 
TCCGAATGGCT
TTTCTTTTG 
Tfam Exon 5 
CGGACTTTATC
GTCCTCTGC 
ND1 
CCACTTAATTAACCCCCTAGC
C 
ATGTTTGTGGG
GGTAGACCA 
B2M 
CGCCTGAAAACTACGTTCTAC
AC 
ACTTTCGGAGT
GGCTGAAAA 
Antibody Company Dilution Incubation 
Primary-anti-
MF20-mouse 
DSHB, Myosin Heavy Chain 
Pro 1:20 dilution 
4°C incubation 
overnight 
Primary-anti-
Zebrin I-mouse 
DSHB, Aldolase C like 
Protein 1:100 dilution 
4°C incubation 
overnight 
Secondary-anti-
mouse/rabbit 
Dako REAL EnVision 
Detection System 
Peroxidase/DAB Ready to use 
room-temperature 
incubation for 30 
minutes 
Table S2. Analysed transcripts analysed in microarray analysis (use download link) 
Forward Primer (5’-3’) Reverse Primer (5’-3’)
18S RNA AGCGTGCGGGAAACCA-
CGAG
AAGCCGCAGGCTCCACTCCT
Tfam Exon 2 TGT TAGCTCCAGCGA-
TAAAGA
TGTA G TG AGGG-
GTCTC
f   5 CCC AGGAGCACCTT-
CAACA
TTGC T C TAG AGTTCCC
f   - CG TTGA C AC -
CAAAA
GTGCT CTCCCACGATTTGA
Tfam Exon 1 CTTTTGTTCGGTGGT-
CAACA
Tfam Exon 3 CTTTTG C G G TCAACA
f   TCCGAATGGC TTTCTTTTG
Tfam Exon 5 CGGACTTTATCGTC TCTGC
ND1 CCACTTAATTAACCCCC-
TAGCC
ATGTTTGTGGGGGTAGACCA
B2M CG TGAAAACTACGTT -
TA AC
A TTTC GAGTGGCTGAAAA
Antibody Company Dilution Incubation
Primary-anti-
MF20-mouse
DSHB, Myosin Heavy 
Chain Pro
1:20 dil tion 4°C incubation 
overnight
Primary-
anti-Zebri  
I-mouse
DSHB, Aldolase C like 
Protein
1:100 dilution 4°C incubation 
overnight
Secondary-
anti-mouse/
rabbit
Dako REAL EnVision De-
tection System Peroxida-
se/DAB
Ready to use room-tempera-
ture incubation 
for 30 minutes
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Table S3. Gene expression of mtDNA protein encoding genes 
Supplementary Table S3. 13 
mtDNA protein encoding genes 
Mapped Ids 
Gene Name/ 
Symbol Fold Change STRAND 
ENSDARG00000063895.3 mt-nd1 0,75 H-Strand
ENSDARG00000063899.3 mt-nd2 0,69 H-Strand
ENSDARG00000063914.3 mt-nd3 0,72 H-Strand
ENSDARG00000063916.3 mt-nd4l 0,67 H-Strand
ENSDARG00000063917.3 mt-nd4 0,60 H-Strand
ENSDARG00000063921.3 mt-nd5 0,58 H-Strand
ENSDARG00000063922.3 mt-nd6 1,00 L-Strand
ENSDARG00000063905.3 mt-cox1 0,62 H-Strand
ENSDARG00000063908.3 mt-cox2 0,71 H-Strand
ENSDARG00000063912.3 mt-cox3 not on array H-Strand
ENSDARG00000063910.3 mt-atp8 not on array H-Strand
ENSDARG00000063911.3 mt-atp6 not on array H-Strand
ENSDARG00000063924.3 mt-cytb not on array H-Strand
Table S4. Significantly altered PANTHER GO biological processes including genes 
(Fold Changes) per group (use download link) 
Table S5. Mitochondria-related PANTHER GO biological processes including genes 
(Fold Changes) per group (use download link) 
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Fig. S1 Sanger sequencing of tfam. Sanger sequencing of tfam after PCR amplification of 
DNA isolated from tfam splice-MO-treated zebrafish (n= 6 per injected condition from 
gene expression analysis samples) showed deletion of exon 2 c.84_211del, which predicts 
a frameshift and premature stopcodon on protein level (p.(Cys29Hisfs*36)).
Fig. S2 Q-PCR analysis of total tfam expression. qPCR analysis of total tfam expression 
showed a 5.3 fold decrease in exon 2 expression (range 1.5 – 19.7) at day 4 in zebrafish 
injected with 2 ng tfam splice-MO compared to the Ctrl-MO (n= 6 per injected condition 
from gene expression analysis samples). Analysis of tfam exon 5 and exon 6-7 showed 
respectively 41% and 40% expression in tfam splice-MO injected embryos at day 4. This 
indicates that ~60% of tfam RNA is subjected to nonsense-mediated decay and that only 
half of the residual 40% tfam RNA is exon 2 containing wild-type RNA . Bars indicate 
mean values with SEM. P-values are calculated using Bonferroni’s Multiple Comparison 
Test. * P-value < 0.05.
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Fig. S3 mtDNA effect of tfam knockdown on the mitochondrial DNA copy number. The 
relative mitochondrial DNA copy number has been assessed by mitochondrial ND1 / 
nuclear B2M ratio at 2 dpf and 5 dpf in non-injected control (NIC, n= 8 per time point) 
embryos, 2 or 4ng control-morpholino-injected (ctrl-MO) embryos and 2 or 4ng Tfam
splice-MO injected embryos (n= 20 per injected condition). Data are normalized to the 
NIC embryos. Bars indicate mean values with SD. P-values are calculated using 
Bonferroni’s Multiple Comparison Test. * P-value < 0.05, ** P-value < 0.01.
Fig. S4 The macroscopic phenotype scoring. The macroscopic phenotype (n= 100 per 
condition) included overall oedema, curved tails, necrotized yolk sacs and small eyes. 
Fish injected with 4 ng tfam splice-MO were more severely affected, as they had a higher 
count for oedema, curved tails, necrosed yolk sac, small eyes, and developmental delay. 
The percentage of dead embryos was < 1% for both concentrations of tfam MO-injections 
at 4 dpf. 
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The Difficulty in Establishing a Genetic Diagnosis in Mitochondrial Disease 
Difficulties in establishing a genetic diagnosis are due to the clinical and genetic 
heterogeneity of mitochondrial diseases. Extensive evaluation of clinical 
symptoms, biochemistry, immunohistochemistry, and quality or quantity of the 
mitochondria are usually not sufficient to pinpoint a specific genetic cause. Since 
two genomes (mtDNA and nDNA) are involved with possibly more than 1,500 
genes, it is evident that finding the genetic cause can be a real odyssey for 
clinicians and patients [1, 2].  
Identifying genetic variants in mitochondrial disease 
The work presented in this thesis demonstrates the impact next-generation 
sequencing (NGS) and more specific whole-exome sequencing (WES) has on the 
genetic diagnostics of mitochondrial disease [3]. A diagnostic rate of 25% was 
common in pre-NGS days at the start of the work, presented in this thesis, 
resulting from an extensive, costly, and time-consuming usually Sanger-based 
sequencing process of sequentially selected individual candidate genes [4, 5]. 
Family studies and linkage analysis were fundamental to characterize unknown 
genes in combination with functional assays. Application of NGS resulted in a 
diagnostic yield of 69% in our cohort of patients with mitochondrial and 
neuromuscular disease (Chapter 2), consisting of 20% pathogenic mtDNA 
variants and 49% pathogenic nuclear gene variants [3]. No laboratory assays 
were required to select candidate genes, only assays were needed for validation 
of unclassified variants in known genes and pathogenic variants in novel genes. 
In these cases, functional, complementation assays were required to prove 
pathogenicity and link the genetic variant to the phenotype (Chapter 4-5). In 
two previous studies using targeted nuclear mitochondrial gene panels the 
diagnostic yield was 22% [6] and 24% [7], which is less than in our study, 
screening all nuclear genes (49%). This can be explained by incompleteness of 
the mitochondrial panels, as up to 30% of the disease-causing genes identified in 
our patient cohort were not present in the MitoCarta database at the time of 
discovery. A previous NGS-based study using WES in 109 paediatric and young 
adult patients with clinical characterized mitochondrial disease showed a 
diagnostic yield of 39%, closer to our 49% [8]. Another mitochondrial disease 
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study resulted in a diagnostic yield of 59% after screening both mtDNA and WES, 
compared to our 69% [9]. A possible explanation is that we included only well-
characterized patients who were likely to have an autosomal recessive inherited 
gene defect (consanguineous parents or multiple affected siblings with healthy 
non-consanguineous parents). As consanguineous parents have a higher risk of 
having children that suffer from multiple genetic diseases, we emphasize that WES 
data should be screened completely in those cases and investigations should not 
be stopped by finding a single genetic defect to which the entire clinical 
manifestation is attributed. As this has been done in the past, one should carefully 
evaluate genotype-phenotype correlations for over-interpretation of a single gene 
defect. The same is true for patients from non-consanguineous parents when a 
combination of genetic defects is more likely than a single gene defect. Then the 
whole exome should be analysed. We demonstrated for a few patients that they 
can carry more than one genetic defect and that for prognosis and prevention of 
transmission it is crucial to identify all possible causes [10].  
Nowadays, genetic defects causing mitochondrial diseases can be found in any of 
the processes, involved in mitochondrial structure, stability and function. In 
Chapter 5, we described a number of novel defects in genes (QRSL1, MTO1, and 
AARS2) in WES data, involved in the mitochondrial translation process, in which 
the brain (Leigh-like syndrome) and the heart (HCM) were prominently affected 
[11]. During our studies, two sibling with HCM were reported having a disease-
causing genetic defect in the QRSL1 gene. A second unrelated non-HCM patient 
harboured compound-heterozygous mutations in the QRSL1 gene causing 
interstitial pneumonia and mitochondrial respiration deficiencies, showing the 
complexity and variability of disease progression between patients in time with 
the same gene affected [12]. Furthermore, we reported two novel variants in the 
MTO1 gene in a paediatric patient with early-onset HCM, causing a diffuse cerebral 
atrophy with an intraventricular septum, and multiple OXPHOS deficiencies, which 
was lethal at the age of 19 months. An unrelated patient with a homozygous MTO1 
mutation showed HCM without lethality, and normal brain development. Finally, 
we identified two variants in the AARS2 gene, manifesting with paediatric 
cardiomyopathy, Leigh-like syndrome, and multiple OXPHOS deficiencies in the 
patient. Although, multiple pathogenic AARS2 variants have been reported in 
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literature, resulting in hypertrophic cardiomyopathy and lethality after 3 months 
of birth [13, 14], other AARS2 patients presented with leukodystrophy, and 
ovarian failure. In general, mitochondrial translational defects lead to a broad 
variety of clinical manifestations, of which the underlying tissue-specific 
mechanisms can not be fully explained yet [15] (Figure 1).  
 
Figure 1. Summary of the genes and disease mechanisms implicated in mitochondrial 
translation deficiencies with associated clinical phenotypes, Picture adapted from: 
Veronika Boczonadi et al. Essays Biochem. 2018;62:321-340.  
 
Part of the variability of clinical manifestations can be attributed to the 
involvement of multiple genes. Especially, heterogeneous clinical phenotypes may 
not always be caused by a monogenic defect, especially in consanguineous 
families, and it is important to follow-up all pathogenic variants that can be related 
to the clinical symptoms. Cases with multiple underlying genetic causes have been 
reported with overlapping (blended) or separate (composite) clinical symptoms 
[10]. These patients suffer from multiple genetic diseases. Alternatively, the 
variation could be caused by so-called genetic risk factors that modify the clinical 
manifestation of the primary gene defect. A clear example for this, is the 
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m.3243A>G mutation, which can lead to Mitochondrial Encephalopathy, Lactic 
Acidosis, and Stroke-like (MELAS) syndrome, but also can manifest with diabetes, 
epilepsy, cardiac arrhythmia, hearing loss, kidney problems, and even acute 
collapse, and death [15] separately or in combination. This can not be explained 
by differences in mutation load only and additional genetic or environmental 
factors, like physical exercise, seem to be involved [15]. Leber’s Hereditary Optic 
Neuropathy (LHON) is an example of reduced penetrance, as it is caused by, in 
general, homoplasmic mutations in the mtDNA, but only 50% of the males and 
10% of the females suffer from visual loss. Again, genetic and environmental 
factors, like smoking, seem to be involved. A WES study revealed an interaction 
between the mtDNA mutation (m.11778G>A) and a homozygous mutation 
(c.572G>T, p.191Gly>Val) in the YARS2 as a nuclear-modifier gene of the severity 
of vision loss [16]. Furthermore, LHON have been associated with other 
neurological symptoms and multiple sclerosis, but a for the latter it may also be 
a coincidental observation [17]. Genome-wide association studies (GWAS) have 
been performed in common diseases to identify genetic risk factors, however, 
large sample size and replication cohorts are required, which are not available for 
mitochondrial diseases as such [18]. Still, the identification of genetic risk factors 
and the current strategy to convert them cumulatively in polygenic risk scores 
(PRS) could explain a considerable part of the missing variability in common 
disease, which could be expanded to mitochondrial disease [19] as example, a 
PRS study in Parkinson Disease (PD) revealed that cumulatively, small effect 
variants in primary and secondary mitochondrial genes are significantly associated 
with increased PD risk. It would be worthwhile to check if these variants could 
also be involved in the clinical variability observed in primary mitochondrial 
disease. It would also be worthwhile to study if part of the remaining cases with 
mitochondrial disease, currently without genetic diagnosis, could be explained by 
a high PRS, based on multiple small effect variants. 
As said before, the high diagnostic yield (69%) in our cohort (Chapter 2) might 
result from a selection for patients with a highly likely genetic cause and the ability 
to perform functional tests for validation. The substantial part of novel disease 
genes still identified and the overlapping clinical phenotypes, makes panel-based 
or targeted NGS cumbersome and less effective for mitochondrial diseases. An 
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unbiased approach is highly preferable for these genetically and clinically 
heterogeneous disorders. Still, a genetic diagnosis is lacking in 31% of the cases. 
These patients might have mutations, missed by the recessive disease model 
used, and could carry for example de novo mutations, which have been checked 
only for the clinical exome. Including WES analysis of the parents and perform a 
trio analysis, could easily solve this issue [20]. However, de novo mutations will 
not explain the entire missing group. As WES analysis is limited to the protein-
coding region (exons) of the genome and to a few intronic nucleotides, which are 
the most conserved splice sites adjacent to the exon, WES does not cover the 
remaining of the introns, promoter regions and non-coding RNAs. In addition, 
computer-based tools and pipeline analyses are less accurate in predicting the 
effect of DNA-variants on gene-expression or RNA splicing. Therefore, mutations 
with a potential pathogenic effect on RNA expression or processing are either not 
included in the regions of interest in WES sequencing or are missed by 
bioinformatics analysis [21-24]. Sequencing the transcriptome by RNA-Seq is 
therefore a valuable addition to detect variants affecting RNA levels and 
composition. RNA-Seq allows analysis of the transcriptome at an unprecedented 
depth [25-28]. Recently, a publication reported the identification of causative, 
non-exonic regulatory variants in an additional 10% of mitochondrial patients 
using RNA-Seq [29]. In another study of rare muscular disorders this was 35%, 
which clearly shows the added value of this approach. However, one should realize 
that by RNA-Seq only the genes are interrogated, which are expressed in the 
tissue of investigation, which might limit the success rate for diseases, in which 
the affected tissue cannot be easily collected.  
Whole Genome Sequencing (WGS) has the potential to solve issues of missing 
variants and it will be a matter of time, before WGS will be the standard in 
diagnostics. Apart from analysing the entire genome, the major technical 
advantage of WGS is that the library preparation does not require any enrichment 
or amplification and the specificity is theoretically 100% (achieving around 95%–
98% in practice) with a uniform coverage throughout the input material. 
Therefore, the possibility to miss a disease-causing variant (or any other 
information) for technical reasons such as inefficient probe targeted enrichment, 
inefficient amplification of a specific ROI or PCR amplification artefacts do not 
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apply to WGS [30-32]. WGS, using long-read sequencing, is the best approach 
for detecting all variants, as short-read sequencing still misses repeats and 
structural genomic variants. However, long-read is more expensive and more 
error prone than short-read sequencing and also the throughput is considerably 
less, making a combination of long-read and short-read sequencing currently the 
preferred strategy for comprehensive genome sequencing.  
Although WGS data are still limited compared to WES, a number of successes 
have been reported. In a proband with possible GSD-1a, WGS long-read 
sequencing identified a causal structural variant, being a 7.1kb deletion (covering 
two exons on the first allele) in the G6PC gene in a WES negative case.  An 
additional missense variant; c.326G>A; p.(C109Y) was reported on the second 
allele [33]. A second study used paired-end short-read and direct long-read WGS 
to investigate an unresolved autosomal dominant dementia family linked to 7q36. 
A chromosomal inversion of ca. 4Mb was identified and validated by long-read 
sequencing, which disrupted the coding sequence of the DPP6 gene, being a novel 
gene causing dementia [34]. Genetic diseases are the leading cause of infant 
mortality in Western countries, particular in infants admitted to paediatric and 
cardiovascular intensive care units (ICUs). Rapid WGS (rWGS) showed a 
diagnostic yield of 42 to 57% in serious ill infants in ICUs, and changes in medical 
management in 30 to 72%, and finally altered outcomes in 24 to 34% of the cases 
[35]. This retrospective study reported a successful diagnosis in three out of seven 
seriously ill ICU infants [35]. rWGS successes in these cases obviously accelerate 
the implementation of WGS in clinical diagnostics and care. In 2016 a Dutch 
Consortium (RADICON-NL), consisting of 8 Academic Genetic Centres, 2 non-
Academic Neonatal Intensive Care Units (NICU’s) and several patient 
organizations, also started with WGS for this patient group [36]. 
Worldwide many large-scale WGS projects have been started. WGS has been 
shown to be instrument for cancer care and therapy. The International Cancer 
Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA) report on the 
presence of somatic mutations in different solid tumours to define an optimal, 
personalized treatment strategy [37, 38]. The 100,000 Genomes Project is a UK 
Government project that is sequencing whole genomes from National Health 
Service patients. The project is focusing on rare diseases, some common types of 
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cancer, and infectious diseases. The project was initiated in 2012 to develop an 
infrastructure for massive routine use of WGS. The medical and genomic data is 
shared with researchers, to improve knowledge of the causes, treatment and care 
of diseases [39]. Other countries that have initiated national genome projects are 
Japan (Initiative on Rare and Undiagnosed Diseases), China (100,000 Genomes 
project), Australia (Australian Genomics Health Futures Mission), Saudi Arabia 
(Saudi Human Genome Program), United Arab Emirates (Dubai Genomics), 
Turkey (Turkish Genome Project; 100,000 Genomes) and Estonia (Personalized 
Medicine Program; 100,000 Genomes). The French Plan for Genomic Medicine 
2025 started in 2016. By 2020, 235 000 genomes will be sequenced each year in 
France, primarily for cancer and rare diseases. The largest WGS project has been 
initiated in the United States (All of Us Research Program; 1,000,000 Genomes) 
[40]. This does not focus on rare diseases or cancer, it is a precision medicine 
initiative aimed to enrol a diverse group of one million people. Participants submit 
their medical records to the National Institutes of Health, fill out online surveys 
about their lifestyles, furnish blood and urine samples, and have their genomes 
sequenced. The Genome of the Netherlands (GoNL) project was launched in 2012, 
in which they sequenced whole genomes of 250 Dutch parent-offspring families 
and constructed a haplotype map of 20.4 million single-nucleotide variants and 
1.2 million insertions and deletions. The intermediate coverage (~13x) and trio 
design enabled extensive characterization of structural variation, including 
midsize events (30-500bp) previously poorly catalogued and de novo mutations 
[41]. 
It is beyond any doubt, that WGS will bring the paradigm shift started by WES to 
the next level: for a genetic diagnosis, geneticists and expert clinicians will no 
longer need to narrow down the differential clinical diagnosis to request 
sequencing of a specific gene or sets of genes, but all genetic information will be 
available at once from start. The results of this genetic analysis will directly guide 
the diagnostic patient evaluation, moving towards personalized patient care and 
treatment. Still, a drawback of whole genome sequencing as addressed in the next 
paragraph is the large amounts of variants detected, for which bioinformatics or 
functional approaches to characterize their significance are not fully developed yet 
[42]. 
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Interpreting genetic variants in mitochondrial disease 
To identify the genetic cause of a disease in an affected patient, it is essential to 
assign clinical significance to the variants identified. First, one can check if the 
variant has been reported before and how the variant had been classified. Several 
databases (e.g. OMIM [43], LOVD [44], ClinVar [45]) are available and list 
variants and their reported pathogenicity. Alternatively, one can predict the 
pathogenicity using a variety of bioinformatics tools, which can predict the effect 
of a variant on the protein level, the protein activity, RNA splicing, and ultimately 
help to assess the presence of protein damaging alterations. Alamut [46], 
Polyphen [47], Sift [48] are all suitable variant prediction tools. This analytical 
process is either performed manually for each variant or can be automated. 
International guidelines are available to assist such classification [49]. The scoring 
system for mtDNA mutations in protein-encoding genes is comparable to these 
accepted criteria of pathogenicity [50] , in which reported mtDNA variants with a 
score of 6 or less points were considered neutral polymorphisms, between 7 and 
10 points possibly pathogenic, between 11 and 13 points probably pathogenic, 
and 14 or more as definitely pathogenic, with a maximum of 20. The criteria 
included; more than one independent report, evolutional conservation of the base 
or base-pair, variant heteroplasmy level, segregation of the mutation with 
disease, histochemical evidence of mitochondrial disease, biochemical defects in 
complexes (I, III, or IV), evidence of mutation segregation with biochemical defect 
from single-fiber studies, or evidence of pathogenicity in trans-mitochondrial 
cybrid studies (see below). The pathogenicity scoring system was similar for 
mitochondrial tRNA mutations, including specific characteristics of the tRNA and 
excluding criteria only relevant for proteins [51]. This system was refined in later 
publications [52, 53]. Co-segregation of the variant with the disease in the family 
further supports a possible role, but the ultimate proof of the pathogenicity of a 
variant would be a second unrelated, phenotypically similar patient or functional 
confirmation (see below). An updated list of mtDNA point mutations and their 
classification can be found in MitoMAP [54]  (http://www.mitomap.org/MITOMAP),  
the Mamit-tRNA database [55], (http://mamit-trna.u-strasbg.fr/), in HGVS 
(www.hgvs.org/mutnomen/), and in mtDB (http://www.mtdb.igp.uu.se/). The 
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reference mtDNA sequence is the revised Cambridge Reference Sequence (rCRS), 
GenBank number NC_012920.1. 
The systematic screening of mtDNA and nDNA using in silico prediction tools and 
pathogenicity scores revealed a substantial number of novel variants of unknown 
significance (VUS). About 6.5% of the mitochondrial patients carries a VUS, 
creating uncertainty and anxiety [56]. Trans-mitochondrial cybrid studies can be 
used to functionally characterize mtDNA mutations that cause a measurable 
OXPHOS defect in fibroblasts and to determine the threshold of expression [57]. 
Cybrids are cytoplasmic hybrid cell lines. Cells devoid of mtDNA (rho zero cells) 
are fused with patient-derived mitochondria from fibroblasts with an OXPHOS 
deficiency. OXPHOS measurements in the cybrids will reveal whether the transfer 
of mitochondria from the patient induced the same OXPHOS deficiency or not. In 
that case an mtDNA defect is likely the cause. In this way, the pathogenicity of 
many mtDNA mutations was functionally established [57].  
For classification of potential novel disease-causing genes, functional assays are 
essential. For mitochondrial disease, (electron) microscopy (EM), biochemical 
(ATP, lactate), and/or enzyme measurements (e.g. respiratory chain complex 
deficiency) can show abnormalities, which could either be linked to the genetic 
defect or used for complementation assays (Chapter 4-5), which is particularly 
easy in case the enzyme deficiency is also present in patient-derived cells. 
Currently, also ~600 metabolites can be measured quantitative in metabolomics 
studies or even more than ~5,400 proteins in proteomics [58] or the complete 
mitochondrial proteome analysis [59]. A successful integration of metabolomics 
showed to be useful for variant classification of exome data in the spermine 
synthase gene (SMS) that causes Snyder‐Robinson syndrome (SRS). Untargeted 
plasma metabolome analysis revealed significantly elevated levels of N8‐
acetylspermidine, a precursor derivative of spermine biosynthesis, as a potential 
novel plasma biomarker for SRS [60]. This study illustrates the potential of 
metabolomics as a translational technique to support exome data on a functional 
and clinical level in case of clinical exome sequencing identified a novel mutation 
or gene. Finally, transgenic animal models (mice, zebrafish) can be constructed 
to relate the genetic defect to clinical or morphological manifestations.   
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Treatment and Prevention of Mitochondrial Disease 
Despite considerable efforts in developing therapies, still no cure exists for 
mitochondrial diseases in general. Several strategies have been investigated, 
ranging from physical exercise and diets, to small molecules and gene therapy 
[61, 62]. No broadly accepted, validated biomarkers exist to identify mitochondrial 
pathology and monitor the efficacy of the interventions. FGF-21 seems promising 
as it can be elevated in both mtDNA and nDNA encoded mitochondrial disease 
[63, 64]. As a limitation, FGF-21 also seems be elevated in other conditions, 
including obesity and fastening [65]. Furthermore, the identification of the gene 
defect in the patient has not led to a major breakthrough in novel treatments. 
Only in few cases, a gene specific-treatment is possible and our studies and others 
show that riboflavin can be beneficial for patients with ACAD9 gene defects [66-
68], high-fat diet for those with TMEM126B gene defects [69] and thiamine for 
those with SLC19A3 gene defects as reported in Chapter 4, [70-72]. Early start 
with these treatments prevents symptoms from occurring and can be lifesaving, 
for example, by preventing fatal Leigh Syndrome in patients with SLC19A3 
mutations. 
If not treatable, the aim is to prevent further transmission of mitochondrial 
diseases. As mitochondrial diseases have a dual genetic origin, this has 
implications for the transmission and recurrence risks. Nuclear gene defects may 
inherit in autosomal recessive or X-linked fashion or in autosomal dominant 
modus, but also de novo dominant variants are quite frequent (16%) and should 
be considered. Generally available options, like prenatal diagnosis (PND) or 
preimplantation genetic diagnosis (PGD), currently referred to as Prenatal Genetic 
Testing (PGT) apply, although these can not prevent de novo disease. For mtDNA 
mutations the situation is different. The mtDNA is transmitted by a mother to her 
children and during oogenesis a drastic decrease in mtDNA copy occurs, which is 
followed by an amplification of this subset in maturing oocytes, the so-called 
mitochondrial genetic bottleneck (Figure 3). In carriers of a heteroplasmic mtDNA 
mutation, due to this bottleneck, the mtDNA mutation load can vary considerably 
among the oocytes of such a carrier and in the resulting offspring [73]. Currently, 
if a patient carries an mtDNA mutation as the cause of disease, three situations 
can apply with respect to recurrence risk. If the mutation is de novo in the patient, 
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which is the case for about 25% of patients with an mtDNA disease, the recurrence 
is low, as the mother does not carry the mutation, and prenatal diagnostics (PND) 
is offered for reassurance [74].  If the mother is carrier of a heteroplasmic 
mutation, preimplantation genetic diagnostics (PGD) can be offered and 
unaffected embryos with a mutation load below the threshold of expression can 
be transferred [75]. In case of a homoplasmic mutation or a very high mutation 
load in the mother, it is impossible or unlikely to select healthy embryos, 
mitochondrial replacement therapy (MRT) is the method of choice. Currently MRT 
is offered in the UK for severe mtDNA disease only, in which PGD is unlikely to be 
successful [76], https://www.umdf.org/mitochondrial-replacement-therapy/.  
Despite the high impact the bottleneck has on the transmission of mtDNA disease, 
the underlying mechanism is still poorly understood. The size of the bottleneck 
remains an issue of debate and if positive or negative selection occur on mutations 
in addition to random genetic drift and at which level is largely unknown. Recently, 
in a human study available oocytes, zygotes, and blastomeres of five carriers of 
the MTTL1;m.3243A>G, one carrier of the ATP6;m.8993T>G, and one carrier of 
the ND6;m.14487T>C mutation were analysed for the mtDNA mutation load. 
Genetic drift with a variable bottleneck could explain the distribution, but it was 
far more likely that selection mechanisms could play a role as well [77]. The 
absence of mutation loads above 80-90% for MTTL1;m.3243A>G, which could not 
be explained by random segregation, indicated that at these levels OXPHOS 
function was insufficient for oogenesis, which heavily relies on OXPHOS. It has 
been reported that above 90% OXPHOS assembly is lost (Complex I) and >80% 
ATP production almost drops to zero. The ATP6;m.8993T>G shows in general 
either very high or very low levels of the mutation load. This binomial distribution 
was long enigmatic, but might be explained by a combination of genetic drift and 
positive selection on the mutation. At high mutation loads (up to 100%) ATP 
production drops to 20-30%, which seems sufficient for proper oogenesis.  As this 
can not explain why high mutation loads would be preferred, we proposed, based 
on data [77], that the mutation leads to a high membrane potential, which due to 
the defect in complex V is not consumed for ATP production. As a high membrane 
potential is usually a hallmark of healthy mitochondria, this could reflect a 
selection mechanism based on the membrane potential. The ND6;m.14487T>C 
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showed a random distribution with no apparent selection, which is consistent with 
the mutation being milder than the m.3243A>G. Based on this data, the 
mitochondrial bottleneck and genetic drift can be complemented with mutation-
specific negative or positive selection mechanism. Probably, these mutation-
specific events should be evaluated for each mtDNA mutation as the potential of 
preferential segregation of mutated mtDNA can have consequences for the 
threshold of transfer in case of PGD and the risk that mtDNA carry over can lead 
to clinical consequences [78, 79].  
A number of limitations prevents an accurate study of transmission of mtDNA 
disease in humans. The main issue is the availability of oocytes and embryos to 
study the transmission of mtDNA [80]. Due to these limitations, multiple family 
studies have been performed in order to get indirect information on the 
segregation of mtDNA. These studies have revealed random segregation and 
selection alike [81-83]. It is evident that further insight in these mechanisms 
might have implications for the reproductive choices and the chances of having 
unaffected offspring. If selective mechanisms can be identified, these might also 
reveal possible therapeutic interventions.  
The Use of Animal Models to Study the mtDNA Bottleneck 
Animal models have provided insight in the occurrence of mtDNA variants and the 
mechanism by which they are either filtered out or spread to high levels in the 
entire body, the germ cells or in a specific organ upon segregation. The 
mechanism of the bottleneck during development seems to be well-conserved 
although the amounts of mtDNA in oocytes differ largely among animal models 
[73]. In any case, the mature oocyte is the cell with the highest number of mtDNA 
copies and mitochondria in each species [73]. The mtDNA copy numbers is tightly 
regulated during oogenesis and development, in line with the metabolic demands 
of the cell. The mtDNA is also packed together with its proteins into nucleoids. 
Each nucleoid contains one or two mtDNA molecules [84]. Based on studies in 
animals a number of different mechanisms were postulated for the mtDNA 
bottleneck to explain the changes in heteroplasmy levels observed [85, 86]. In 
Holstein cows it was reported that de novo occurring, transmitted heteroplasmic 
variants could become fixed as homoplasmic variants within three generations 
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[87]. This was explained by the first hypothesis for the mitochondrial bottleneck, 
which postulated that only a small proportion of the total mtDNA passed on from 
mother to offspring, assuming genetic drift as the driving force.  
Rodents have higher numbers of offspring, making them more suitable for 
studying the bottleneck, but the number of strains carrying an mtDNA mutation 
is still small [88]. A commonly used model to study the transmission of mtDNA 
variants is the ‘mutator mouse’, a model with many mtDNA mutations due to a 
proofreading-deficient mitochondrial DNA polymerase (Polga). In the offspring, 
the mtDNA mutations are randomly distributed and can accumulate clonally in 
somatic cells, causing a mosaic of respiratory chain deficiencies in tissues such as 
heart, skeletal muscle and brain. Moreover, analysis of these tissues has shown 
that mtDNA mutator mice contain an increased load (~3-5 times) of the somatic 
point mutations in the mtDNA and an increased amount of eliminated mtDNA. 
Eventually, the increase in somatic mtDNA mutations is associated with a 
reduction in the life-span and early onset of aging-related phenotypes [86]. As 
the number of mutations is too high to study the mitochondrial bottleneck, a mice 
model was derived from the mutator mouse, carrying only a single heteroplasmic 
mutation (Figure 2). A strong reduction of the amount of mtDNA was reported in 
2 independent studies in primordial germ cells [89, 90], however, the results were 
interpreted quite differently. In the first paper [87] a mathematical stimulation 
was used to predict the mtDNA bottleneck, based on random genetic drift and a 
single mitochondrion/mtDNA molecule as segregating unit. A minimal amount of 
approximately ~200 mtDNA copies could explain the variation in heteroplasmy 
seen in the offspring of heteroplasmic mice [89]. About 70% of the heteroplasmy 
variance was credited to the physical restriction of mtDNA levels in early PGCs 
and the remaining 30% was due to a rapid proliferation in PGCs during maturation. 
The conclusion was that the mtDNA bottleneck consisted of unequal segregation 
of a drastically reduced mitochondrial genome population in early post 
implantation development (Figure 2a). So, the unequal partitioning (segregation) 
of mutated (red) and wild-type (blue) genotypes and resulting shifts in 
heteroplasmy in oocytes is explained by the strong reduction in mtDNA copy 
number immediately prior to expansion of the primordial germ cell (PGC) 
population [87]. The second paper also reported a reduction of mtDNA copy 
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number in PGCs at 8.5 days in mice, but a limited number of heteroplasmy 
measurements did not appear to show an increase in heteroplasmy variance in 
the early PGCs. Therefore, the authors concluded that the variation in 
heteroplasmy does not develop until maturation in the primary follicles. They 
proposed that mtDNA molecules were packaged into homoplasmic nucleoids, or 
simply kept separate within discrete homoplasmic mitochondria, thereby reducing 
the number of segregating units and accelerating the rate of drift (Figure 2b) 
[90]. Alternatively, as a third explanation, the replication of a subpopulation of 
mitochondrial genome would also lead to a bottleneck effect (Figure 2c). There 
is some evidence that this might occur during postnatal oocyte maturation [90, 
91]. Further experiments are needed to show, which of the predicted models can 
explain the data best.
Figure 2. The dynamics of mitochondrial DNA heteroplasmy: implications for human 
health and disease. Picture adapted from Stewart JB, Chinnery PF, Nat Rev Genet. 2015 
Sep;16(9):530-42.
All 3 mechanisms assumed that segregation of mtDNA mutations would only 
depend on random genetic drift. This can also explain the segregation in families 
by postulating a variable sized, mutation-dependent bottleneck [81-83]. However, 
as mentioned above, evidence was reported for selection processes during 
oogenesis and embryogenesis in humans and mice models. A mice model 
containing two mutations (ND6;m.13885insC and COI;m.6589T>C) that affect 
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oxidative phosphorylation showed  different segregation, which could be explained 
by selection occurring [92]. The severe ND6 mutation was clearly selected against 
and was eliminated within four generations. The milder COI mutation was still 
present throughout multiple generations, showing genetic drift and no apparent 
selection on the mutation despite symptoms of myopathy and cardiomyopathy 
later in life. 
Figure 3. The mtDNA copy number per cell during embryonic and foetal development in 
mammals. During oogenesis, mtDNA copy number increases up to the metaphase II 
stage. In larger animals, it then undergoes significant reduction during preimplantation 
development. At the blastocyst stage, replication is initiated, but this is confined to the 
trophectoderm. mtDNA copy number undergoes a continual reduction in the inner cell 
mass cells to establish this mtDNA set point which guarantees that specialised cell types 
once they have differentiated, acquire the appropriate mtDNA copy number to meet their 
needs for ATP production in a cell specific manner (adapted from: St John et al in 2014. 
The control of mtDNA replication during differentiation and development. Biochim Biophys 
Acta, 2014. 1840(4): p. 1345-54.
Studies on the mitochondrial bottleneck are still hampered by the lack of data and 
of appropriate animal models with heteroplasmic mtDNA mutations in which the 
bottleneck can be manipulated. Zebrafish are potentially an attractive model, as 
it is possible to isolate at low costs large numbers of oocytes, primordial-germ-
cells, and somatic embryonic cells to characterize the mitochondrial bottleneck 
during early embryonic development. Potential factors underlying this bottleneck 
can be easily manipulated, as shown for TFAM in Figure 4 [93]. Different levels 
of TFAM can lead to differences in mtDNA replication and transcription of the light 
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and heavy strand. Based on mtDNA and transcript levels of mtDNA encoded 
transcripts, the zebrafish tfam knockdown as described in Chapter 6, most likely 
reflects a switch or preferable transcription from the Light-Strand Promoter (LSP), 
which is induced by low amounts of tfam and which also primes H-strand 
replication[93]. It can be expected that overexpressing of Tfam will lead to an 
increased mtDNA copy number [94], which will allow us to manipulate mtDNA 
copy number in both directions. A drawback of the zebrafish model is the current 
lack of fish with heteroplasmic mtDNA mutations, which would allow us to perform 
similar studies as has been done for a mouse model with a heteroplasmic mtDNA 
mutation, in which Tfam was either overexpressed or knocked-out [87]. 
Heteroplasmic mutations do exist in the mtDNA in oocytes of zebrafish although 
generally at low level [85]. Our next aim is to develop heteroplasmic zebrafish 
models to study the bottleneck, the role of the specific mutations and possible 
selection mechanisms in further detail. 
Figure 4. The core human mitochondrial transcription machinery. The hypothetical model 
of transcription initiation determined by the amount of mammalian mtTFA associated with 
the number of mtDNA molecules per nucleoids. In a schematic representation of an 
mtDNA molecule (Circle in black) including the two basal components of the transcription 
process (in blue POLRMT and in green human-mtTFB2) bound at the HSP1 and LSP 
promoter sites. The arrow thickness represent the amount of transcription initiation 
activity from both strands. The human mtTFA in red and figure shape is representing 
other nucleoid components as the ones in orange bound to the mtDNA. This red and 
orange situation symbolizing different nucleoids containing several mtDNA molecules (A-
D states). (A) An mtDNA state with very little or no h-mtTFA bound is shown to visualize 
that basal levels of transcription from both promoters could be present in this situation. 
(B) An mtDNA state with relatively low amounts of h-mtTFA bound, but importantly bound 
at the high-affinity LSP site where it initially activates transcription of this promoter 
preferentially. Although, transcription from the LSP also primes H-strand mtDNA 
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replication, a switch occurs from a state akin to state A towards a state B, which could 
be a switch to activate mtDNA replication. (C) An mtDNA state with significantly higher 
amounts of h-mtTFA bound that leads to a significant activation of both promoters. In 
this various states in this range of h-mtTFA saturation could result in dynamic regulation 
of the relative amounts of HSP1 and LSP transcription. (D) A quiescent mtDNA state 
represent extreme high level or even saturation levels of h-mtTFA amounts, which would 
predict in silencing of transcription and replication. So in mammals, cells could have 
similar states in vivo, with heterogeneity potentially occurring at the level of cell or either 
tissue type, or individual organelles or maybe even at level of each nucleoid as adapted 
from Shutt et al in 2011. The core human mitochondrial transcription initiation complex 
- It only takes two to tango. Transcription 2:2, 55-59; March/April 2011. 
 
Role of the mtDNA Bottleneck beyond mtDNA Disease Transmission 
As the mitochondria content per cell declines during blastomere formation, the 
glucose transporter expression increases and glucose uptake accelerates to 
increase glycolysis activity in the blastocyst. Although, the transition in 
mitochondria and energy metabolism is well known during early embryogenesis, 
less information is reported on the metabolic maturation of specific organs or the 
role for mitochondria in fertility and successful embryonic development (Figure 
3). Organ specific development can be modelled in vitro by using stem cell 
differentiation, which is corroborated by a metabolic transition from predominantly 
glycolysis to mitochondrial dependent oxidative phosphorylation (OXPHOS) [95] 
as shown in Figure 5. Embryonic stem cells (ES) derived from the inner mass of 
the blastocyst, are excellent models to study either the differentiation process into 
multiple tissue-specific lineages or self-renewal by the possibility to self-replicate 
while in the undifferentiated state. The shape of the mitochondria in ES is similar 
as in the fertilized oocyte, spherical and poor cristae development, but in contrast, 
only contains a low mtDNA copy number. Unbalanced mitochondrial homeostasis 
in ES results in loss of pluripotency and lower efficiency in differentiation capacity 
and ES maintenance. The bioenergetics requirements of pluripotency can also be 
studied in induced pluripotent stem cells (iPS) cell lines, derived from somatic 
cells. During reprogramming a massive mitochondrial restructuring is shown with 
a shape transition from mature cristae rich mitochondria (somatic phenotype) 
towards immature poor shaped mitochondria with reduced mtDNA copy number 
in iPS cells. This mitochondrial reprogramming results in a decrease of cellular 
respiration in iPS cells providing a switch from somatic OXPHOS metabolism into 
glycolysis. These observations suggest that glycolytic activity of pluripotent stem 
Discussion
201
7
 
cells is a critical factor to maintain this pluripotent state, but that metabolic energy 
capacity and mitochondrial activity are essential for the differentiation process. 
Establishing a comprehensive roadmap of all cellular bioenergetics during 
developmental stages would offer a fundamental metabolic guide in the energetic 
requirements of somatic and germ-line cells, which is important for reproduction 
and healthy development [100-102], but also for tissue regeneration [95]. 
As shown in Figure 3 during early embryogenesis the mtDNA copy number 
undergoes significant reduction, affecting both germ line and somatic cells and 
tissues [96]. In line with what has been described above, differentiation and 
organogenesis lead to mtDNA replication and a switch to OXPHOS, at first 
observed in the trophectoderm. A somatic bottleneck also occur often  in cancer 
and tumorigenesis, where a mtDNA copy number set-point has to be crossed for 
further tumor progression [97]. The critical role for a somatic bottleneck in 
increasing the effect of subclinical mtDNA mutations is demonstrated in HIV 
patients treated with anti-retroviral drugs (NRTIs). This treatment leads to a 
reversible reduction in the amount of mtDNA (mtDNA depletion) and a progressive 
accumulation of the load of somatic mtDNA mutations, which cause  age-related 
mitochondrial disease in these patients at an earlier age [98].  
Especially in IVF the role of mitochondria and mitochondrial copy number has been 
studied to select embryos for successful implantation with somehow controversial 
observations [99]. A sufficiently high mtDNA copy number appears to be 
important for successful oogenesis and development [100]. As a consequence 
oocytes without sufficient wild-type mtDNA would not have the capacity to 
generate enough ATP to mature, which prohibits healthy embryonic development  
[97]. Therefore, the direct relationship between mtDNA copy number in the oocyte 
and its viability was proposed [99]. A possible relation between mtDNA content of 
human blastocysts, female age, embryonic or chromosomic status, and 
implantation studied in 379 IVF embryos, of which NGS data from preimplantation 
genetic screening (PGS) revealed the opposite  [100]. Blastocysts that 
successfully implanted tended to contain lower mtDNA quantities than those 
failing to implant independent from age. Also, aneuploid blastocysts contained 
significantly higher amounts of mtDNA than euploid samples. This observation 
was confirmed in a second study by another group [106], analysing 290 euploid 
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embryos of a group of 270 patients undergoing preimplantation genetic screening 
(PGS) before single embryo transfer. Implantation and pregnancy rates were 
calculated. This study showed that an increased amount of mtDNA in euploid 
embryos is indeed related to poor implantation potential. This data seems 
contradictory to the observation that sufficient mtDNA is required for oogenesis 
and embryogenesis, but it could be possible that a too low mtDNA copy number 
in oocytes triggers mtDNA replication earlier than normal during embryogenesis, 
leading to an increased mtDNA copy number in the blastocyst with advancing age 
[101]. However, in 2017, this data was challenged when  a third study showed 
that human blastocysts contained uniform levels irrespective of ploidy, or age, or 
implantation potential [102]. In addition, this study raised concerns on the 
methodology used in the previous reports [100, 103]. Especially, their critique on 
technical protocols used to determine mtDNA copy number from NGS data of 
preimplantation genetic testing was heavily debated and did not lead to consensus 
among all groups involved. Also, the the way the nuclear genome should be taken 
into account as the embryo gender and ploidy can undermine the calculated 
mtDNA scores, was a topic of fierce discussion. Another interfering factor is that 
the collection of viability data on embryos is performed in a reference laboratory, 
but the data is collected from multiple centers with subsequently different 
protocols (e.g. culture media, method of collecting biopsies, equipment, or 
personnel). So, the issue of mtDNA copy number as a marker for successful 
implantation is still not resolved and awaits further confirmation. 
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Figure 5. Energy metabolism fuels developmental organogenesis and stem cell 
differentiation. Developmental organogenesis reflects an ongoing metamorphosis in 
energy metabolism underscoring continues interplay of infrastructural inherited 
metabolism and evolve energy production as adapted from Folmes et al in 2014. 
Metabolic determinants of embryonic development and stem cell fate. Reproduction 
Fertility Development. 2014 December; 27(1): 82-88.doi:10.1071/RD14383.
All these examples show the importance of controlling mtDNA copy number and 
metabolism for healthy development and combating disease. Insight in the 
mechanisms may lead to better risk prediction for mtDNA mutation carriers, to 
interventions for reducing mtDNA mutation load, or to higher pregnancy rates for 
IVF, and maybe treatment options for cancer.
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Mitochondrial diseases result from a reduced energy production capacity in the 
mitochondria due to deficiencies in oxidative phosphorylation (OXPHOS). They are 
characterized by clinically highly heterogeneous and tissue-specific 
manifestations, typically involving tissues and organs with high energy 
requirements, like brain, heart and muscle. As the OXPHOS system is under dual 
genetic control, mutations in both the mitochondrial DNA and nuclear DNA can 
lead to a mitochondrial disease (Chapter 1). Mainly as a consequence of the large 
genetic heterogeneity (possibly more than 1500 genes involved) and clinical 
variability, for the majority of patients a genetic cause was unknown or not 
feasible at the start of the project. So, the first aim of the work described in this 
thesis was to identify and functionally characterize the underlying genetic cause 
in either the mtDNA or in nuclear genes in patients with OXPHOS disease. Based 
on a genetic diagnosis, counselling can be offered to the family and prenatal or 
preimplantation diagnosis to prevent the transmission of the mitochondrial 
disorder to further offspring. In case of an mtDNA disease this is less 
straightforward than for nuclear gene defects, as a mitochondrial bottleneck 
occurs during oogenesis, defining the mutation load and disease risk in the 
offspring. Although crucial for understanding the role of mitochondria in 
oogenesis, embryogenesis and the transmission of mtDNA disease, the 
mitochondrial bottleneck is still poorly understood, also because of the lack of 
appropriate animal models. The second aim our work was to develop an animal 
model for studying and manipulating the mitochondrial bottleneck. 
 
In Chapter 2 we described the use of next-generation sequencing (NGS) 
technology and discussed the impact it has on identifying pathogenic variants 
causing genetic disease, or on identifying genetic risk factors. The potential and 
limitations of different technologies and diagnostic approaches (i.e. targeted NGS, 
whole-exome sequencing (WES), RNA-Seq and whole genome sequencing (WGS)) 
are discussed. NGS technology expanded rapidly in the last decades with 
significant improvements in reliability, sequencing chemistry, pipeline analyses, 
data interpretation and costs. Such advances made the use of NGS the preferred 
choice today not only in clinical genetics practice.   
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A number of clinical applications of NGS have been addressed, like detection of 
the causative mutation in inherited cancer syndromes by DNA-sequencing and of 
splice variants by RNA-sequencing. Applications for pre-implantation genetic 
diagnosis, cancer somatic mutation analysis, pharmacogenetics, using blood DNA 
or liquid biopsy were discussed. Clinical limitations and ethical considerations 
related to the use of NGS for these applications are mentioned. Although this 
chapter reviews more general clinical application of NGS, it is evident that the 
topics addressed are relevant for the neurological and mitochondrial diseases, 
which are the prime topic of this thesis.  
 
NGS is successfully used to determine the primary underlying genetic defect in 
clinically highly heterogeneous inherited mitochondrial diseases which has 
facilitated a rapid introduction in diagnostics and clinical care of these and other 
diseases, as described in Chapter 2. WES as first strategy includes all variants in 
the coding part of the genome, allowing also the identification of risk factors, 
which can increase the risk for a disease by themselves or in combination with a 
primary genetic defect or with other risk factors. It is likely that genetic risk factors 
are involved in mitochondrial disease, illustrated by the highly variable 
manifestation of the m.3243A>G mutation or the male preponderance in LHON. 
Also, in a substantial part of the patients with mitochondrial diseases, no primary 
genetic cause has been identified, which means that it is either missed by WES or 
that the disease is not caused by a single primary genetic defect. A combination 
of multiple genetic risk factors, defined by a polygenic risk score could provide an 
alternative explanation, as has been demonstrated for example in the cancer field. 
These polygenic scores have been calculated by summing-up genetic risks 
associated with known SNPs in GWAS data. In Chapter 3 we describe as a proof 
of concept the identification and contribution of genetic risk factors in candidate 
genes to the severity of clinical manifestation in Lynch syndrome. A similar 
approach could be applied to identify genetic factors explaining the clinical 
heterogeneity of in mtDNA or nuclear mitochondrial genes. 
 
In Chapter 3 we used targeted NGS to detect co-occurring rare variants as 
possible genetic modifiers in Lynch syndrome by analysing a panel of candidate 
genes in 35 Lynch syndrome mutation carriers with a poor clinical phenotype. The 
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gene panel consisted of 154 genes involved in endometrial physiology and 
carcinogenesis. Data analysis was done by using a simple pipeline, in which 
variants were selected based on an allele frequency lower than 0.001 and on 
predicted non-conservative amino-acid substitutions. A total of 54 variants 
(categories 3 = VUS, or 4 = likely pathogenic, or 5 = pathogenic) were considered 
as putative risk modifiers. Risk prediction based on these variants was difficult to 
validate, but we proposed potential risk-variants and the predicted protein change 
for 6 functional known genes (RET; p.(Asn361Lys), CYP1A1; p.(Cys457*), 
IGF1R;p.(Thr758Met), NCOR2;p.(Ser1964Cys), COMT; p.(Lys159del), mTOR; 
p.(Met1313Leu). Logistic regression analysis, including two or more risk modifying 
variants in women carrying a primary pathogenic mutation, was associated with 
a poor clinical phenotype. A similar strategy could be performed to characterize 
genetic modifiers in mitochondrial disease. Further, in silico modeling, and in 
vitro, and in vivo studies will be needed to explore the impact of these variants 
on protein function and cellular OXPHOS processes. The role of genetic modifiers 
in mitochondrial disease patients will be relevant to explain the group without a 
genetic diagnosis or as a contributing factor in heterogeneous disease 
manifestation and could elucidate potential treatment options in future.  
 
A search for genetic modifiers, will complement the search for primary genetic 
causes in families with mitochondrial diseases, as described in Chapter 4 and 5. 
The diagnosis was based on clinical symptoms, including MRI and deficiencies in 
OXPHOS complexes in muscle or fibroblasts of patients. Evidence for the 
pathogenicity of novel variants and novel genes was provided by complementation 
assays. Leigh syndrome (Chapter 4) is an early onset, often fatal progressive 
neurodegenerative disorder caused by mutations in the mitochondrial or nuclear 
DNA. Until now, mutations in more than 60 genes had been reported to cause 
Leigh syndrome, indicating an extreme genetic heterogeneity for this disorder, 
but still only explaining part of the cases. WES was combined with homozygosity 
mapping as an additional filtering step to identify the underlying genetic defect in 
a Moroccan family with fatal Leigh syndrome in early childhood and specific MRI 
abnormalities in the brain. We detected a homozygous nonsense mutation 
(c.20C>A; p.Ser7Ter) in the thiamine transporter SLC19A3. In vivo 
overexpression of wild-type SLC19A3 showed an increased thiamine uptake, 
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whereas overexpression of mutant SLC19A3 did not, confirming that the 
mutations resulted in an absent or non-functional transporter. Seventeen 
additional patients with LS were screened for mutations in SLC19A3 using 
conventional Sanger sequencing. Two unrelated patients both Moroccan origin and 
one from consanguineous parents were homozygous for the same p.Ser7Ter 
mutation. One of these patients showed the same MRI abnormalities as the 
patients from the first family. Strikingly, patients who received thiamine had an 
improved life-expectancy. One patient in the third family deteriorated upon 
interruption of the thiamine treatment and recovered after reinitiating. Although 
unrelated, all patients came from the province Al Hoceima in Northern Morocco. 
Based on the recombination events the foundermutation was estimated to have 
occurred 1250-1750 years ago. Our data showed that the SLC19A3 gene is a new 
candidate for mutation screening in patients with Leigh syndrome, who might 
benefit from high doses of thiamine. Especially Moroccan Leigh patients should be 
tested for the c.20C>A founder mutation in SLC19A3. 
 
In Chapter 5, we describe the application of whole-exome sequencing in three 
patients with paediatric cardiomyopathy and early-onset brain disease with 
OXPHOS deficiencies. The brain pathology was studied by MRI analysis. In 
consanguineous patient 1 we identified a homozygous intronic variant (c.850-
3A>G) in the QRSL1 gene, which was predicted to cause abnormal splicing. The 
variant segregated with the disease and affected the protein function, which was 
confirmed by complementation studies, restoring OXPHOS function only with wild-
type QRSL1. Patient 2 was compound heterozygous for two novel disease causing 
variants (c.[253G>A]; [938G>A]) in the MTO1 gene. In patient 3 we detected one 
unknown disease-causing variant (c.2872C>T) and one known disease-causing 
variant (c.1774C>T) in the AARS2 gene. The c.1774C>T variant was present in 
the paternal copy of the AARS2 gene, the c.2872C>T in the maternal copy. All 
genes were involved in translation of mtDNA-encoded proteins. Defects in mtDNA-
encoded protein translation lead to severe paediatric cardiomyopathy and brain 
disease with OXPHOS abnormalities. This suggests that the heart and brain are 
particularly sensitive to defects in mitochondrial protein synthesis during late 
embryonic or early postnatal development, probably due to the massive 
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mitochondrial biogenesis occurring at that stage. If both the heart and brain are 
involved, the prognosis is poor with a likely fatal outcome at young age.  
 
In the families, described in Chapter 4 and 5, but also in many others, as 
mentioned in Chapter 2, we demonstrated the importance of NGS and WES in 
genetic testing for mitochondrial disease, increasing the diagnostic yield from 25% 
to 69% and a turn-around time from years to months.  Furthermore, we identified 
in 30% of the cases defects in novel genes, indicating that unbiased Whole Exome 
Sequencing combined with RNA-Seq is still superior to panel-based approaches in 
mitochondrial diseases. 
 
Our second aim was to develop an animal model for studying and manipulating 
the mitochondrial bottleneck. We have shown before that zebrafish is an excellent 
model, as both timing and size of the bottleneck are highly conserved from fish to 
man. Zebrafish provide sufficient numbers of offspring and are easy to 
manipulate. Both the embryonic development and oogenesis can be studied in full 
detail. To understand the pathology and mechanisms associated with low mtDNA 
copy numbers, we manipulated the mtDNA bottleneck by knocking down Tfam, a 
key regulator of mtDNA replication, during early zebrafish development in 
Chapter 6. Reduction of Tfam using a splice-MO, resulted in a 42%±17% 
decrease in the mtDNA copy number in zebrafish embryos at 4 days post 
fertilization (dpf). Morphant embryos displayed abnormal development of the eye, 
brain, heart and muscle, as well as a 50%±22% decrease in ATP production. 
Transcriptome analysis revealed a decrease in protein-encoding transcripts from 
the heavy strand of the mtDNA, and down-regulation of genes involved in haem 
production and the metabolism of metabolites, which appear to trigger increased 
rRNA and tRNA synthesis in the nucleoli. However, this stress or compensatory 
response appears to fall short as pathology emerges and expression of genes 
related to eye development are severely down-regulated. Taken together, this 
study highlights the importance of sufficient mtDNA copies for early zebrafish 
development. Zebrafish is an excellent model to manipulate the mtDNA bottleneck 
and study its effect on embryogenesis rapidly and in large numbers of offspring. 
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In Chapter 7, we discussed the impact of NGS not only the diagnosis of 
mitochondrial disease, but also for personalized medicine in general. It is beyond 
any doubt, that WGS in combination with RNA-Seq will bring the paradigm shift 
started by WES to the diagnostic next level. There will be limited need to narrow 
down the differential clinical diagnosis to request sequencing of a specific gene or 
sets of genes, as all genetic information will be available at once from start. The 
results of this genetic analysis will directly guide the diagnostic patient evaluation, 
moving towards personalized patient care and treatment in mitochondrial 
diseases. Complete analysis of both the mtDNA and exome generated a diagnostic 
yield of 69%, obtained in months, which by far exceeds the 25% yield using 
conventional, targeted sequencing. As indicated before, this means there is still 
an era for improvement in unravelling the genetic cause of the undiagnosed cases 
using WGS, RNA-Seq or polygenic risk scores in these unsolved mitochondrial 
patients.  
Furthermore, as we succeeded in the development of the first tuneable zebrafish 
model to study the mtDNA bottleneck in embryogenesis, we discuss on the impact 
this will have on characterizing and manipulating the mitochondrial bottleneck and 
the processes triggered by a reduced mtDNA copy number in zebrafish embryos 
in further detail. If we will be able to generate mtDNA mutations in those 
zebrafish, then this will become an excellent model for testing the current three 
different mitochondrial bottleneck theories, for identifying possible selection 
mechanisms and for risk assessment of mtDNA disease transmission.  
  
8CHAPTER 8
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Mitochondrial diseases are the most common genetic metabolic diseases, affecting 
approximately 1 in 5,000 individuals [1]. Mitochondrial diseases are a clinically 
and genetically heterogeneous group of disorders, which generally manifest in 
tissues or organs with a high-energy requirement [2]. Due to this complexity and 
the lack of proper genotype-phenotype correlations, at the start of the work 
performed in this thesis, a genetic diagnosis was obtained in only 25% of patients 
by sequential analysis of the mtDNA and single candidate genes. The application 
of next-generation sequencing as a research tool to first sequence gene panels 
and later all genes (the exome) has increased this figure considerably, which has 
facilitated a rapid introduction in diagnostics and clinical care [3]. The valorisation 
paragraph will deal with the introduction of NGS in routine genetic diagnostics.  
Next-generation sequencing: from research to diagnostics 
A genetic diagnosis is important for counseling patient and relatives, for 
preventing the transmission, for providing a more accurate prognosis and in some 
cases for offering therapeutic interventions. During the past years, NGS 
technology has developed as the preferred  tool for identifying the genetic defects 
in patients with clinically and genetically heterogenous diseases (Chapter 2). NGS 
has contributed in identifying the genetic cause in either the mtDNA (20%) or 
nDNA (WES; 49%), leading to an overall diagnostic yield of 69% [4]. Given the 
impressive increase not only in the percentage of patients, in which a genetic 
diagnosis is established (from 25% to 69%), but also in the speed (from years to 
months) and in costs (expenisve Sanger Sequencing), a rapid introduction of NGS 
in routine genetic diagnosis of mitochondrial disease was warranted and has been 
established in the last couple of years. NGS costs rapidly declined and the capacity 
of platforms as the Illumina NovaSeq 6000 increased tremendously. For example 
200 exomes can be sequenced in a single sequencing run. Crucial in this respect 
was also the development of novel improved bioinformatics tools to predict variant 
pathogenicity and the availability of superior databases with information on 
exomes (Exac) and genetic variants (ClinVar). The adagium will be NGS first and 
guided by the genes and variants found, specific clinical and laboratory 
investigations can be carried out to unambiguously link the genetic defect(s) to 
the clinical manifestations. The laboratory findings may also be important, in case 
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functional validation is required. Our results show a few key points for proper 
introduction into the clinic: 
1. NGS of both the mtDNA and the whole exome 
It is essential investigate both the mtDNA and the exome to identify the 
genetic cause in mitochondrial disease [4-6]. Although the mtDNA can be 
analysed in the exome DNA, the coverage is insufficient to detect the 
necessary low level mutation loads in blood DNA, which might indicate a 
higher mutation load and follow-up in affected tissues. NGS of the mtDNA 
allows detection of point mutations and rearragements alike with immediate 
characterization of the breakpoints. Only the mtDNA copy number has to be 
established by a separate test. 
2. Novel mitochondrial disease genes 
Novel genes are still being identified as a possible cause of mitochondrial 
disease. These are either genes, in which no genetic defect has been found so 
far, or genes, in which defects have been found in apparently non-
mitochondrial disease. This implies that gene panel-based approaches fall 
short, as the mitochondrial panel is still not  complete. Complete analysis of 
all genes in the exome (open exome) [4] is preferable to start with to identify 
all relevant genetic defects in the shortest timeframe and at the lowest cost. 
3. Overlap between mitochondrial and other neuromuscular disorders 
Our results demonstrate that many neuromuscular diseases exist, in which a 
mitochondrial defect can be the cause in the minority of cases. In case of gene 
panels, this would imply sequential analysis of multiple, and probably partly 
overlapping gene panels. Again, it is preferable to start with an open exome 
[4], as this would allow an unbiased identification of the underlying genetic 
causes.  
4. De novo mutations 
As we detected de novo mutations in the clinical exome, it would be preferable 
to include immediately the parents for whole exome sequencing [7] and 
analyze the data, using an autosomal recessive and de novo dominant disease 
model.  
5. Multigenic disease 
Especially in clinically heterogeneous disease and when consanguinity is 
involved, the option of having multiple genes causing the disease in the 
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patient, should be investigated. This can be done by investigating all gene 
defects, which could be potentially contribute to the clinical phenotype. One 
should not address all symptoms to the first gene identifed. As this has been 
done in the past, it is clear that genotype-phenotype correlations from 
literature [8], when based on few patients and single gene analysis, should 
be considered with care.  
 
Our proposed diagnostic strategy for most mitochondrial diseases will be NGS of 
the mtDNA, followed by whole exome sequencing of patients and parents, followed 
by analysis of all genes, using an autosomal recessive or de novo dominant genetic 
model. In case of new genes or unclassified variants, functional follow-up sudies 
should be offered to demonstrate pathogenicity. In case an OXPHOS deficiency is 
observed in patient-derived fibroblasts, this can be done straightforward by 
complementation assays. If this is not the case, animal studies might provide the 
answer, which will often go beyond the capabilities of routine diagnostic labs. An 
in vivo model as zebrafish could  fill this gap, but standardization, validation and 
high-throughput processing is required to keep-up with the rapid generation of 
unclassified variants and novel genes by WES and WGS these days. 
As the combined approach will identifiy at max 69% of the genetic causes, still 
31% of the patients will remain without a genetic diagnosis. As these are carefully 
selcted patients from our cohort, it is likely that that there will be technical issues, 
prohibiting the identification of the underlying defects. Applying WGS could solve 
the issue, but routine use is still limited by the financial costs and the complexity 
of data interpretation. Rapid and life-saving genetic diagnosis in less than 24 hours 
using rapid WGS (rWGS) is possible and already offered  for early intervention 
cases within paediatric Intensive Care Units (ICUs) as discussed in Chapter 7. 
Introducing rWGS showed a diagnostic yield of 42 to 57% in serious ill infants in 
ICUs, and changes in medical management in 30 to 72%, and finally altered 
outcomes in 24 to 34% of the cases [9]. Sequencing the transcriptome by RNA-
Seq seems at this moment a more realistic addition to WES to solve the remaining 
cases. RNA-Seq allowed analysis of the transcriptome at an unprecedented depth 
and reported the identification of causative, non-exonic regulatory variants in an 
additional 10% diagnostic yield of mitochondrial patients using RNA-Seq [10]. In 
another study of rare muscular disorders this was 35% yield, which clearly shows 
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the added value of this RNA-Seq approach [11]. It is beyond any doubt, that WGS 
and RNA-Seq will bring the paradigm shift started by WES to the next level: for a 
genetic diagnosis, geneticists and expert clinicians will no longer need to narrow 
down the differential clinical diagnosis to request sequencing of a specific gene or 
sets of genes, but all genetic information will be available at once from start. The 
results of this genetic analysis will directly guide the diagnostic patient evaluation, 
moving towards personalized patient care and treatment.  
Gene-based treatment options 
The identification of the gene defect in the patients has unfortunately not led to 
the anticipated major breakthrough in novel treatments. Only in few cases, a gene 
specific-treatment is possible and early start with these treatments prevents 
symptoms from occurring and can be lifesaving, as for example administration of 
thiamine to patients with  fatal Leigh Syndrome due to SLC19A3 mutations [5]. 
In case of SLC25A32 mutations riboflavin is also the preferred treatment [12]. 
Our study revealed that SLC25A32 patients improved when treated with riboflavin 
as a vitamin B2 precursor of FAD which will compensate the lack of FAD 
functioning as a crucial co-factor in the mitochondrial transport chain [13]. In 
these cases, the genetic defect directly revealed a successful treatment option.  
In other cases, clinical improvement by specific treatments at a moment when the 
genetic defect was not known, revealed when the genetic defect was found, which 
patients might benefit from a comparable treatment. We demonstrated that again 
riboflavin could be beneficical for patients in case of ACAD9 defects [14]. Since 
increasing the levels of the riboflavin restored Complex I activity by compensating 
a disturbed ACAD9 and FAD binding or by stimulating Complex I assembly factors. 
However, not all ACAD9 patients are treatable with riboflavin [15]. A recent study 
on ACAD9 disease-causing variants in 70 patients showed improvement of at least 
20/31 (65%) ACAD9 deficient patients to riboflavin and 11/31 (35%) patients had 
no effect, although 20 patients were not treated and additional data about the 
treatment were missing for approximately 19 patients in this cohort. However, 
this justifies administration of riboflavin to every ACAD9 patient. Given the high 
frequency of ACAD9 deficiency, we also propose that early riboflavin 
administration for phenotypically consistent patients whilst their genetic 
investigations are still underway [16]. Another, successful treatment of infantile-
onset ACAD9-related cardiomyopathy was achieved by a combination of sodium 
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pyruvate, beta-blocker, and coenzyme Q10 [17]. Finally, also a high fat diet 
resulted in clinical improvement in a patient with a OXPHOS Complex I deficiency 
due to a mutation in the TMEM126B gene [18].  
Conclusively, still this is a minority, and gene and pathway based treatment 
strategies might fall short. More general, gene-correction/editing (CRISPR/Cas9) 
or cell-based strategies are more promising as a general treatment strategy, 
complemented by classical compound-screening strategies of the pharmaceutical 
industry. 
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Mitochondriële ziekten zijn het gevolg van een verminderde energiecapaciteit in 
de mitochondriën als gevolg van deficiënties in oxidatieve fosforylering (OXPHOS). 
Ze worden gekenmerkt door klinisch zeer heterogene en weefselspecifieke 
symptomen, die meestal weefsels en organen met hoge energiebehoeften, zoals 
hersenen, hart en spieren, raken. Aangezien het OXPHOS-systeem onder dubbele 
genetische controle staat, kunnen mutaties in zowel het mitochondriële DNA als 
het nucleaire DNA leiden tot een mitochondriële ziekte (hoofdstuk 1). 
Voornamelijk door de grote genetische heterogeniteit (mogelijk meer dan 1500 
betrokken genen) en klinische variabiliteit, was bij de meerderheid van de 
patiënten een genetische oorzaak onbekend bij het begin van mijn onderzoek. Het 
eerste doel van het in dit proefschrift beschreven werk was dan ook het 
identificeren en functioneel karakteriseren van de onderliggende genetische 
oorzaak in het mtDNA of in nucleaire genen bij patiënten met OXPHOS-
aandoeningen. Op basis van een genetische diagnose kan counseling worden 
aangeboden aan de familie en prenatale of pre-implantatie-diagnostiek om de 
overdracht van de mitochondriële aandoening naar nakomelingen te voorkomen. 
In het geval van een mtDNA ziekte is dit minder eenvoudig dan bij nucleaire 
gendefecten, aangezien er tijdens de oὅgenese een mitochondriële bottleneck 
optreedt, die het mutatiepercentage en het ziekterisico bij de nakomelingen vaak 
onvoorspelbaar maakt. Hoewel cruciaal voor het begrijpen van de rol van 
mitochondriën bij oὅgenese, embryogenese en de overdracht van mtDNA ziektes, 
is het mechanisme van de mitochondriële bottleneck grotendeels onbekend, ook 
omdat geschikte diermodellen ontbreken. Het tweede doel van ons werk was 
dan ook het ontwikkelen van een diermodel voor het bestuderen en manipuleren 
van de mitochondriële bottleneck. 
In hoofdstuk 2 wordt next generatie sequencing (NGS) technologie beschreven 
en de impact, die NGS heeft op het identificeren van pathogene varianten die 
genetische ziekten veroorzaken of van genetische risicofactoren. De 
mogelijkheden en beperkingen van verschillende technologieën en diagnostische 
benaderingen (d.w.z. gerichte NGS, sequentiebepaling van het gehele exoom 
(Whole Exome Sequencing - WES), RNA-Seq en sequentiebepaling van het gehele 
genoom (WGS)) worden besproken. Het gebruik van NGS-technologie in de 
genetische diagnostiek is de afgelopen decennia enorm toegenomen, mede 
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dankzij aanzienlijke verbeteringen in betrouwbaarheid, sequencing-chemie, 
analyse-pijplijnen, data-interpretatie en kosten. Dit maakt NGS de methode, die 
bij voorkeur wordt gebruikt niet alleen binnen de klinische genetica, maar ook 
daarbuiten. 
Een aantal klinische toepassingen van NGS wordt besproken, zoals de detectie 
van de oorzakelijke mutaties in erfelijke kankersyndromen door DNA sequencing 
en van splice-varianten door RNA sequencing. Toepassingen in het kader van pre-
implantatie genetische diagnostiek, somatische mutatieanalyse bij kanker, 
farmacogenetica, op basis van DNA uit bloed of liquid biopsies worden beschreven. 
Klinische beperkingen en ethische overwegingen met betrekking tot het gebruik 
van NGS voor deze toepassingen worden bediscussieerd. Hoewel dit hoofdstuk 
een meer algemene klinische toepassing van NGS behandelt, is het duidelijk dat 
NGS zeer relevant is voor de neurologische en mitochondriële ziekten, die het 
belangrijkste onderwerp van dit proefschrift zijn. 
NGS is met succes gebruikt om het primaire onderliggende genetische defect bij 
de klinisch en genetisch zeer heterogene erfelijke mitochondriële ziekten te 
bepalen, wat een snelle introductie in de diagnostiek en klinische zorg voor deze 
ziekten heeft vergemakkelijkt (hoofdstuk 2). WES als eerste onderzoek, 
identificeert alle varianten in het coderende deel van het genoom, waardoor ook 
risicofactoren kunnen worden geïdentificeerd, die het risico op een ziekte alleen 
of in combinatie met een primair genetisch defect of andere risicofactoren kunnen 
verhogen. Het is waarschijnlijk dat genetische risicofactoren betrokken zijn bij 
mitochondriële ziektes, wat blijkt uit de zeer variabele manifestatie van bijv. de 
m.3243A>G-mutatie of het grotere percentage mannelijke patiënten met Leber 
erfelijke optische neuropathie (LHON). Nog steeds wordt bij een substantieel deel 
van de patiënten met mitochondriële ziekten geen primaire genetische oorzaak 
geïdentificeerd, wat betekent dat het ofwel wordt gemist door WES of dat de ziekte 
niet wordt veroorzaakt door een enkel primair genetisch defect. Een combinatie 
van meerdere genetische risicofactoren, gedefinieerd door een polygene 
risicoscore, zou een alternatieve verklaring kunnen zijn, zoals bijvoorbeeld is 
aangetoond op het gebied van kanker. Deze polygene scores worden berekend op 
basis van de genetische risico’s van bekende met de ziekte gebaseerde SNP's uit 
GWAS-gegevens. In hoofdstuk 3 beschrijven we als proof-of-concept de 
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identificatie en bijdrage van genetische risicofactoren in kandidaatgenen aan de 
ernst van klinische manifestatie bij het Lynch syndroom. Een vergelijkbare 
benadering zou kunnen worden toegepast om genetische factoren te identificeren 
die de heterogene klinische manifestatie van defecten in het mtDNA of nucleaire 
mitochondriële genen kunnen verklaren. 
In hoofdstuk 3 gebruikten we gerichte NGS om zeldzame varianten te detecteren 
als mogelijke genetische modifiers in het Lynch syndroom door een panel van 
kandidaat-genen te analyseren in 35 Lynch syndroom mutatiedragers met een 
slecht klinisch beeld. Het genenpaneel bestond uit 154 genen die betrokken zijn 
bij de endometrium-fysiologie en carcinogenese. Data-analyse werd uitgevoerd 
met behulp van een pipeline, waarin varianten werden geselecteerd met een 
allelfrequentie lager dan 0,001 die tot niet-conservatieve aminozuursubstituties 
leiden. In totaal werden 54 varianten (categorieën 3 = VUS of 4 = waarschijnlijk 
pathogeen of 5 = pathogeen) beschouwd als risico-modifiers. Risicovoorspelling 
op basis van deze varianten is moeilijk te valideren, maar we voorspelden 
potentiële risicovarianten en functionele eiwitveranderingen voor 6 bekende 
genen (RET; p.(Asn361Lys), CYP1A1; p.(Cys457 *), IGF1R; p.(Thr758Met), 
NCOR2; p.(Ser1964Cys), COMT; p.(Lys159del), mTOR; p.(Met1313Leu). 
Logistische regressive-analyse op basis van twee of meer risico-modificerende 
varianten bij vrouwen met een primaire pathogene mutatie was geassocieerd met 
een slecht klinisch fenotype. Een vergelijkbare benadering zou kunnen worden 
toegepast om genetische modifiers in mitochondriële ziekten te karakteriseren. 
Verder zullen in silico-modellering en in-vitro en in-vivo studies nodig zijn om de 
impact van deze varianten op de eiwitfunctie en cellulaire OXPHOS-processen te 
onderzoeken. De rol van genetische modifiers bij patiënten met mitochondriële 
ziekten zal relevant zijn binnen de groep zonder een genetische diagnose of als 
een risicofactor in de ernst van de ziektemanifestatie en zou tot mogelijk nieuwe 
behandelingsopties in de toekomst kunnen leiden. 
Een zoektocht naar genetische modifiers zal de zoektocht naar primaire 
genetische oorzaken in families met mitochondriële ziekten aanvullen, zoals 
beschreven in hoofdstuk 4 en 5. De diagnose in deze families was gebaseerd op 
klinische symptomen, waaronder MRI en deficiënties in de OXPHOS-complexen in 
spieren of fibroblasten van patiënten. Bewijs voor de pathogeniciteit van nieuwe 
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varianten en nieuwe genen werd geleverd door complementatie-testen. Leigh 
syndroom (hoofdstuk 4) is een vroege, maar vaak een fatale, progressieve 
neurodegeneratieve aandoening, die wordt veroorzaakt door mutaties in het 
mitochondriële of nucleaire DNA. Tot nu toe zijn er mutaties in meer dan 60 genen 
gerapporteerd, die Leigh syndroom veroorzaken, wat wijst op een extreme 
genetische heterogeniteit voor deze aandoening, maar die nog steeds slechts een 
deel van de gevallen verklaren. WES is gecombineerd met homozygositeits-
bepaling als een extra filterstap om het onderliggende genetische defect te 
identificeren bij een Marokkaanse familie met fataal Leigh syndroom op vroege 
kinderleeftijd en specifieke MRI-afwijkingen in de hersenen. We ontdekten een 
homozygote nonsense mutatie (c.20C>A; p.Ser7Ter) in de thiamine-transporter 
SLC19A3. In vivo over-expressie van wild-type SLC19A3 toonde een verhoogde 
thiamine-opname, terwijl over-expressie van mutant SLC19A3 dat niet deed, wat 
bevestigt dat de mutaties resulteerden in een afwezig of niet-functioneel eiwit. 
Zeventien andere patiënten met Leigh syndroom werden gescreend op mutaties 
in SLC19A3 gen met behulp van conventionele Sanger sequencing. Twee niet-
verwante patiënten, beide van Marokkaanse afkomst en één ook van 
bloedverwante ouders, waren homozygoot voor dezelfde p.Ser7Ter mutatie. Een 
van deze patiënten vertoonde dezelfde MRI-afwijkingen als de patiënten uit de 
eerste familie. Opvallend was dat de patiënten die thiamine kregen een verbeterde 
levensverwachting hadden. Eén patiënt uit de derde familie verslechterde na 
onderbreking van de thiamine behandeling en herstelde na herstart. Hoewel niet 
verwant, kwamen alle patiënten uit de provincie Al Hoceima in Noord-Marokko. 
Op basis van genetisch markeronderzoek werd geschat dat de mutatie 1250-1750 
jaar geleden is ontstaan. Onze resultaten toonden aan dat het SLC19A3 gen een 
nieuw kandidaatgen is voor mutatie-screening bij patiënten met Leigh syndroom, 
die baat zouden kunnen hebben bij hoge doses thiamine. Vooral Marokkaanse 
Leigh patiënten moeten worden getest op de c.20C>A foundermutatie in 
SLC19A3. 
In hoofdstuk 5 beschrijven we de toepassing van WES bij drie kinderen met 
cardiomyopathie en een hersenziekte met OXPHOS-deficiëntie op jonge leeftijd. 
De hersenpathologie werd bestudeerd door MRI-analyse. Bij consanguïne patiënt 
1 identificeerden we een homozygote intron-variant (c.850-3A>G) in het QRSL1 
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gen, waarvan werd voorspeld dat het abnormale splicing zou veroorzaken. De 
variant segregeerde met de ziekte in de familie en had een negatief effect op de 
eiwitfunctie, wat werd bevestigd door complementatie-onderzoeken. De OXPHOS 
functie werd alleen hersteld met wild-type QRSL1 en niet met de mutant. Patiënt 
2 was compound heterozygoot voor twee nieuwe ziekteverwekkende varianten (c. 
[253G>A]; [938G>A]) in het MTO1 gen. Bij patiënt 3 ontdekten we een 
onbekende ziekteverwekkende variant (c.2872C>T) en een bekende 
ziekteverwekkende variant (c.1774C>T) in het AARS2 gen. De c.1774C>T variant 
was aanwezig in de paternale kopie van het AARS2 gen, de c.2872C>T in de 
maternale kopie. Alle genen spelen een rol bij de vertaling van mtDNA gecodeerde 
eiwitten. Defecten in mtDNA gecodeerde eiwitvertaling leiden tot ernstige 
pediatrische cardiomyopathie en hersenziekte met OXPHOS-afwijkingen. Dit 
suggereert dat het hart en de hersenen bijzonder gevoelig zijn voor defecten in 
de mitochondriële eiwitsynthese tijdens de late embryonale of vroege postnatale 
ontwikkeling, waarschijnlijk als gevolg van de sterke mitochondriële biogenese die 
in dat stadium optreedt. Als zowel het hart als de hersenen betrokken zijn, is de 
prognose slecht met een waarschijnlijk dodelijke afloop op jonge leeftijd. 
In de families, beschreven in hoofdstuk 4 en 5, maar ook in vele andere, zoals 
vermeld in hoofdstuk 2, hebben we het belang aangetoond van NGS en WES bij 
genetische onderzoek bij mitochondriële ziekten, waardoor de diagnostische 
opbrengst van 25% naar 69% is gestegen en de doorlooptijd van jaren tot 
maanden is gereduceerd. Bovendien identificeerden we in 30% van de gevallen 
defecten in nieuwe genen, wat aangeeft dat WES in combinatie met RNA-Seq nog 
steeds superieur is aan op genpanels gebaseerde benaderingen bij mitochondriële 
ziekten. 
Ons tweede doel was het ontwikkelen van een diermodel voor het bestuderen 
en manipuleren van de mitochondriële bottleneck. We hebben al eerder laten zien 
dat zebravis een uitstekend model is, omdat zowel de timing als de grootte van 
de bottleneck van vis tot mens zeer goed geconserveerd is. Zebravissen hebben 
grote aantallen nakomelingen en zijn gemakkelijk genetisch te manipuleren. 
Zowel de embryonale ontwikkeling als de oὅgenese kunnen tot in detail worden 
bestudeerd. Om de pathologie en mechanismen bij lage mtDNA kopie-aantallen 
te begrijpen, hebben we in hoofdstuk 6 de mtDNA bottleneck gemanipuleerd 
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door de expressie van Tfam, een belangrijke regulator van mtDNA replicatie, 
tijdens de vroege ontwikkeling van zebravissen te verlagen. Reductie van Tfam 
expressie met behulp van een splice-morpholino resulteerde in een afname van 
42% ± 17% van het mtDNA kopie-aantal in zebravisembryo's op 4 dagen na 
bevruchting (4 dpf). Aangedane embryo's vertoonden een abnormale ontwikkeling 
van het oog, de hersenen, het hart en de spieren, evenals een afname van de 
ATP-productie met 50% ± 22%. Transcriptoom-analyse toonde een afname van 
eiwit-coderende transcripten van de heavy strand van het mtDNA, en een lagere 
expressie van genen die betrokken zijn bij de haem-productie en bij het 
metabolisme van metabolieten, gericht op het verhogen van rRNA- en tRNA-
synthese in de nucleoli.  Deze stress of compenserende respons lijkt echter tekort 
te schieten als pathologie zich manifesteert. De expressie van genen die van 
belang  zijn bij de oogontwikkeling is ook sterk verlaagd. Deze studie toont het 
belang aan van voldoende mtDNA-kopieën voor de vroege ontwikkeling van 
zebravissen. Zebravis blijkt een uitstekend model om de mtDNA bottleneck te 
manipuleren en het effect ervan op de embryogenese snel en bij grote aantallen 
nakomelingen te bestuderen. 
In hoofdstuk 7 bediscussiëren wij de impact van NGS, niet alleen in de diagnose 
van mitochondriële ziekten, maar ook voor personalised medicine in het 
algemeen. Het staat buiten kijf dat WGS in combinatie met RNA-Seq de door WES 
gestarte paradigmaverschuiving naar het volgende diagnostische niveau zal 
brengen. De noodzaak om via uitgebreid klinisch onderzoek het genetisch 
onderzoek richting te geven naar een specifiek gen of sets van genen zal sterk 
verminderen, immers alle genetische informatie zal vanaf het begin in één keer 
beschikbaar zijn. De resultaten van deze genetische analyse zullen direct de 
diagnostische patiënt-evaluatie sturen en gepersonaliseerde patiëntenzorg en 
behandeling bij mitochondriële ziekten mogelijk maken. Volledige analyse van 
zowel het mtDNA als het exoom genereerde een diagnostische opbrengst van 
69%, verkregen in maanden, wat de 25% opbrengst, die met behulp van 
conventionele, gerichte sequencing wordt bereikt, verre overschrijdt. Zoals eerder 
aangegeven, is er nog steeds verbetering mogelijk voor het ontrafelen van de 
genetische oorzaak van de niet-gediagnosticeerde gevallen middels WGS, RNA-
Seq of polygene risicoscores bij deze onopgeloste mitochondriële patiënten. 
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Aangezien we erin zijn geslaagd het eerste tuneable zebravismodel te ontwikkelen 
om de mtDNA bottleneck in de embryogenese te bestuderen, hebben we  de 
impact die dit model zal hebben op het karakteriseren en manipuleren van het 
mitochondriële bottleneck en de processen die worden veroorzaakt door een 
verminderd mtDNA kopie-aantal in embryo's van zebravissen, verder 
bediscussieerd. Als we mtDNA mutaties in die zebravissen kunnen genereren, dan 
wordt dit een uitstekend model voor het testen van de huidige drie verschillende 
mitochondriële bottleneck-theorieën, voor het identificeren van mogelijke 
selectie-mechanismen en voor een betere risicobeoordeling van transmissie voor 
mtDNA ziekte. 
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